# EDGAR Filing Document

**Accession Number:** 0000310764
**File Stem:** 0000310764-26-000013
**Filing Date:** 2026-3
**Character Count:** 276940
**Document Hash:** ff31a89595ed3fb5df82dff16a6d1b4d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000310764-26-000013.hdr.sgml**: 20260323

**ACCESSION NUMBER**: 0000310764-26-000013

**CONFORMED SUBMISSION TYPE**: DEF 14A

**PUBLIC DOCUMENT COUNT**: 35

**CONFORMED PERIOD OF REPORT**: 20260506

**FILED AS OF DATE**: 20260323

**DATE AS OF CHANGE**: 20260323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STRYKER CORP
- **CENTRAL INDEX KEY:** 0000310764
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 381239739
- **STATE OF INCORPORATION:** MI
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEF 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13149
- **FILM NUMBER:** 26781275

**BUSINESS ADDRESS:**
- **STREET 1:** 1941 STRYKER WAY
- **CITY:** PORTAGE
- **STATE:** MI
- **ZIP:** 49002
- **BUSINESS PHONE:** 2693852600

**MAIL ADDRESS:**
- **STREET 1:** 1941 STRYKER WAY
- **CITY:** PORTAGE
- **STATE:** MI
- **ZIP:** 49002

?xml version='1.0' encoding='ASCII'? syk-20260323

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of**

**the Securities Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant ⌧ Filed by a Party other than the Registrant □

Check the appropriate box:

□ Preliminary Proxy Statement

□ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

⌧ Definitive Proxy Statement

□ Definitive Additional Materials

□ Soliciting Material Pursuant to §240.14a-12

---

| |
|:---|
| **STRYKER CORPORATION** |
| (Name of Registrant as Specified In Its Charter) |

---

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)<br>

Payment of Filing Fee (Check all boxes that apply):

⌧ No fee required

□ Fee paid previously with preliminary materials

□ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(4) and 0-11

![stryker_logo2015a09.jpg](syk-20260323_g1.jpg)

**1941 Stryker Way** 

**Portage, MI 49002**

Notice of 2026 Annual Meeting of Shareholders of Stryker Corporation

**Date:**May 6, 2026

**Time:**12:00 p.m. Eastern Time

**Place:**This year's annual meeting of shareholders of Stryker Corporation will be held virtually via the internet only. Shareholders will

be able to listen, vote and submit questions regardless of location via the internet at www.virtualshareholdermeeting.com/SYK2026 by

using the 16-digit control number included on your notice regarding the availability of proxy materials, proxy card (printed in the box and

marked by the arrow) and the instructions that accompanied your proxy materials.

**Items of Business:** 

• Elect ten directors;

• Ratify appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026;

• Conduct an advisory vote to approve named executive officer compensation; and

• Transact any other business that may properly come before the meeting and any adjournment or postponement.

We invite all shareholders to attend the virtual meeting. At the meeting, you will have the opportunity to ask questions of our

management with respect to the matters to be voted on and will hear a report on our business. Stryker's accompanying proxy materials

include instructions on how to participate in the meeting and the means by which you may vote your shares and submit questions. Our

Annual Report on Form 10-K for the year ended December 31, 2025 is available at www.proxymaterials.stryker.com.

Only shareholders of record on March 9, 2026 may vote at the meeting.

Your vote is important. Please vote your shares promptly. To vote your shares, you may use the internet, call the toll-free telephone

number as described on your proxy card or complete, sign, date and return your proxy card by mail.

---

| | |
|:---|:---|
|  | Tina S. French |
|  | Vice President, Corporate Secretary |
| March 23, 2026 |  |

---

**IMPORTANT NOTICE REGARDING AVAILABILITY OF PROXY MATERIALS FOR THE SHAREHOLDERS MEETING ON MAY 6,** 

**2026.** This Proxy Statement, our 2025 Annual Report on Form 10-K and a link to the means to vote by internet are available at

www.proxymaterials.stryker.com.

![Image2.jpg](syk-20260323_g1.jpg)

![missionandvaluescroppeda05.jpg](syk-20260323_g2.jpg)

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **Section** | **Page** |
| **[Proxy Statement Summary](#i2547898784014edd82c5d43eb63a27de_19)** | [1](#i2547898784014edd82c5d43eb63a27de_19) |
| Meeting Information | [1](#i2547898784014edd82c5d43eb63a27de_22) |
| Shareholder Voting Matters | [1](#i2547898784014edd82c5d43eb63a27de_25) |
| Our Director Nominees and Board Characteristics | [1](#i2547898784014edd82c5d43eb63a27de_28) |
| Director Nominee Skills Matrix | [2](#i1fc4a4cfc23e4633b2f97ea3f2cb69a6_0-0-1-5-325133) |
| Corporate Governance Practices | [2](#i9aa2d019fb6b4357aac70e8c96552b18_0-0-1-5-325146) |
| Executive Compensation Philosophy | [2](#i8ea54edf253d4f28b2625e0d5187c1ae_0-0-1-5-325149) |
| Executive Compensation Practices | [3](#i35dbb74bb4044fe2bf86c8a571296872_0-0-1-5-325151) |
| Financial Performance | [4](#i14e86a07b35b43ca82bca69514796209_0-0-1-5-325153) |
| **[General Information](#i2547898784014edd82c5d43eb63a27de_37)** | [5](#i2547898784014edd82c5d43eb63a27de_34) |
| Who Is Entitled to Vote? | [5](#i507eb1e53bf14b089602bbbd55e6d79e_0-0-1-1-324596) |
| How Do I Vote? | [5](#i7dd3de2b44e14908bee2ded0a8b729c5_0-0-1-1-324596) |
| May I Change My Mind after Submitting a Proxy? | [5](#iaaf4e0a7f7ce4ea3b3a9c70b08747505_0-0-1-1-324596) |
| What are Broker Non-Votes? | [5](#i1c65646bdd3f4eee84bd2e7deae98efe_0-0-1-1-324596) |
| What is the Required Vote? | [5](#ic9633dc220ff4399aee41d355cfeebce_0-0-1-1-324596) |
| How Can I Attend the Annual Meeting? | [5](#i725fc7604dc04d8282ab785448cf3a4c_0-0-1-1-324596) |
| How Can I Submit a Question for the Annual Meeting? | [5](#i97062bb599b14825a67e87fcb2a46538_0-0-1-1-324596) |
| What if I Need Technical Assistance? | [5](#i5bb0f9681da240b7b7a079301bc1ec74_0-0-1-1-324596) |
| Can I Vote During the Annual Meeting? | [5](#ia43c0d703b4d4899ba2d5e20bd4e38d8_0-0-1-1-324596) |
| Will a Replay of the Annual Meeting be Available? | [6](#i75f37bf4137f41edbee8e516b88669ef_0-0-1-1-324596) |
| Can I Access These Proxy Materials on the Internet? | [6](#i5ed31aa44bce419a87967076cd7920eb_0-0-1-1-324596) |
| References to Stryker Websites | [6](#iccd85b62f47d4cdd811c1d53ccc34e07_0-0-1-1-324596) |
| **Cautionary Note Regarding Forward Looking Statements** | [6](#i5506a867bfe54b0c8f7f0fbd8683a68f_1969) |
| **Management Proposals** | [7](#i6647121f87f74f2ca5b98306c3e5c6bf_2395) |
| Proposal 1 — Election of Directors | [7](#i2547898784014edd82c5d43eb63a27de_43) |
| Proposal 2 — Ratification of Appointment of our Independent Registered Public Accounting Firm | [11](#i2547898784014edd82c5d43eb63a27de_52) |
| Proposal 3 — Advisory Vote to Approve Named Executive Officer Compensation | [12](#i2547898784014edd82c5d43eb63a27de_64) |
| **[Stock Ownership](#i2547898784014edd82c5d43eb63a27de_70)** | [13](#i2547898784014edd82c5d43eb63a27de_70) |
| Principal Shareholders | [13](#i723fd89f0da84309a59b9bc541d3a929_0-0-1-1-328021) |
| Security Ownership of Directors and Executive Officers | [14](#if4ee1f82d3a24489bb1fa6ad6c382186_0-0-1-1-328027) |
| **[Corporate Governance](#i2547898784014edd82c5d43eb63a27de_73)** | [15](#i2547898784014edd82c5d43eb63a27de_73) |
| Board's Role in Strategic Planning and Risk Oversight | [15](#i93b0c4775452428aaa4f7aa78b7af4b5_0-0-1-1-328031) |
| Independent Directors | [15](#i9db964d3bbc4436f8cba5a4d19e9266f_0-0-1-1-328033) |
| Board Committees | [15](#i6be893412b274df2bf4e3d1460ac13d1_0-0-1-1-328035) |
| Compensation Risks | [17](#i19e8df59cf664629a30b8392fea42164_0-0-1-1-328045) |
| Board Leadership Structure | [17](#ib5f4eaf500a44a92a8c78cef1c46a696_0-0-1-1-328048) |
| Executive Sessions of Independent Directors | [17](#ibdb5f41801a94c4396bbbdde8157a6a3_0-0-1-1-328050) |
| Contacting the Board of Directors | [17](#i998e024759604442bd215c44be5929c1_0-0-1-1-328052) |
| Code of Conduct | [17](#i0262d53dc9a947f7bdaafcc2212f6975_0-0-1-1-328054) |
| Certain Relationships and Related Party Transactions | [18](#i8dea90eefc244a8bbd7c665138556064_0-0-1-1-328056) |

---

---

| | |
|:---|:---|
| Approach to Corporate Responsibility | [18](#i564ce816b3ed46c2981a0b614bbdfc49_0-0-1-5-328058) |
| **[Compensation Discussion and Analysis](#i2547898784014edd82c5d43eb63a27de_79)** | [19](#i2547898784014edd82c5d43eb63a27de_79) |
| Named Executive Officers | [19](#i2db517447c7b4b838f487fd5ce8f853f_0-0-1-1-330526) |
| Overview | [19](#if12f65a5034545abb8a4c10582cc2dac_0-0-1-1-330534) |
| Compensation Objectives | [20](#i074fc6f6a28a4f03816ef57a6874c1b2_0-0-1-1-330536) |
| Executive Compensation Philosophy | [20](#i0837b9c6f8ba447eb21008bce79d7413_0-0-1-1-330538) |
| The Role of Benchmarking in Our Executive Compensation Decisions | [20](#i4371b8fb4ece45d5a786fcd901e098ab_0-0-1-1-330540) |
| Management's Role in Determining Executive Compensation | [21](#ibeae29ab741e49a09798f0945fa5436a_0-0-1-1-330542) |
| 2025 Compensation Decisions | [21](#iac39abfd30bf4c5ca99a51267b59f363_0-0-1-1-330544) |
| 2025 Compensation Elements | [22](#iabc0bd47dda9459786769bf3bb8fca0a_8107) |
| Impact of Decisions Regarding One Compensation Element on Decisions Regarding Other Compensation Elements | [29](#i5c6910ab159743d5a2af8d38251107ae_0-0-1-1-330550) |
| Equity Plans and Equity-Based Compensation Award Granting Policy | [29](#ib047c975ebb64729848700b0f21c38db_0-0-1-1-324596) |
| Executive and Non-Employee Director Stock Ownership Guidelines | [30](#i2d6c9855fa9b4a9eb35d319dc20db2e4_0-0-1-1-330553) |
| Prohibition of Hedging and Pledging Transactions | [30](#i24325e9c5a2e430bb50716b381f27efb_0-0-1-5-330558) |
| Recoupment and Clawback Policies | [31](#ib26d10aff31c4c40b20caf650f5334ac_0-0-1-1-330563) |
| Employment Agreements and Severance Policy | [31](#i88edcc7e61ad4c5db3972f3b667ca527_0-0-1-1-330565) |
| Company Tax and Accounting Issues | [31](#if15bd7e423b1464e996f767529776637_0-0-1-1-330567) |
| 2026 Compensation Decisions | [32](#iebd5f78570384dd9b41d5ae14df85eed_0-0-1-1-330569) |
| **[Compensation](#i2547898784014edd82c5d43eb63a27de_97) and Human Capital Committee Report** | [32](#i2547898784014edd82c5d43eb63a27de_97) |
| **[Executive Compensation](#i2547898784014edd82c5d43eb63a27de_100)** | [33](#i2547898784014edd82c5d43eb63a27de_100) |
| Summary Compensation Table | [33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571) |
| 2025 Grants of Plan-Based Awards | [35](#i04b4cb419c7249599c0f265898451cd9_0-0-1-1-330585) |
| Outstanding Equity Awards at 2025 Fiscal Year-End | [36](#ic0cd64def30f4b9b98a78bce35449f1d_0-0-1-1-330590) |
| 2025 Option Exercises and Stock Vested | [38](#i43d09e69b42c45fe91dd1b4377e7a87d_0-0-1-1-330595) |
| 2025 Pension Benefits | [38](#i9d48774485f5413f95f31448c553575c_0-0-1-1-330600) |
| 2025 Nonqualified Deferred Compensation | [38](#i2c66a95ccadd4629b72915da36e7a71f_0-0-1-1-330605) |
| Potential Payments upon Termination or Change in Control | [39](#icf7002e7decd44ec864d19d2a8323e11_0-0-1-1-330610) |
| Pay versus Performance | [41](#i0912500d9829442d920c3cba89f802ac_0-0-1-1-330615) |
| Ratio of 2025 Compensation of the Chief Executive Officer to that of the Median Employee | [43](#i79093ffa849140228e6489ca366d03ae_0-0-1-1-330624) |
| **[Compensation of Directors](#i2547898784014edd82c5d43eb63a27de_103)** | [44](#i2547898784014edd82c5d43eb63a27de_103) |
| **[Audit Committee Report](#i2547898784014edd82c5d43eb63a27de_106)** | [46](#i2547898784014edd82c5d43eb63a27de_106) |
| **[Additional Information](#i2547898784014edd82c5d43eb63a27de_109)** | [47](#i2547898784014edd82c5d43eb63a27de_109) |
| Proposals for Inclusion in our 2027 Proxy Materials (SEC Rule 14a-8) | [47](#i76d81d805f7d43e6874ad9e375c592ae_0-0-1-1-328060) |
| Director Nominations for Inclusion in our 2027 Proxy Materials (Proxy Access) | [47](#i8be4116cfd1f41be8d9b212fae2e8189_0-0-1-5-328068) |
| Other Proposals or Nominations to be Brought Before our 2027 Annual Meeting (Advance Notice) | [47](#i40565b2489914d3d94a589a2eac5f7dc_0-0-1-5-328070) |
| Delinquent Section 16(a) Reports | [47](#icf2a33bf1396416da2edb4b7d9e8a50c_0-0-1-1-328072) |
| Other Matters | [47](#i5edfe1c428cd4cb0a1cea2fe690e24e5_0-0-1-1-328074) |
| Expenses of Solicitation | [47](#i53ac9a871f104b80a6ffef8cc1190b77_0-0-1-1-328076) |
| Householding | [47](#i74e77100eb2d4222a30b4a6b082ad92e_0-0-1-5-328078) |
| **Appendix A [—](#i2547898784014edd82c5d43eb63a27de_112)Reconciliation of the Most Directly Comparable GAAP Measure to Non-GAAP Financial Measure** | [A-1](#i2547898784014edd82c5d43eb63a27de_112) |

---

PROXY STATEMENT SUMMARY

This summary is intended to provide a broad overview of important information you will find elsewhere in this Proxy Statement and <br>does not contain all the information you should consider. We encourage you to read the entire Proxy Statement before voting.<br>

---

| |
|:---|
| **Meeting Information** |
| **Date and Time** |
| May 6, 2026 at 12:00 p.m. Eastern Time. This year's annual meeting will be held virtually via the internet. See page <u>[5](#i2547898784014edd82c5d43eb63a27de_34)</u> for information <br>on how to attend the meeting.<br>|

---

---

| | | |
|:---|:---|:---|
| **Shareholder Voting Matters** | **Shareholder Voting Matters** | **Shareholder Voting Matters** |
| **Matter** | **Board Vote** <br>**Recommendation**<br>| **See Page** |
| <u>Management Proposals</u> | <u>Management Proposals</u> | <u>Management Proposals</u> |
| Proposal 1 — Election of Directors | For each nominee | [7](#i2547898784014edd82c5d43eb63a27de_43) |
| Proposal 2 — Ratify Appointment of Independent Registered Public Accounting Firm | For | [11](#i2547898784014edd82c5d43eb63a27de_52) |
| Proposal 3 — Advisory Vote to Approve Named Executive Officer Compensation | For | [12](#i2547898784014edd82c5d43eb63a27de_64) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Our Director Nominees and Board Characteristics** | **Our Director Nominees and Board Characteristics** | **Our Director Nominees and Board Characteristics** | **Our Director Nominees and Board Characteristics** | **Our Director Nominees and Board Characteristics** |
| **Name** | **Age\*** | **Director Since** | **Independent** | **Committee Membership**<sup>(3)</sup> |
| Mary K. Brainerd | 72 | 2017 | Yes | Comp&HC, G&N (Chair) |
| Giovanni Caforio, M.D. | 61 | 2020 | Yes | Comp&HC (Chair), G&N |
| Kevin A. Lobo<sup>(1)</sup> | 60 | 2012 | No |  |
| Emmanuel P. Maceda | 63 | 2025 | Yes | Comp&HC, G&N |
| Sherilyn S. McCoy<sup>(2)</sup> | 67 | 2018 | Yes | Comp&HC, G&N |
| Rachel M. Ruggeri | 56 | 2024 | Yes | Audit |
| Andrew K. Silvernail | 55 | 2013 | Yes | Audit (Chair) |
| Lisa M. Skeete Tatum | 58 | 2020 | Yes | Audit |
| Ronda E. Stryker | 71 | 1984 | Yes | G&N |
| Rajeev Suri | 58 | 2018 | Yes | Audit |

---

_________________

\*Age is as of the date of the 2026 Annual Meeting

(1) Chair of the Board and Chief Executive Officer

(2) Lead Independent Director

(3) Audit = Audit Committee, Comp&HC = Compensation and Human Capital Committee, G&N = Governance and Nominating Committee

**Director Nominee Skills Matrix** <br>

Our directors have diverse experience and a wide variety of backgrounds, skills, qualifications and viewpoints that strengthen their

ability to carry out their oversight role. The following matrix is provided to illustrate director nominees' key skills, knowledge and

experience. The matrix does not encompass all of their knowledge, skills and experience, and the fact that a particular area of

knowledge, skill or experience is not listed does not mean that a director nominee does not possess it or that he or she is unable to

contribute to the decision-making process in that area. More information on a director nominee's background can be found in each of

their profiles under Proposal 1.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Brainerd | Caforio | Lobo | Maceda | McCoy | Ruggeri | Silvernail | Skeete <br>Tatum<br>| Stryker | Suri |
| Accounting/Financial Literacy | •  |  | •  |  |  | •  | •  | •  |  | •  |
| Information Technology/<br>Cybersecurity<br>| •  | •  |  | •  |  | •  |  | •  |  | •  |
| Human Capital Management | •  | •  |  | •  | •  | •  | •  | •  | •  | •  |
| Healthcare Industry | •  | •  | •  |  | •  |  |  | •  | •  |  |
| Mergers and Acquisitions | •  | •  | •  | •  | •  |  | •  | •  | •  | •  |
| Global Markets and International <br>Business<br>|  | •  | •  | •  | •  | •  | •  | •  |  | •  |
| Manufacturing and Supply Chain |  |  | •  | •  |  | •  | •  |  |  |  |
| Public Company Executive <br>Experience<br>|  | •  | •  |  | •  | •  | •  |  |  | •  |
| Strategy and Innovation | •  | •  | •  | •  | •  | •  | •  | •  | •  | •  |
| Corporate Responsibility and <br>Sustainability<br>| •  |  |  | •  | •  |  |  |  | •  |  |
| Legal/Risk Management/<br>Governance<br>|  |  | •  |  |  |  |  |  | •  |  |

---

**Corporate Governance Practices**<br>

Stryker Corporation (the "Company" or "Stryker") is committed to exercising good corporate governance. Our policies and practices in

this regard include the following:

• All directors elected annually.

• Majority voting in uncontested elections, coupled with a resignation policy.

• Robust Lead Independent Director position with clearly defined duties and significant responsibilities related to Board functioning,

leadership and governance.

• All directors are independent other than the Chair and Chief Executive Officer.

• Regular executive sessions of independent directors.

• All members of Board Committees are independent.

• Multiple members of our Audit Committee are "audit committee financial experts" pursuant to the United States Securities and

Exchange Commission ("SEC") rules.

• Regular Board refreshment, including the appointment of two new independent directors in the last two years.

• Annual Board and Committee self-evaluations.

• Annual independent director evaluation of the Chair and Chief Executive Officer.

• All directors are in compliance with the overboarding policy set forth in our Corporate Governance Guidelines.

• Active Board and Committee oversight of risk and risk management.

• Independent Board Committee oversight of corporate responsibility, which includes sustainability, environmental, social and

governance topics, with regular presentations to the Governance and Nominating Committee.

• Independent Board Committee oversight of cybersecurity, with regular presentations to directors.

• No "poison pill" takeover defense plan.

• Proxy access right for shareholders.

• Shareholders' right to call special shareholder meetings.

**Executive Compensation Philosophy**<br>

Our executive compensation programs are a key component of our ability to attract, motivate and retain talented, qualified executives.

Our programs are designed to provide a meaningful level of total compensation that is aligned with organizational and individual

performance and with the interests of our shareholders in line with the following principles and practices:

• We monitor a comparison group of medical technology and other related companies to ensure that our compensation programs

are generally within observed competitive practices.

• We aim to provide market competitive total direct compensation consisting of base salary, annual bonus and long-term equity

incentives (stock awards).

• We emphasize pay for performance. In 2025, the value of the variable performance and stock-based compensation for our

Named Executive Officers ("NEOs") that received a grant of stock awards in 2025 averaged 87% of total direct compensation.

• Our annual and long-term incentives align the interests of our executives with those of our shareholders, utilizing challenging

performance goals that should result in profitable, sustained business growth over the long term as well as stock price increases

over time.

• We regularly evaluate our executive compensation programs to ensure that they do not encourage excessive risk taking.

• Our stock ownership guidelines reflect our conviction that our senior executives and non-employee directors should have

meaningful share ownership positions in the Company to reinforce the alignment of the interests of our management and

shareholders.

• Our recoupment policy applies to all cash and equity incentive awards (including all time-vesting equity awards) and payments

made to our elected corporate officers after 2014 in the event of either a material restatement of our financial statements as a

result of misconduct or an officer's material misconduct or negligence that results in a material violation of a law or regulation or

material Company policy.

• In October 2023, our Board adopted a separate, mandatory clawback policy regarding accounting restatements in connection

with the SEC's adoption of new rules to implement Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection

Act of 2010 and corresponding New York Stock Exchange ("NYSE") listing standards.

• We hold an annual advisory vote regarding NEO compensation, which in 2025 resulted in an approximately 92% favorable vote.

**Executive Compensation Practices**<br>

Stryker employs a number of practices that reflect our executive compensation philosophy as it relates to our NEOs and other executive

officers, including the following:

• Our Compensation and Human Capital Committee retains an independent compensation consultant that reports solely to it.

• We link the majority of NEO compensation to Company performance.

• We balance short-term and long-term incentives.

• We cap payouts of incentive awards.

• Our guidelines require significant stock ownership and prohibit hedging and pledging transactions.

• We provide limited perquisites and personal benefits to our NEOs.

• We do not have employment or severance agreements.

• We do not allow for contractual change-in-control payments.

• We do not pay tax gross-ups (unless pursuant to our relocation and expatriate assignment practices).

• We do not reprice, exchange or buy out stock options.

**Financial Performance**<br>

---

| | |
|:---|:---|
| **Net Sales** | **Net Earnings** |
| $ in billions | $ per diluted share |

---

![9](syk-20260323_g3.gif)

![10](syk-20260323_g4.gif)

---

| | |
|:---|:---|
| **Adjusted Net Earnings**<sup>(1)</sup> | **Dividends Paid** |
| $ per diluted share | $ per share of common stock |

---

![14](syk-20260323_g5.gif)

![15](syk-20260323_g6.gif)

---

| | | | |
|:---|:---|:---|:---|
| **Financial Overview** |  |  |  |
| (in millions, except per share amounts) | **2025** | **2024** | **% Change** |
| **Net sales** | $25116 | $22595 | 11.2 |
| **Earnings before income taxes** | 4514 | 3492 | 29.3 |
| **Income taxes** | 1268 | 499 | 154.1 |
| **Net earnings** | 3246 | 2993 | 8.5 |
| **Adjusted net earnings**<sup>(1)</sup> | 5267 | 4700 | 12.1 |
| **Net earnings per diluted share of common stock:** |  |  |  |
| **Reported** | 8.40 | 7.76 | 8.2 |
| **Adjusted**<sup>(1)</sup> | 13.63 | 12.19 | 11.8 |
| **Dividends paid per share of common stock** | 3.36 | 3.20 | 5.0 |
| **Cash, cash equivalents, and marketable securities** | 4100 | 3743 | 9.5 |

---

______________

(1) Adjusted net earnings and adjusted net earnings per diluted share are non-GAAP financial measures. Refer to "Appendix A [—](#i2547898784014edd82c5d43eb63a27de_112)Reconciliation of the

Most Directly Comparable GAAP Measure to Non-GAAP Financial Measure" for additional information.

GENERAL INFORMATION

We are providing these proxy materials in connection with the

solicitation by the Board of Directors of proxies to be used during

the annual meeting of shareholders of Stryker to be held on

May 6, 2026 and at any adjournment or postponement of the

meeting. The solicitation will begin on or about March 23, 2026.

**Who Is Entitled to Vote?**<br>

At the close of business on March 9, 2026, the record date for the

meeting, 382,984,253 shares of our common stock, $0.10 par

value ("Common Stock"), were outstanding. For each proposal to

be voted on, each shareholder is entitled to one vote for each

share of Common Stock owned at the record date.

**How Do I Vote?**<br>

If you are a shareholder of record, you may vote by proxy in any

of the following ways:

• By Internet or Telephone — If you have internet or telephone

access, you may submit your proxy by following the voting

instructions on the proxy card. If you vote by internet or

telephone, you should not return your proxy card if you

received a paper copy as well.

• By Mail — If you elected to receive a paper copy of your proxy

card, you may vote by mail by completing, dating and signing

your proxy card and mailing it in the envelope provided. You

must sign your name exactly as it appears on the proxy card. If

you are signing in a representative capacity (for example, as

officer of a corporation, guardian, executor, trustee or

custodian), you must indicate your name and title or capacity.

If you vote via the internet or by telephone, your vote must be

received by 11:59 p.m., Eastern Time, on May 5, 2026.

You may also vote during the annual meeting via the internet at

www.virtualshareholdermeeting.com/SYK2026. At this site, you

will be able to vote electronically. You also will be able to submit

questions in writing during the annual meeting.

If your shares are held in a stock brokerage account or by a bank

or other holder of record, you are considered the beneficial owner

of shares held in "street name." The street name holder will

provide you with instructions that you must follow to have your

shares voted.

If you hold your shares in street name and you wish to vote

during the meeting, you must obtain a proxy issued in your name

from the street name holder.

**May I Change My Mind after Submitting a Proxy?**<br>

If you are a shareholder of record, you may revoke your proxy

before it is exercised by:

• Written notice to the Vice President, Corporate Secretary of the

Company at 1941 Stryker Way, Portage, Michigan 49002;

• Timely delivery of a valid, later-dated proxy or later-dated vote

by internet or telephone; or

• Voting during the annual meeting.

If you are a beneficial owner of shares held in street name, you

may submit new voting instructions by contacting your brokerage

firm, bank or other holder of record.

**What are Broker Non-Votes?**<br>

A broker non-vote occurs when the broker, bank or other holder

of record that holds your shares in street name is not entitled to

vote on a matter without instruction from you and you do not give

any instruction. Unless instructed otherwise by you, brokers,

banks and other street name holders will have discretionary

authority to vote only on Proposal 2 (ratification of the

appointment of Ernst & Young LLP as our independent registered

public accounting firm for 2026).

**What is the Required Vote?**<br>

In the election of directors, a director nominee will be elected only

if he or she receives a majority of the votes cast with respect to

his or her election (that is, the number of votes cast "for" a

director nominee must exceed the number of votes cast "against"

that nominee). On all other matters, the vote required to pass is

the affirmative vote of a majority of the votes cast. Abstentions

and broker non-votes will not be counted as votes cast and will

therefore have no effect on the outcome of any of the matters.

**How Can I Attend the Annual Meeting?**<br>

To attend the annual meeting, log in at

www.virtualshareholdermeeting.com/SYK2026. Shareholders will

need their unique control number which appears on the notice

regarding the availability of proxy materials, the proxy card

(printed in the box and marked by the arrow) and the instructions

that accompany the proxy materials. In the event that you do not

have a control number, please contact your broker, bank or other

nominee as soon as possible so that you can be provided with a

control number and gain access to the meeting.

**How Can I Submit a Question for the Annual Meeting?**<br>

By accessing www.proxyvote.com, our shareholders will be able

to submit questions in writing in advance of the annual meeting,

vote, view the annual meeting procedures, and obtain copies of

proxy materials and our 2025 Annual Report on Form 10-K.

Shareholders also may submit questions in writing on the day of

or during the annual meeting at

www.virtualshareholdermeeting.com/SYK2026. Shareholders will

need their unique control number which appears on the notice

regarding the availability of proxy materials, the proxy card

(printed in the box and marked by the arrow) and the instructions

that accompanied the proxy materials.

As part of the annual meeting, we will hold a live question and

answer session, during which we intend to answer all questions

submitted in writing before or during the meeting in accordance

with the annual meeting procedures which are pertinent to

Stryker and the meeting matters, as time permits. Answers to any

questions submitted in writing before or during the meeting in

accordance with the annual meeting procedures which are

pertinent to Stryker and the meeting matters that are not

addressed during the meeting will be published following the

meeting on our website at www.proxymaterials.stryker.com.

Questions and answers will be grouped by topic and substantially

similar questions will be grouped and answered once.

**What if I Need Technical Assistance?**<br>

During the registration period, which begins 30 minutes prior to

the start of the annual meeting, we will have a support team

ready to assist shareholders with any technical difficulties they

may have accessing or hearing the virtual meeting. If you

encounter any technical difficulties accessing the virtual meeting

during the check-in time, you can call our support team using the

numbers provided on the meeting site.

**Can I Vote During the Annual Meeting?**<br>

Yes. To log in to the annual meeting and to cast your vote

electronically during the meeting, you will need the unique control

number which appears on the notice regarding the availability of

proxy materials, the proxy card (printed in the box and marked by

the arrow) and the instructions that accompany the proxy

materials. In the event that you do not have a control number,

please contact your broker, bank or other nominee as soon as

possible so that you can be provided with a control number.

**Will a Replay of the Annual Meeting be Available?**<br>

A replay of the annual meeting will be made publicly available

beginning 24 hours after the meeting at

www.virtualshareholdermeeting.com/SYK2026 until the definitive

proxy statement for our 2027 annual meeting of shareholders is

filed with the SEC.

**Can I Access These Proxy Materials on the Internet?**<br>

This Proxy Statement, our 2025 Annual Report on Form 10-K and

a link to the means to vote by internet are available at

www.proxymaterials.stryker.com.

**References to Stryker Websites**<br>

References to Stryker websites are for informational purposes

only. Information contained on, or accessible through, such

websites is not incorporated by reference into, and does not

constitute a part of, this Proxy Statement.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Proxy Statement contains statements that are not historical facts and are considered "forward-looking statements" within the

meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current projections about operations,

industry conditions, financial condition and liquidity. Words that identify forward-looking statements include, without limitation, words

such as "may," "could," "will," "should," "possible," "plan," "predict," "forecast," "potential," "anticipate," "estimate," "expect," "project,"

"intend," "believe," "may impact," "on track," "goal," "strategy" and words and terms of similar substance used in connection with any

discussion of future operating or financial performance, an acquisition or our businesses. In addition, any statements that refer to

expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are

forward-looking statements. Those statements are not guarantees and are subject to risks, uncertainties and assumptions that are

difficult to predict. Therefore, actual results could differ materially and adversely from these forward-looking statements, historical

experience or our present expectations. A detailed discussion of risks, uncertainties and changes in circumstances that could cause

actual results and events to differ materially from such forward-looking statements is included in our filings with the SEC, including in

the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025. We disclaim any intention or

obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or

circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained

in the forward-looking statements.

MANAGEMENT PROPOSALS

**Proposal 1 — Election of Directors**<br>

Ten directors are to be elected to serve until the next annual meeting of shareholders and until their successors have been duly elected

and qualified. All of the nominees listed below are currently members of our Board of Directors. The nominees have consented to serve

if elected, and we have no reason to believe that any of them will be unable to serve. If any nominee becomes unavailable for any

reason, proxies will be voted for the alternate candidate, if any, chosen by the Board or the number of directors constituting the full

Board will be reduced to eliminate the vacancy.

The proxies will be voted for the election of each of the nominees unless instructed otherwise. **The Board recommends that** 

**shareholders vote FOR all nominees in Proposal 1.**

Our Restated Articles of Incorporation provide that a director nominee will be elected only if he or she receives a majority of the votes

cast in an uncontested election (that is, the number of shares voted "for" a director nominee must exceed the number of votes cast

"against" that nominee). If a nominee who is currently serving as a director is not re-elected, Michigan law provides that the director

would continue to serve as a "holdover director." Accordingly, under our Corporate Governance Guidelines, each director has submitted

an advance, contingent, irrevocable resignation that may be accepted if the shareholders do not re-elect the director. In that situation,

the Governance and Nominating Committee will promptly consider the resignation and recommend to the Board whether to accept the

resignation or reject it. The Board will act on the Governance and Nominating Committee's recommendation no later than 90 days after

certification of the election results. The Company will promptly publicly disclose in a filing with the SEC the Board's decision whether to

accept or reject the resignation and, if applicable, the reasons for rejecting the tendered resignation. If one or more resignations are

accepted by the Board, the Governance and Nominating Committee will recommend to the Board whether to fill the vacancy or

vacancies or reduce the size of the Board.

Set forth below are the nominees for election as directors that were approved by the Board following the recommendation of our

Governance and Nominating Committee.

---

| | |
|:---|:---|
| **Mary K. Brainerd** | **Mary K. Brainerd** |
| ![Brainerd, Mary_2 resize2.jpg](syk-20260323_g7.jpg) | **Experience** |
| ![Brainerd, Mary_2 resize2.jpg](syk-20260323_g7.jpg) | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |
| ![Brainerd, Mary_2 resize2.jpg](syk-20260323_g7.jpg) | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |
| ![Brainerd, Mary_2 resize2.jpg](syk-20260323_g7.jpg) | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |
| ![Brainerd, Mary_2 resize2.jpg](syk-20260323_g7.jpg) | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |
| ![Brainerd, Mary_2 resize2.jpg](syk-20260323_g7.jpg) | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |
| **Director Since: 2017** | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |
| **Age: 72** | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |
|  | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |
|  | •President and Chief Executive Officer of HealthPartners (2002-2017)<br>•Various leadership roles with HealthPartners (1992-2002)<br>•Various leadership roles with Blue Cross and Blue Shield of Minnesota (1984-1992)<br>**Other Affiliations**<br>•Director, Bremer Financial Corporation<br>•Director, Securian Financial<br>•Vice Chair, The Nature Conservancy, Minnesota-North Dakota-South Dakota<br>•Director, The Opus Group<br>**Stryker Board Committees**<br>•Compensation and Human Capital<br>•Governance and Nominating |

---

---

| | |
|:---|:---|
| **Giovanni Caforio, M.D.** | **Giovanni Caforio, M.D.** |
| ![Caforio, Giovanni_2 resize.jpg](syk-20260323_g8.jpg) | **Experience** |
| ![Caforio, Giovanni_2 resize.jpg](syk-20260323_g8.jpg) | •Chief Executive Officer, Bristol-Myers Squibb (2015-2023); Chairman of the Board (2017-2024)<br>•Various leadership roles with Bristol-Myers Squibb (2000-2015)<br>**Other Affiliations**<br>•Chair of the Board, Novartis AG<br>•Director, Pharmaceutical Research and Manufacturers of America<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![Caforio, Giovanni_2 resize.jpg](syk-20260323_g8.jpg) | •Chief Executive Officer, Bristol-Myers Squibb (2015-2023); Chairman of the Board (2017-2024)<br>•Various leadership roles with Bristol-Myers Squibb (2000-2015)<br>**Other Affiliations**<br>•Chair of the Board, Novartis AG<br>•Director, Pharmaceutical Research and Manufacturers of America<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![Caforio, Giovanni_2 resize.jpg](syk-20260323_g8.jpg) | •Chief Executive Officer, Bristol-Myers Squibb (2015-2023); Chairman of the Board (2017-2024)<br>•Various leadership roles with Bristol-Myers Squibb (2000-2015)<br>**Other Affiliations**<br>•Chair of the Board, Novartis AG<br>•Director, Pharmaceutical Research and Manufacturers of America<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![Caforio, Giovanni_2 resize.jpg](syk-20260323_g8.jpg) | •Chief Executive Officer, Bristol-Myers Squibb (2015-2023); Chairman of the Board (2017-2024)<br>•Various leadership roles with Bristol-Myers Squibb (2000-2015)<br>**Other Affiliations**<br>•Chair of the Board, Novartis AG<br>•Director, Pharmaceutical Research and Manufacturers of America<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![Caforio, Giovanni_2 resize.jpg](syk-20260323_g8.jpg) | •Chief Executive Officer, Bristol-Myers Squibb (2015-2023); Chairman of the Board (2017-2024)<br>•Various leadership roles with Bristol-Myers Squibb (2000-2015)<br>**Other Affiliations**<br>•Chair of the Board, Novartis AG<br>•Director, Pharmaceutical Research and Manufacturers of America<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| **Director Since: 2020** | •Chief Executive Officer, Bristol-Myers Squibb (2015-2023); Chairman of the Board (2017-2024)<br>•Various leadership roles with Bristol-Myers Squibb (2000-2015)<br>**Other Affiliations**<br>•Chair of the Board, Novartis AG<br>•Director, Pharmaceutical Research and Manufacturers of America<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| **Age: 61** | •Chief Executive Officer, Bristol-Myers Squibb (2015-2023); Chairman of the Board (2017-2024)<br>•Various leadership roles with Bristol-Myers Squibb (2000-2015)<br>**Other Affiliations**<br>•Chair of the Board, Novartis AG<br>•Director, Pharmaceutical Research and Manufacturers of America<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
|  | •Chief Executive Officer, Bristol-Myers Squibb (2015-2023); Chairman of the Board (2017-2024)<br>•Various leadership roles with Bristol-Myers Squibb (2000-2015)<br>**Other Affiliations**<br>•Chair of the Board, Novartis AG<br>•Director, Pharmaceutical Research and Manufacturers of America<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |

---

---

| | |
|:---|:---|
| **Kevin A. Lobo, Chair and Chief Executive Officer** | **Kevin A. Lobo, Chair and Chief Executive Officer** |
| ![KevinLobo-V2 v.1 resize2.jpg](syk-20260323_g9.jpg) | **Experience** |
| ![KevinLobo-V2 v.1 resize2.jpg](syk-20260323_g9.jpg) | •Chair and Chief Executive Officer, Stryker (2018-2021, January 2026-present); Chair, Chief Executive <br>Officer and President (2014-2018, 2021-2025); Chief Executive Officer and President (2012-2014) <br>•Group President, Stryker Orthopaedics (2011-2012) <br>•Various leadership roles with Johnson & Johnson (2003-2011)<br>**Other Affiliations**<br>•Director, The Advanced Medical Technology Association (AdvaMed)<br>•GE Healthcare Technologies Inc.<br>•Director, Parker-Hannifin Corporation\*<br>•Chair, Valley Health System Board of Trustees<br>\*<br>\* Mr. Lobo has informed Parker-Hannifin that he will not stand for reelection to its Board of Directors at <br>Parker-Hannifin's 2026 Annual Meeting of Shareholders.  |
| ![KevinLobo-V2 v.1 resize2.jpg](syk-20260323_g9.jpg) | •Chair and Chief Executive Officer, Stryker (2018-2021, January 2026-present); Chair, Chief Executive <br>Officer and President (2014-2018, 2021-2025); Chief Executive Officer and President (2012-2014) <br>•Group President, Stryker Orthopaedics (2011-2012) <br>•Various leadership roles with Johnson & Johnson (2003-2011)<br>**Other Affiliations**<br>•Director, The Advanced Medical Technology Association (AdvaMed)<br>•GE Healthcare Technologies Inc.<br>•Director, Parker-Hannifin Corporation\*<br>•Chair, Valley Health System Board of Trustees<br>\*<br>\* Mr. Lobo has informed Parker-Hannifin that he will not stand for reelection to its Board of Directors at <br>Parker-Hannifin's 2026 Annual Meeting of Shareholders.  |
| ![KevinLobo-V2 v.1 resize2.jpg](syk-20260323_g9.jpg) | •Chair and Chief Executive Officer, Stryker (2018-2021, January 2026-present); Chair, Chief Executive <br>Officer and President (2014-2018, 2021-2025); Chief Executive Officer and President (2012-2014) <br>•Group President, Stryker Orthopaedics (2011-2012) <br>•Various leadership roles with Johnson & Johnson (2003-2011)<br>**Other Affiliations**<br>•Director, The Advanced Medical Technology Association (AdvaMed)<br>•GE Healthcare Technologies Inc.<br>•Director, Parker-Hannifin Corporation\*<br>•Chair, Valley Health System Board of Trustees<br>\*<br>\* Mr. Lobo has informed Parker-Hannifin that he will not stand for reelection to its Board of Directors at <br>Parker-Hannifin's 2026 Annual Meeting of Shareholders.  |
| ![KevinLobo-V2 v.1 resize2.jpg](syk-20260323_g9.jpg) | •Chair and Chief Executive Officer, Stryker (2018-2021, January 2026-present); Chair, Chief Executive <br>Officer and President (2014-2018, 2021-2025); Chief Executive Officer and President (2012-2014) <br>•Group President, Stryker Orthopaedics (2011-2012) <br>•Various leadership roles with Johnson & Johnson (2003-2011)<br>**Other Affiliations**<br>•Director, The Advanced Medical Technology Association (AdvaMed)<br>•GE Healthcare Technologies Inc.<br>•Director, Parker-Hannifin Corporation\*<br>•Chair, Valley Health System Board of Trustees<br>\*<br>\* Mr. Lobo has informed Parker-Hannifin that he will not stand for reelection to its Board of Directors at <br>Parker-Hannifin's 2026 Annual Meeting of Shareholders.  |
| ![KevinLobo-V2 v.1 resize2.jpg](syk-20260323_g9.jpg) | •Chair and Chief Executive Officer, Stryker (2018-2021, January 2026-present); Chair, Chief Executive <br>Officer and President (2014-2018, 2021-2025); Chief Executive Officer and President (2012-2014) <br>•Group President, Stryker Orthopaedics (2011-2012) <br>•Various leadership roles with Johnson & Johnson (2003-2011)<br>**Other Affiliations**<br>•Director, The Advanced Medical Technology Association (AdvaMed)<br>•GE Healthcare Technologies Inc.<br>•Director, Parker-Hannifin Corporation\*<br>•Chair, Valley Health System Board of Trustees<br>\*<br>\* Mr. Lobo has informed Parker-Hannifin that he will not stand for reelection to its Board of Directors at <br>Parker-Hannifin's 2026 Annual Meeting of Shareholders.  |
| **Director Since: 2012** | •Chair and Chief Executive Officer, Stryker (2018-2021, January 2026-present); Chair, Chief Executive <br>Officer and President (2014-2018, 2021-2025); Chief Executive Officer and President (2012-2014) <br>•Group President, Stryker Orthopaedics (2011-2012) <br>•Various leadership roles with Johnson & Johnson (2003-2011)<br>**Other Affiliations**<br>•Director, The Advanced Medical Technology Association (AdvaMed)<br>•GE Healthcare Technologies Inc.<br>•Director, Parker-Hannifin Corporation\*<br>•Chair, Valley Health System Board of Trustees<br>\*<br>\* Mr. Lobo has informed Parker-Hannifin that he will not stand for reelection to its Board of Directors at <br>Parker-Hannifin's 2026 Annual Meeting of Shareholders.  |
| **Age: 60** | •Chair and Chief Executive Officer, Stryker (2018-2021, January 2026-present); Chair, Chief Executive <br>Officer and President (2014-2018, 2021-2025); Chief Executive Officer and President (2012-2014) <br>•Group President, Stryker Orthopaedics (2011-2012) <br>•Various leadership roles with Johnson & Johnson (2003-2011)<br>**Other Affiliations**<br>•Director, The Advanced Medical Technology Association (AdvaMed)<br>•GE Healthcare Technologies Inc.<br>•Director, Parker-Hannifin Corporation\*<br>•Chair, Valley Health System Board of Trustees<br>\*<br>\* Mr. Lobo has informed Parker-Hannifin that he will not stand for reelection to its Board of Directors at <br>Parker-Hannifin's 2026 Annual Meeting of Shareholders.  |
|  | •Chair and Chief Executive Officer, Stryker (2018-2021, January 2026-present); Chair, Chief Executive <br>Officer and President (2014-2018, 2021-2025); Chief Executive Officer and President (2012-2014) <br>•Group President, Stryker Orthopaedics (2011-2012) <br>•Various leadership roles with Johnson & Johnson (2003-2011)<br>**Other Affiliations**<br>•Director, The Advanced Medical Technology Association (AdvaMed)<br>•GE Healthcare Technologies Inc.<br>•Director, Parker-Hannifin Corporation\*<br>•Chair, Valley Health System Board of Trustees<br>\*<br>\* Mr. Lobo has informed Parker-Hannifin that he will not stand for reelection to its Board of Directors at <br>Parker-Hannifin's 2026 Annual Meeting of Shareholders.  |

---

---

| | |
|:---|:---|
| **Emmanuel P. Maceda**  | **Emmanuel P. Maceda**  |
| ![Maceda, Manny_1 resize.jpg](syk-20260323_g10.jpg) | **Experience** |
| ![Maceda, Manny_1 resize.jpg](syk-20260323_g10.jpg) | •Chair, Bain & Company (2025-present)<br>•Worldwide Managing Partner and CEO, Bain & Company (2018-2024)<br>•Various leadership roles with Bain & Company (1989-2018)<br>**Other Affiliations**<br>•Board of Trustees, The Bridgespan Group<br>•Director, Ayala Corporation<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![Maceda, Manny_1 resize.jpg](syk-20260323_g10.jpg) | •Chair, Bain & Company (2025-present)<br>•Worldwide Managing Partner and CEO, Bain & Company (2018-2024)<br>•Various leadership roles with Bain & Company (1989-2018)<br>**Other Affiliations**<br>•Board of Trustees, The Bridgespan Group<br>•Director, Ayala Corporation<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![Maceda, Manny_1 resize.jpg](syk-20260323_g10.jpg) | •Chair, Bain & Company (2025-present)<br>•Worldwide Managing Partner and CEO, Bain & Company (2018-2024)<br>•Various leadership roles with Bain & Company (1989-2018)<br>**Other Affiliations**<br>•Board of Trustees, The Bridgespan Group<br>•Director, Ayala Corporation<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![Maceda, Manny_1 resize.jpg](syk-20260323_g10.jpg) | •Chair, Bain & Company (2025-present)<br>•Worldwide Managing Partner and CEO, Bain & Company (2018-2024)<br>•Various leadership roles with Bain & Company (1989-2018)<br>**Other Affiliations**<br>•Board of Trustees, The Bridgespan Group<br>•Director, Ayala Corporation<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![Maceda, Manny_1 resize.jpg](syk-20260323_g10.jpg) | •Chair, Bain & Company (2025-present)<br>•Worldwide Managing Partner and CEO, Bain & Company (2018-2024)<br>•Various leadership roles with Bain & Company (1989-2018)<br>**Other Affiliations**<br>•Board of Trustees, The Bridgespan Group<br>•Director, Ayala Corporation<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| **Director Since: 2025** | •Chair, Bain & Company (2025-present)<br>•Worldwide Managing Partner and CEO, Bain & Company (2018-2024)<br>•Various leadership roles with Bain & Company (1989-2018)<br>**Other Affiliations**<br>•Board of Trustees, The Bridgespan Group<br>•Director, Ayala Corporation<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| **Age: 63** | •Chair, Bain & Company (2025-present)<br>•Worldwide Managing Partner and CEO, Bain & Company (2018-2024)<br>•Various leadership roles with Bain & Company (1989-2018)<br>**Other Affiliations**<br>•Board of Trustees, The Bridgespan Group<br>•Director, Ayala Corporation<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
|  | •Chair, Bain & Company (2025-present)<br>•Worldwide Managing Partner and CEO, Bain & Company (2018-2024)<br>•Various leadership roles with Bain & Company (1989-2018)<br>**Other Affiliations**<br>•Board of Trustees, The Bridgespan Group<br>•Director, Ayala Corporation<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |

---

---

| | |
|:---|:---|
| **Sherilyn S. McCoy, Lead Independent Director** | **Sherilyn S. McCoy, Lead Independent Director** |
| ![McCoy, Sherilyn_1.jpg](syk-20260323_g11.jpg) | **Experience** |
| ![McCoy, Sherilyn_1.jpg](syk-20260323_g11.jpg) | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![McCoy, Sherilyn_1.jpg](syk-20260323_g11.jpg) | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![McCoy, Sherilyn_1.jpg](syk-20260323_g11.jpg) | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![McCoy, Sherilyn_1.jpg](syk-20260323_g11.jpg) | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| ![McCoy, Sherilyn_1.jpg](syk-20260323_g11.jpg) | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| **Director Since: 2018** | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
| **Age: 67** | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
|  | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
|  | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |
|  | •Chief Executive Officer and Director, Avon Products, Inc. (2012-2018)<br>•Various leadership roles with Johnson & Johnson (1982-2012)<br>**Other Affiliations**<br>•Director, AstraZeneca PLC <br>•Lead Director, Kimberly-Clark<br>•Vice-Chair of the Board, Galderma<br>•Director, Novocure (2018-2022)<br>•Chair of the Board, Certara, Inc. (2018-2021)<br>**Stryker Board Committees**<br>**•**Compensation and Human Capital<br>•Governance and Nominating |

---

---

| | |
|:---|:---|
| **Rachel M. Ruggeri** | **Rachel M. Ruggeri** |
| ![Ruggeri, Rachel_1 resize.jpg](syk-20260323_g12.jpg) | **Experience** |
| ![Ruggeri, Rachel_1 resize.jpg](syk-20260323_g12.jpg) | •Executive Vice President and Chief Financial Officer, Starbucks Corporation (2021-2025)<br>•Senior Vice President, Americas, Starbucks (2020-2021)<br>•Chief Financial Officer and Corporate Secretary, Continental Mills, Inc. (2018-2020)<br>•Various leadership roles with Starbucks Finance (2001-2018)<br>**Stryker Board Committees**<br>•Audit |
| ![Ruggeri, Rachel_1 resize.jpg](syk-20260323_g12.jpg) | •Executive Vice President and Chief Financial Officer, Starbucks Corporation (2021-2025)<br>•Senior Vice President, Americas, Starbucks (2020-2021)<br>•Chief Financial Officer and Corporate Secretary, Continental Mills, Inc. (2018-2020)<br>•Various leadership roles with Starbucks Finance (2001-2018)<br>**Stryker Board Committees**<br>•Audit |
| ![Ruggeri, Rachel_1 resize.jpg](syk-20260323_g12.jpg) | •Executive Vice President and Chief Financial Officer, Starbucks Corporation (2021-2025)<br>•Senior Vice President, Americas, Starbucks (2020-2021)<br>•Chief Financial Officer and Corporate Secretary, Continental Mills, Inc. (2018-2020)<br>•Various leadership roles with Starbucks Finance (2001-2018)<br>**Stryker Board Committees**<br>•Audit |
| ![Ruggeri, Rachel_1 resize.jpg](syk-20260323_g12.jpg) | •Executive Vice President and Chief Financial Officer, Starbucks Corporation (2021-2025)<br>•Senior Vice President, Americas, Starbucks (2020-2021)<br>•Chief Financial Officer and Corporate Secretary, Continental Mills, Inc. (2018-2020)<br>•Various leadership roles with Starbucks Finance (2001-2018)<br>**Stryker Board Committees**<br>•Audit |
| ![Ruggeri, Rachel_1 resize.jpg](syk-20260323_g12.jpg) | •Executive Vice President and Chief Financial Officer, Starbucks Corporation (2021-2025)<br>•Senior Vice President, Americas, Starbucks (2020-2021)<br>•Chief Financial Officer and Corporate Secretary, Continental Mills, Inc. (2018-2020)<br>•Various leadership roles with Starbucks Finance (2001-2018)<br>**Stryker Board Committees**<br>•Audit |
| **Director Since: 2024** | •Executive Vice President and Chief Financial Officer, Starbucks Corporation (2021-2025)<br>•Senior Vice President, Americas, Starbucks (2020-2021)<br>•Chief Financial Officer and Corporate Secretary, Continental Mills, Inc. (2018-2020)<br>•Various leadership roles with Starbucks Finance (2001-2018)<br>**Stryker Board Committees**<br>•Audit |
| **Age: 56** | •Executive Vice President and Chief Financial Officer, Starbucks Corporation (2021-2025)<br>•Senior Vice President, Americas, Starbucks (2020-2021)<br>•Chief Financial Officer and Corporate Secretary, Continental Mills, Inc. (2018-2020)<br>•Various leadership roles with Starbucks Finance (2001-2018)<br>**Stryker Board Committees**<br>•Audit |

---

---

| | |
|:---|:---|
| **Andrew K. Silvernail** | **Andrew K. Silvernail** |
| ![Silvernail, Andrew 3 resize.jpg](syk-20260323_g13.jpg) | **Experience** |
| ![Silvernail, Andrew 3 resize.jpg](syk-20260323_g13.jpg) | •Chairman, Chief Executive Officer, International Paper (2024-present)<br>•Chairman, President and Chief Executive Officer, Madison Industries (2021)<br>•Chairman, President and Chief Executive Officer, IDEX Corporation (2011-2020); Vice President, Group <br>Executive (2009-2011)<br>**Other Affiliations**<br>•Director, Boys & Girls Club of Lake County<br>**Stryker Board Committees**<br>**•**Audit |
| ![Silvernail, Andrew 3 resize.jpg](syk-20260323_g13.jpg) | •Chairman, Chief Executive Officer, International Paper (2024-present)<br>•Chairman, President and Chief Executive Officer, Madison Industries (2021)<br>•Chairman, President and Chief Executive Officer, IDEX Corporation (2011-2020); Vice President, Group <br>Executive (2009-2011)<br>**Other Affiliations**<br>•Director, Boys & Girls Club of Lake County<br>**Stryker Board Committees**<br>**•**Audit |
| ![Silvernail, Andrew 3 resize.jpg](syk-20260323_g13.jpg) | •Chairman, Chief Executive Officer, International Paper (2024-present)<br>•Chairman, President and Chief Executive Officer, Madison Industries (2021)<br>•Chairman, President and Chief Executive Officer, IDEX Corporation (2011-2020); Vice President, Group <br>Executive (2009-2011)<br>**Other Affiliations**<br>•Director, Boys & Girls Club of Lake County<br>**Stryker Board Committees**<br>**•**Audit |
| ![Silvernail, Andrew 3 resize.jpg](syk-20260323_g13.jpg) | •Chairman, Chief Executive Officer, International Paper (2024-present)<br>•Chairman, President and Chief Executive Officer, Madison Industries (2021)<br>•Chairman, President and Chief Executive Officer, IDEX Corporation (2011-2020); Vice President, Group <br>Executive (2009-2011)<br>**Other Affiliations**<br>•Director, Boys & Girls Club of Lake County<br>**Stryker Board Committees**<br>**•**Audit |
| ![Silvernail, Andrew 3 resize.jpg](syk-20260323_g13.jpg) | •Chairman, Chief Executive Officer, International Paper (2024-present)<br>•Chairman, President and Chief Executive Officer, Madison Industries (2021)<br>•Chairman, President and Chief Executive Officer, IDEX Corporation (2011-2020); Vice President, Group <br>Executive (2009-2011)<br>**Other Affiliations**<br>•Director, Boys & Girls Club of Lake County<br>**Stryker Board Committees**<br>**•**Audit |
| **Director Since: 2013** | •Chairman, Chief Executive Officer, International Paper (2024-present)<br>•Chairman, President and Chief Executive Officer, Madison Industries (2021)<br>•Chairman, President and Chief Executive Officer, IDEX Corporation (2011-2020); Vice President, Group <br>Executive (2009-2011)<br>**Other Affiliations**<br>•Director, Boys & Girls Club of Lake County<br>**Stryker Board Committees**<br>**•**Audit |
| **Age: 55** | •Chairman, Chief Executive Officer, International Paper (2024-present)<br>•Chairman, President and Chief Executive Officer, Madison Industries (2021)<br>•Chairman, President and Chief Executive Officer, IDEX Corporation (2011-2020); Vice President, Group <br>Executive (2009-2011)<br>**Other Affiliations**<br>•Director, Boys & Girls Club of Lake County<br>**Stryker Board Committees**<br>**•**Audit |
|  | •Chairman, Chief Executive Officer, International Paper (2024-present)<br>•Chairman, President and Chief Executive Officer, Madison Industries (2021)<br>•Chairman, President and Chief Executive Officer, IDEX Corporation (2011-2020); Vice President, Group <br>Executive (2009-2011)<br>**Other Affiliations**<br>•Director, Boys & Girls Club of Lake County<br>**Stryker Board Committees**<br>**•**Audit |

---

---

| | |
|:---|:---|
| **Lisa M. Skeete Tatum** | **Lisa M. Skeete Tatum** |
| ![Skeete Tatum, Lisa_3 (1) resize.jpg](syk-20260323_g14.jpg) | **Experience** |
| ![Skeete Tatum, Lisa_3 (1) resize.jpg](syk-20260323_g14.jpg) | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
| ![Skeete Tatum, Lisa_3 (1) resize.jpg](syk-20260323_g14.jpg) | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
| ![Skeete Tatum, Lisa_3 (1) resize.jpg](syk-20260323_g14.jpg) | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
| ![Skeete Tatum, Lisa_3 (1) resize.jpg](syk-20260323_g14.jpg) | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
| ![Skeete Tatum, Lisa_3 (1) resize.jpg](syk-20260323_g14.jpg) | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
| **Director Since: 2020** | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
| **Age: 58** | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
|  | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
|  | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |
|  | •Founder and Chief Executive Officer, Landit, Inc. (2014-present)<br>•Angel and Fund Investor (2010-2014)<br>•General Partner, Cardinal Partners (1998-2009)<br>•Founder, STI, Inc. (1995-1998)<br>•Various global and functional roles with Procter and Gamble (1989-1994)<br>**Other Affiliations**<br>•Board Member, Union Square Hospitality Group<br>•Director, USHG Acquisition Corporation (2021-2022)<br>•Trustee Emeritus, Cornell University<br>**Stryker Board Committees**<br>•Audit |

---

---

| | |
|:---|:---|
| **Ronda E. Stryker** | **Ronda E. Stryker** |
| ![Stryker, Ronda_1 resize.jpg](syk-20260323_g15.jpg) | **Experience** |
| ![Stryker, Ronda_1 resize.jpg](syk-20260323_g15.jpg) | •Director of Stryker Corporation for over 40 years<br>•Vice Chair and Director, Greenleaf Trust (1988-present)<br>**Other Affiliations**<br>•Vice Chair, Spelman College Board of Trustees<br>•Member, Harvard Medical School Board of Fellows<br>**Stryker Board Committees**<br>•Governance and Nominating |
| ![Stryker, Ronda_1 resize.jpg](syk-20260323_g15.jpg) | •Director of Stryker Corporation for over 40 years<br>•Vice Chair and Director, Greenleaf Trust (1988-present)<br>**Other Affiliations**<br>•Vice Chair, Spelman College Board of Trustees<br>•Member, Harvard Medical School Board of Fellows<br>**Stryker Board Committees**<br>•Governance and Nominating |
| ![Stryker, Ronda_1 resize.jpg](syk-20260323_g15.jpg) | •Director of Stryker Corporation for over 40 years<br>•Vice Chair and Director, Greenleaf Trust (1988-present)<br>**Other Affiliations**<br>•Vice Chair, Spelman College Board of Trustees<br>•Member, Harvard Medical School Board of Fellows<br>**Stryker Board Committees**<br>•Governance and Nominating |
| ![Stryker, Ronda_1 resize.jpg](syk-20260323_g15.jpg) | •Director of Stryker Corporation for over 40 years<br>•Vice Chair and Director, Greenleaf Trust (1988-present)<br>**Other Affiliations**<br>•Vice Chair, Spelman College Board of Trustees<br>•Member, Harvard Medical School Board of Fellows<br>**Stryker Board Committees**<br>•Governance and Nominating |
| ![Stryker, Ronda_1 resize.jpg](syk-20260323_g15.jpg) | •Director of Stryker Corporation for over 40 years<br>•Vice Chair and Director, Greenleaf Trust (1988-present)<br>**Other Affiliations**<br>•Vice Chair, Spelman College Board of Trustees<br>•Member, Harvard Medical School Board of Fellows<br>**Stryker Board Committees**<br>•Governance and Nominating |
| **Director Since: 1984** | •Director of Stryker Corporation for over 40 years<br>•Vice Chair and Director, Greenleaf Trust (1988-present)<br>**Other Affiliations**<br>•Vice Chair, Spelman College Board of Trustees<br>•Member, Harvard Medical School Board of Fellows<br>**Stryker Board Committees**<br>•Governance and Nominating |
| **Age: 71** | •Director of Stryker Corporation for over 40 years<br>•Vice Chair and Director, Greenleaf Trust (1988-present)<br>**Other Affiliations**<br>•Vice Chair, Spelman College Board of Trustees<br>•Member, Harvard Medical School Board of Fellows<br>**Stryker Board Committees**<br>•Governance and Nominating |

---

---

| | |
|:---|:---|
| **Rajeev Suri** | **Rajeev Suri** |
| ![Suri, Rajeev_2 resize.jpg](syk-20260323_g16.jpg) | **Experience** |
| ![Suri, Rajeev_2 resize.jpg](syk-20260323_g16.jpg) | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |
| ![Suri, Rajeev_2 resize.jpg](syk-20260323_g16.jpg) | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |
| ![Suri, Rajeev_2 resize.jpg](syk-20260323_g16.jpg) | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |
| ![Suri, Rajeev_2 resize.jpg](syk-20260323_g16.jpg) | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |
| ![Suri, Rajeev_2 resize.jpg](syk-20260323_g16.jpg) | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |
| **Director Since: 2018** | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |
| **Age: 58** | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |
|  | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |
|  | •Chief Executive Officer and Director, Inmarsat (2021-2023)<br>•President and Chief Executive Officer, Nokia (2014-2020); Chief Executive Officer, Nokia Solutions and <br>Networks (2009-2014)<br>•Various leadership roles with Nokia (1995-2009)<br>**Other Affiliations**<br>•Chairman of the Board, Digicel Group<br>•Chairman of the Board, M-KOPA<br>•Director, Singtel<br>•Chairman of the Advisory Board, Netceed<br>•Director, Viasat (2023-2025)<br>**Stryker Board Committees**<br>•Audit |

---

**Director Nominee Demographics**<br>

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Brainerd** | **Caforio** | **Lobo** | **Maceda** | **McCoy** | **Ruggeri** | **Silvernail** | **Skeete** <br> **Tatum**<br>| **Stryker** | **Suri** |
| **Racially/Ethnically Diverse** |  |  | •  | •  |  |  |  | •  |  | •  |
| **Born Outside U.S.** |  | •  | •  |  |  |  |  |  |  | •  |
| **Male** |  | •  | •  | •  |  |  | •  |  |  | •  |
| **Female** | •  |  |  |  | •  | •  |  | •  | •  |  |
| **Years of Service** | 9 | 6 | 14 | 1 | 8 | 2 | 13 | 6 | 42 | 8 |
| **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** | **Average Director Tenure: 11 years** |

---

**Proposal 2 — Ratification of Appointment of our Independent Registered Public Accounting Firm**<br>

The Audit Committee is directly responsible for the appointment, compensation, retention and oversight of the Company's independent

registered public accounting firm and such firm reports directly to the Audit Committee. Ernst & Young LLP and its predecessor firms,

Ernst & Ernst and Ernst & Whinney, have been retained as the Company's independent auditor continuously since 1974. The Audit

Committee reviews the qualifications, performance, fees and independence of Ernst & Young LLP and considers whether the firm

should be reappointed or whether a different independent registered public accounting firm should be appointed. SEC rules mandate

that the independent auditor's lead audit partner be rotated every five years. The process for the selection of the new lead audit partner,

which occurred most recently in 2022, included the involvement of the Chair of the Audit Committee in the selection process and

discussion by the full Audit Committee and management.

The members of the Audit Committee and the Board believe that the continued retention of Ernst & Young LLP is in the best interest of

the Company and our shareholders. At its February 2026 meeting, the Audit Committee appointed Ernst & Young LLP to serve as our

independent registered public accounting firm for 2026, subject to approval of the scope of the audit engagement and the estimated

audit fees, which will be presented to the Audit Committee at its August 2026 meeting. While not required, we are submitting the

appointment to the shareholders as a matter of good corporate practice to obtain their views. We expect representatives of Ernst &

Young LLP to attend the annual meeting with the opportunity to make a statement if they desire to do so. If the appointment is not

ratified, it will be considered as a recommendation that the Audit Committee consider the appointment of a different firm to serve as our

independent registered public accounting firm for the year 2026. Even if the appointment is ratified, the Audit Committee may select a

different independent registered public accounting firm at any time if it determines that such a change would be in the best interests of

Stryker and its shareholders.

**Fees and Services**

The fees (amounts in $) billed by Ernst & Young LLP with respect to the years ended December 31, 2025 and 2024 were as follows:

![2322](syk-20260323_g17.gif)

![2323](syk-20260323_g18.gif)

Audit Fees includes amounts billed for the annual audit of our annual Consolidated Financial Statements, the audit of internal control

over financial reporting, the review of the Consolidated Financial Statements included in the quarterly reports on Form 10-Q filed by us

during each year, the completion of statutory audits required in certain foreign jurisdictions and consultations concerning accounting

matters associated with the annual audit. Audit-Related Fees includes amounts billed for audits of our employee benefit plans. Tax

Compliance Fees includes amounts for tax compliance services. Other Tax Fees includes amounts for tax advice and tax planning

services. We expect that Ernst & Young LLP will provide non-audit services of a similar nature during 2026.

Under its charter, the Audit Committee must pre-approve all audit and non-audit services performed by Ernst & Young LLP, other than

non-audit services that satisfy a de minimis exception provided by applicable law, and is ultimately responsible for the determination of

the audit fees to be paid to Ernst & Young LLP. All of the services for which fees were disclosed under "Audit Fees," "Audit-Related

Fees," "Tax Compliance Fees" and "Other Tax Fees" in the charts above were approved under the Audit Committee's charter. In the

event we wish to engage Ernst & Young LLP to perform non-audit services, management prepares a summary of the proposed

engagement, detailing the nature of the engagement and cost of the engagement. At the Audit Committee's February meeting, certain

recurring non-audit services and the proposed fees are reviewed and evaluated. At subsequent meetings, management may present

additional services for approval. The Audit Committee has delegated to the Chair of the Audit Committee or, in the Chair's absence, any

other member of the Audit Committee, the authority to evaluate and approve projects and related fees if circumstances require approval

between meetings of the Audit Committee. Any such approval is reported to the full Audit Committee at its next meeting. In connection

with its review and evaluation of non-audit services, the Audit Committee is required to and does consider and conclude that the

provision of the non-audit services is compatible with maintaining the independence of Ernst & Young LLP.

**Vote Required**

The affirmative vote of a majority of the votes cast at the annual meeting on Proposal 2 is required for ratification. **The Board** 

**recommends that shareholders vote FOR ratification of the appointment of Ernst & Young LLP as our Company's independent** 

**registered public accounting firm for 2026.**

**Proposal 3 — Advisory Vote to Approve Named Executive Officer Compensation**<br>

As described under "Compensation Discussion and Analysis" beginning on page <u>[19](#i2547898784014edd82c5d43eb63a27de_79)</u>, our objective in setting executive compensation is

to provide a total compensation package that allows us to continue to attract, motivate and retain talented executives who drive our

Company's success while aligning compensation with the interests of our shareholders and the achievement of our key business

objectives. Consistent with this philosophy, a significant percentage of the total compensation opportunity for each of our NEOs is

based on measurable corporate financial performance and on the performance of our shares on a long-term basis.

Shareholders are urged to read the Compensation Discussion and Analysis section of this Proxy Statement, which discusses how our

compensation policies and procedures implement our compensation philosophy, as well as the "Summary Compensation Table" and

other related compensation tables and narrative disclosure under "Executive Compensation" beginning on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u> that describe the

compensation of our NEOs. The Compensation and Human Capital Committee and the Board believe that these policies and

procedures are effective in implementing our compensation philosophy and in achieving its goals.

Pursuant to Section 14A of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), our shareholders are entitled to an

advisory vote to approve the compensation of our NEOs. This advisory vote is commonly referred to as a "say-on-pay" advisory vote.

We are required to seek an advisory shareholder vote on the frequency of future "say-on-pay" votes at least once every six years,

although we may seek shareholder input more frequently. Pursuant to a policy we reaffirmed most recently in 2023, we provide our

shareholders with the opportunity to vote on a "say-on-pay" advisory vote at each annual meeting. Accordingly, in compliance with

these requirements and as a matter of good corporate governance, we are asking shareholders to approve the following resolution at

our annual meeting:

RESOLVED, that the shareholders of Stryker Corporation (the "Corporation") approve, on an advisory basis, the compensation of

the Corporation's named executive officers as disclosed in the Corporation's Proxy Statement for this annual meeting pursuant to

the rules of the Securities and Exchange Commission, including "Compensation Discussion and Analysis," the "Summary

Compensation Table" and the compensation tables and narrative disclosure under "Executive Compensation."

This advisory vote is non-binding. Although non-binding, the Compensation and Human Capital Committee and the Board will review

the results of the vote and take them into account in future determinations concerning our executive compensation program. **The Board** 

**recommends that shareholders vote FOR the resolution set forth in Proposal 3.**

STOCK OWNERSHIP

**Principal Shareholders**<br>

The following table sets forth certain information with respect to beneficial ownership of Common Stock by the only persons known by

us to be the beneficial owners of more than 5% of our Common Stock based on filings with the SEC pursuant to Section 13(d) or 13(g)

of the Exchange Act.

---

| | |
|:---|:---|
| **Name and Address of Beneficial Owner** | **Percentage of**<br>**Class (%)**<br>|
| The Vanguard Group, Inc.<br>31149173<sup>(1)</sup> | 8.1 |
| 100 Vanguard Boulevard |  |
| Malvern, Pennsylvania 19355 |  |
| BlackRock, Inc.<br>24924572<sup>(2)</sup> | 6.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;55 East 52nd Street |  |
| &nbsp;&nbsp;&nbsp;&nbsp;New York, New York 10055 |  |
| John W. Brown<br>20056245<sup>(3)</sup> | 5.2 |
| 3060 Peachtree Road, NW |  |
| Atlanta, Georgia 30305 |  |

---

______________

(1)This information is based solely on information most recently reported by The Vanguard Group, Inc. on Schedule 13G/A, which was filed with the

SEC on February 13, 2024. According to the Schedule 13G/A, The Vanguard Group, Inc. has shared voting power with respect to 434,563 shares,

sole dispositive power with respect to 29,693,953 shares and shared dispositive power with respect to 1,455,220 shares. The information contained

in the Schedule 13G/A is as of December 29, 2023 and may not reflect current ownership of our Common Stock. Ownership percentage assumes

continued ownership of the shares reflected in the table above as of February 28, 2026.

(2)This information is based solely on information most recently reported by BlackRock, Inc. on Schedule 13G/A, which was filed with the SEC on

January 29, 2024. According to the Schedule 13G/A, BlackRock, Inc. has sole voting power with respect to 22,376,171 shares and sole dispositive

power with respect to 24,924,572 shares. The information contained in the Schedule 13G/A is as of December 31, 2023 and may not reflect current

ownership of our Common Stock. Ownership percentage assumes continued ownership of the shares reflected in the table above as of February

28, 2026.

(3)This information is based solely on information most recently reported by Mr. John W. Brown on Schedule 13G/A, which was filed with the SEC on

February 9, 2021. Mr. Brown has sole voting and dispositive power with respect to 19,796,245 shares shown as beneficially owned by him and

shared voting and dispositive power with respect to 260,000 shares. The information contained in the Schedule 13G/A is as of December 31, 2020

and may not reflect current ownership of our Common Stock. Ownership percentage assumes continued ownership of the shares reflected in the

table above as of February 28, 2026.

**Security Ownership of Directors and Executive Officers**<br>

The following table sets forth certain information about the ownership of Common Stock as of February 28, 2026 by our current

directors, the executive officers identified as our NEOs in the "Compensation Discussion and Analysis" section beginning on page <u>[19](#i2547898784014edd82c5d43eb63a27de_79)</u> 

and the persons who were our executive officers and directors as of February 28, 2026 as a group.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of Shares** <br>**Owned (#)**<sup>(2)</sup><br>| **Right to** <br>**Acquire (#)**<sup>(3)</sup><br>| **Total (#)**<sup>(6)</sup> | **Percentage of** <br>**Outstanding Shares (%)**<br>|
| **Directors:** |  |  |  |  |
| Mary K. Brainerd | 6468 | 3005 | 9473 | \* |
| Giovanni Caforio, M.D. | 2892 | 316<sup>(4)</sup> | 3208 | \* |
| Kevin A. Lobo | 197661 | 1004973 | 1202634 | \* |
| Emmanuel P. Maceda |  | —<sup>(5)</sup> |  | \* |
| Sherilyn S. McCoy | 1832 | 1985<sup>(45)</sup> | 3817 | \* |
| Rachel M. Ruggeri | 26 | 653<sup>(4)</sup> | 679 | \* |
| Andrew K. Silvernail | 11928 | 9380<sup>(4)</sup> | 21308 | \* |
| Lisa M. Skeete Tatum | 2892 | 991<sup>(4)</sup> | 3883 | \* |
| Ronda E. Stryker | 15351668 | 3605 | 15355273 | 4.0 |
| Rajeev Suri | 5868 |  | 5868 | \* |
| **Named Executive Officers**<sup>(1)</sup>: |  |  |  |  |
| Preston W. Wells | 6115 | 22971 | 29086 | \* |
| Spencer S. Stiles | 70652 | 172534 | 243186 | \* |
| J. Andrew Pierce | 73853 | 172534 | 246387 | \* |
| Viju S. Menon | 12709 | 165079 | 177788 | \* |
| Glenn S. Boehnlein | 13216 | 182630 | 195846 | \* |
| Executive officers and directors as a <br>group (21 persons)<br>| 15832514 | 1946355 | 17778869 | 4.6 |

---

______________

\*Less than 1%.

(1)Other than Kevin A. Lobo, who is also a director.

(2)Excludes shares that may be acquired within 60 days after February 28, 2026 upon exercise of options and vesting of shares underlying restricted

stock units or performance stock units.

(3)Includes shares that may be acquired within 60 days after February 28, 2026 upon exercise of options and vesting of shares underlying restricted

stock units or performance stock units.

(4)Includes vested shares underlying restricted stock units for which the director has elected to delay delivery until departure from the Board.

(5)Excludes vested shares underlying restricted stock units for which the director has elected to delay delivery to a future date.

(6)Except for the shared beneficial ownership of certain shares by Ms. Stryker (13,120,495 shares), such persons hold sole voting and dispositive

power with respect to the shares shown in this column.

CORPORATE GOVERNANCE

We manage our business under the direction of our Board of Directors. The Board conducts its business through meetings of the Board

and its Committees. The Board has adopted Corporate Governance Guidelines that are available in the Governance area of the

Investor Relations section of our website at www.stryker.com/investors/governanceguidelines. During 2025, the Board held seven

meetings. Each director attended at least 75% of the total meetings of the Board and the Committees on which he or she served in

2025. We expect our directors to attend the annual meeting of shareholders unless they have a schedule conflict or other valid reason.

All members of the Board who stood for reelection and Mr. Maceda attended the 2025 annual meeting.

**Board's Role in Strategic Planning and Risk Oversight**<br>

Our Board is responsible for directing and overseeing the management of the Company's business in the best interests of the

shareholders and consistent with good corporate practice. The Board oversees strategic direction and priorities for the Company,

approves the selection of the senior management team and monitors the Company's risk, performance and impact on its stakeholders.

On an annual basis, the Board and management focus on the Company's overall strategic plan and direction, as well as the capital plan

and budget for the next year. A fundamental part of setting the Company's business strategy is the assessment of the risks the

Company faces and how they are managed. The Board assesses risks both through review and discussion by the full Board and by

delegating certain risk oversight responsibilities to the Board Committees. The Company's enterprise risk management program is

monitored at both the Board and Committee levels and evaluated at least annually by the full Board. The Board, the Audit Committee

and the Governance and Nominating Committee meet regularly throughout the year with our Group Presidents and the management

teams of our Finance, Information Security, Tax, Treasury, Internal Audit, Legal and Compliance functions to assess the financial, legal/

compliance, cybersecurity and operational/strategic risks throughout our businesses and review our insurance and other risk

management programs and policies to enable the Board to exercise its ultimate oversight responsibility for the Company's risk

management processes.

**Independent Directors**<br>

Under the listing standards of the NYSE, a director is not independent unless the Board determines that he or she has no material

relationship with Stryker, either directly or through any organization with which he or she is affiliated that has a relationship with Stryker.

While the NYSE listing standards require that at least a majority of the directors be independent, our Corporate Governance Guidelines

provide that at least two-thirds of the directors will be independent. The Board has determined that all of our current directors (other

than Mr. Lobo) are independent under the NYSE listing standards. That determination was based on a review of the responses of the

current directors to questions about employment history, affiliation and family and other relationships, and discussions with the current

directors. In the case of Ms. Stryker, the Board also considered that the Company spent $1,215,000 in 2025 on functions and meetings

held at hotel, restaurant and entertainment properties in Kalamazoo, Michigan (principally the Radisson Plaza Hotel) that are owned by

Greenleaf Hospitality and that the Company also reimbursed employees for hotel, restaurant and other expenses incurred by them at

such properties while they were in Kalamazoo for business meetings. Management of Stryker has been advised by Greenleaf

Hospitality that Greenleaf Hospitality is 100% owned by Ms. Stryker's husband. The Board has determined that the relationship with

Greenleaf Hospitality is not material under the circumstances, including the modest nature of the transactions compared to the total

revenues of Stryker and Greenleaf Hospitality, the ordinary course status of the transactions and the arm's length nature of the

transactions, including a Stryker discounted rate from Greenleaf Hospitality. In the case of Mr. Maceda, the Board considered that the

Company contracts for consulting services from Bain & Company, where Mr. Maceda is a partner and serves as Chair. The agreements

governing these consulting services are entered into in the ordinary course of business and payments from the Company to Bain &

Company in 2025 did not exceed 2% of Bain & Company's consolidated gross revenue. The Board believes that these transactions in

2025 were on arm's-length terms that were reasonable. Transactions and relationships of this nature may take place in the ordinary

course of business in the future.

**Board Committees**<br>

Our Board has three Committees. The current membership, number of meetings held during 2025 and the function performed by each

of these Committees are described below. These Committees act under written charters approved by the Board. The applicable

Committee and the Board review and reassess the charters annually.

No member of any Committee is or ever has been an employee of the Company. The Board has determined that the members of the

Audit, Compensation and Human Capital and Governance and Nominating Committees meet the independence standards for those

Committees within the meaning of the NYSE listing standards and applicable law and SEC regulations.

***Audit Committee:*** Mr. Silvernail (Chair), Ms. Ruggeri, Ms. Skeete Tatum and Mr. Suri currently are members of the Audit Committee,

which met nine times during 2025. The Audit Committee, which is a separately designated standing committee established in

accordance with Section 3(a)(58)(A) of the Exchange Act, oversees the Company's financial reporting process on behalf of the Board.

In addition, the Audit Committee has oversight responsibility with respect to compliance with legal and regulatory requirements related

to financial reporting, auditing and accounting. The Audit Committee also oversees the Company's policies and practices with respect to

risk assessment and risk management, including those related to cybersecurity, and receives at least three briefings a year from our

Chief Information Security Officer on the Company's policies and practices with respect to cybersecurity risk assessment and risk

management. The Audit Committee coordinates with the Governance and Nominating Committee with regard to matters of mutual

interest within the context of each Committee's responsibilities for compliance with legal and regulatory requirements, with the Audit

Committee being responsible for compliance with financial laws and regulations (including financial reporting, auditing and accounting)

and the Governance and Nominating Committee being responsible for compliance with non-financial laws and regulations. The Audit

Committee meets with management and the Company's independent registered public accounting firm throughout the year and reports

the results of its activities to the Board. Further information regarding the role of the Audit Committee is contained in its charter that is

available in the Governance area of the Investor Relations section of our website at www.stryker.com/investors/charters. For further

information, see "Audit Committee Report" on page <u>[46](#i2547898784014edd82c5d43eb63a27de_106)</u>. The Board has determined that Ms. Ruggeri and Mr. Silvernail are "audit

committee financial experts" for purposes of applicable SEC rules.

***Compensation and Human Capital Committee:*** Dr. Caforio (Chair), Ms. Brainerd, Mr. Maceda and Ms. McCoy currently are members

of the Compensation and Human Capital Committee, which met six times during 2025. The purpose of the Compensation and Human

Capital Committee is to assist the Board in discharging its overall responsibilities relating to executive and stock-based compensation

and human capital matters. The Compensation and Human Capital Committee reviews and approves corporate goals and objectives

relevant to the compensation of the Chief Executive Officer and other executive officers, evaluates their performance for the current

year in light of those goals and establishes compensation levels, including annual salary and bonus targets. The Compensation and

Human Capital Committee also administers and grants awards under the Company's equity-based compensation plans. Management

provides recommendations to the Compensation and Human Capital Committee concerning salary, bonus potential and stock awards

for members of our executive leadership team other than the Chief Executive Officer, whose pay recommendations are provided to the

Compensation and Human Capital Committee by its independent compensation consultant. The Chief Executive Officer's compensation

is subject to final approval by the independent members of the Board. The Compensation and Human Capital Committee also reviews

the level and form of non-employee director compensation and makes recommendations to the full Board regarding any changes to

such compensation as it deems appropriate. For further information, see the Compensation and Human Capital Committee's charter

that is available in the Governance area of the Investor Relations section of our website at www.stryker.com/investors/charters and

"Compensation Discussion and Analysis" beginning on page <u>[19](#i2547898784014edd82c5d43eb63a27de_79)</u>.

Our Compensation and Human Capital Committee has the authority to retain and terminate a compensation consulting firm to assist the

Compensation and Human Capital Committee in the evaluation of executive and non-employee director compensation. Since 2015,

Semler Brossy Consulting Group, LLC ("Semler Brossy") has been engaged on an annual basis directly by the Compensation and

Human Capital Committee as its executive compensation consultant to assist by:

• Providing information and education on executive and non-employee director compensation trends and developments and the

implications for Stryker;

• Reviewing the competitiveness of our non-employee director compensation program;

• Reviewing the competitiveness of total compensation for the members of our executive leadership team;

• Providing recommendations for the compensation levels of our Chief Executive Officer;

• Reviewing and giving its opinion on management's recommendations for executive compensation and equity plan design and

practices; and

• Participating in Compensation and Human Capital Committee meetings when requested by the Compensation and Human

Capital Committee Chair.

The Compensation and Human Capital Committee has annually determined Semler Brossy to be independent from the Company and

that no conflicts of interest existed. In reaching this conclusion, the Compensation and Human Capital Committee assessed Semler

Brossy's independence, taking into consideration all relevant factors, including the compensation consultant independence factors set

forth in the SEC rules and the NYSE listing standards and appropriate assurances provided by Semler Brossy regarding its

independence. Additionally, Semler Brossy did not separately provide any advice or services to management or otherwise to the

Company other than the services provided to the Compensation and Human Capital Committee.

***Governance and Nominating Committee:*** Ms. Brainerd (Chair), Dr. Caforio, Mr. Maceda, Ms. McCoy and Ms. Stryker currently serve

on the Governance and Nominating Committee. The Governance and Nominating Committee, which met four times during 2025,

makes recommendations to the Board regarding director nominations and Committee assignments, oversees the evaluation of the

Board and considers other matters relating to corporate governance. In addition, the Governance and Nominating Committee has

oversight responsibility with respect to compliance with laws and regulations (other than laws and regulations related to financial

reporting, auditing and accounting, which are the responsibility of the Audit Committee), regulatory affairs/quality assurance matters,

and corporate responsibility matters, including sustainability. The Governance and Nominating Committee coordinates with the Audit

Committee with regard to matters of mutual interest within the context of each Committee's responsibilities for compliance with legal

and regulatory requirements, with the Governance and Nominating Committee being responsible for oversight of the Company's

compliance with non-financial laws and regulations and the Audit Committee being responsible for oversight of the Company's

compliance with financial laws and regulations (including financial reporting, auditing and accounting). The Governance and Nominating

Committee receives a report at least once a year from one or more senior executives, either individually or jointly, with responsibility for

regulatory affairs and quality assurance, compliance and risk management on the status of the Company's compliance with relevant

laws, regulations and internal procedures and on the key regulatory affairs and quality assurance, compliance, risk management and

legal issues facing the Company, and may meet with such senior executives in executive session as the Governance and Nominating

Committee deems appropriate. The Governance and Nominating Committee also receives a report regularly from one or more senior

executives, either individually or jointly, with responsibility for corporate responsibility matters and may meet with such senior executives

in executive session as the Governance and Nominating Committee deems appropriate. For further information, see the charter of the

Governance and Nominating Committee that is available in the Governance area of the Investor Relations section of our website at

www.stryker.com/investors/charters.

When seeking to identify an individual to become a director to fill a new position or vacancy, the Governance and Nominating

Committee will consult with incumbent directors, management and others, including a professional search firm, and will review

information obtained from a variety of sources. The Governance and Nominating Committee is committed to an inclusive process for

identifying, recruiting and advancing candidates with diverse perspectives in any search process. The Governance and Nominating

Committee will consider, among other factors, the background and reputation of potential candidates in terms of their character,

personal and professional integrity, business and financial experience and acumen, experience in healthcare, corporate compliance or

regulatory and governmental affairs, how a person would contribute to and strengthen the Board and complement the other directors in

terms of expertise, diversity of viewpoint and opinion, professional experience, education and skills and a person's availability to devote

sufficient time to Board duties. Shareholders may recommend director candidates for consideration by the Governance and Nominating

Committee by writing to the Vice President, Corporate Secretary at 1941 Stryker Way, Portage, Michigan 49002, and giving the

candidate's name, relationship, if any, to the shareholder making the recommendation, biographical data and qualifications. The

submission should also include a statement from the candidate consenting to being considered and, if nominated and elected, to

serving as a director. The Governance and Nominating Committee evaluates recommendations from shareholders in the same manner

that it considers recommendations from other sources.

**Compensation Risks**<br>

Pay Governance LLC ("Pay Governance"), a consulting firm that was determined by the Compensation and Human Capital Committee

to be independent using the factors discussed above with regard to Semler Brossy, conducted a risk assessment of our executive

compensation program in 2025 that concluded that our executive compensation policies, practices and programs do not create risks

that are reasonably likely to have a material adverse effect on Stryker. The Compensation and Human Capital Committee reviewed the

Pay Governance report, discussed it with management at the time it was received and concurred with the report's conclusion.

In addition, Korn Ferry, a consulting firm that was determined by the Compensation and Human Capital Committee to be independent

using the factors discussed above with regard to Semler Brossy, conducted a risk assessment of our sales compensation program in

2021 that concluded that our sales compensation policies, practices and programs do not create risks that are reasonably likely to have

a material adverse effect on Stryker. The Compensation and Human Capital Committee reviewed the Korn Ferry report, discussed it

with management at the time it was received and concurred with the report's conclusion. An updated risk assessment of our sales

compensation program commenced in the second half of 2025 and is scheduled to be finalized in 2026. We intend to disclose the

findings of this assessment in the proxy statement for our 2027 annual meeting.

**Board Leadership Structure**<br>

The Board believes that it is important to retain flexibility to make the determination as to whether the interests of the Company and our

shareholders are best served by having the same person serve as both Chief Executive Officer and Chair of the Board or whether the

roles should be separated based on the circumstances at any given time. At different times in the past, both approaches have been

used. The Board periodically reassesses the leadership structure of the Board and, after considering the pros and cons of the

alternatives in light of the Company's operating and governance environment, has concluded that the most effective current leadership

structure is for Mr. Lobo to serve in the combined role of Chair of the Board and Chief Executive Officer and have full responsibility for

the day-to-day management of the Company. When the same person serves as Chief Executive Officer and Chair of the Board, we

have a Lead Independent Director, designated by the other independent directors. That position, which is currently held by Ms. McCoy,

entails significant responsibility and opportunity for independent Board leadership. As the Lead Independent Director, Ms. McCoy chairs

the executive sessions of the independent directors and also acts as an intermediary between the independent directors and senior

management on sensitive issues, including matters considered by the independent directors in executive session. Other matters that

she is responsible for as the Lead Independent Director include working with Mr. Lobo and the Vice President, Corporate Secretary to

set the agenda for Board meetings, assuring the adequacy of the flow of information from management to the non-management

directors, setting the meeting schedules to assure there is sufficient time for discussion of all agenda items and directing the retention of

consultants who report directly to the Board when deemed appropriate. The Lead Independent Director participates, along with the

members of the Compensation and Human Capital Committee and the other independent directors of the Board, in the evaluation of the

Chief Executive Officer and, together with the Chair of the Compensation and Human Capital Committee or an independent director

designated by the Compensation and Human Capital Committee in the event the Lead Independent Director is also the Chair of the

Compensation and Human Capital Committee, meets with the Chief Executive Officer to discuss such evaluation, consults with the

Governance and Nominating Committee concerning the members and Chairs of Board Committees and assists management and the

Board in assuring compliance with and implementation of our Corporate Governance Guidelines. The Lead Independent Director also

facilitates discussion among the non-management directors on key issues and concerns outside of Board meetings.

**Executive Sessions of Independent Directors**<br>

Our Corporate Governance Guidelines require the independent directors to meet in executive session at least once per year. Non-

management directors meet on a regular basis in executive session in conjunction with meetings of the Board and its Committees to

provide an opportunity for discussion of topics of concern without any member of management being present.

**Contacting the Board of Directors**<br>

Shareholders and other interested persons may communicate directly with the Board, our Lead Independent Director, our independent

directors as a group or with any individual director on a confidential basis by mail to Stryker Board of Directors at 1941 Stryker Way,

Portage, Michigan 49002. All such communications will be received directly by the Chair of the Governance and Nominating Committee

and will not be screened or reviewed by any Stryker personnel.

**Code of Conduct**<br>

We have adopted a Code of Conduct that applies to our employees, officers and directors in the performance of their duties and

responsibilities. The Code of Conduct is posted in the Governance area of the Investor Relations section of our website at

www.stryker.com/investors/codeofconduct, and we will mail it to any shareholder upon request to the Vice President, Corporate

Secretary at 1941 Stryker Way, Portage, Michigan 49002. Any amendments to the Code of Conduct or waiver of the Code of Conduct

granted for the benefit of an executive officer or director will be disclosed in the Governance area of the Investor Relations section of

our website.

**Certain Relationships and Related Party Transactions**<br>

Under our Related Party Transactions Policy, which is in writing and was adopted by the Board, the Audit Committee must approve or

ratify transactions involving directors, executive officers or principal shareholders or members of their immediate families or entities

controlled by any of them or in which they have a substantial ownership interest in which the amount involved exceeds $120,000 and

that are otherwise reportable under SEC disclosure rules. Such transactions include employment of immediate family members of any

director or executive officer. Management advises the Audit Committee at its regularly scheduled meeting in February of each year and

at subsequent meetings of any such transaction that is proposed to be entered into or continued and seeks approval. In the event any

such transaction is proposed and a decision is required prior to the next regularly scheduled meeting of the Audit Committee, it may be

presented to the Audit Committee Chair for approval, in which event the decision will be reported to the full Audit Committee at its next

meeting.

**Approach to Corporate Responsibility**<br>

We reflect our mission to make healthcare better in our corporate responsibility ("CR") objective: to positively impact people and our

planet through responsible, sustainable practices that create a better, healthier world.

Learn more about our CR efforts at https://www.stryker.com/us/en/about/corporate-responsibility.html.

COMPENSATION DISCUSSION AND ANALYSIS

This section includes information regarding, among other things, the overall objectives of our compensation program for our NEOs and

each element of compensation that we provide. Please read this section in conjunction with the detailed tables and narrative

descriptions of our NEO compensation under "Executive Compensation" beginning on page <u>[33](#i2547898784014edd82c5d43eb63a27de_100)</u>.

**Named Executive Officers**<br>

The names and titles of our NEOs for purposes of this Proxy Statement are:

---

| | |
|:---|:---|
| **Name** | **Title** |
| Kevin A. Lobo | Chair, Chief Executive Officer and President<sup>(1)</sup> |
| Preston W. Wells | Vice President, Chief Financial Officer<sup>(2)</sup> |
| Spencer S. Stiles | Group President, Orthopaedics<sup>(3)</sup> |
| J. Andrew Pierce | Group President, MedSurg and Neurotechnology |
| Viju S. Menon | Group President, Global Quality and Operations |
| Glenn S. Boehnlein | Advisor to the Chief Executive Officer and Former Vice President, Chief Financial Officer<sup>(4)</sup> |

---

______________

(1)Mr. Lobo's title changed to Chair and Chief Executive Officer effective January 1, 2026.

(2)Mr. Wells who previously served as Vice President, Group Chief Financial Officer for Orthopaedics, became Vice President, Chief Financial Officer

effective April 1, 2025 upon Mr. Boehnlein's retirement from that role.

(3)Mr. Stiles became President and Chief Operating Officer effective January 1, 2026.

(4)Mr. Boehnlein retired from his role as Vice President, Chief Financial Officer effective April 1, 2025 and is employed (in a non-executive officer

capacity) as Advisor to the Chief Executive Officer through March 31, 2026.

**Overview**<br>

Stryker has a history of delivering solid financial results. Our executive pay programs have played a significant role in our ability to

attract, motivate and retain the experienced executive team that has successfully driven our financial results over time.

The primary elements of compensation for our NEOs in 2025 were salary, bonus and stock awards. The stock awards granted to our

NEOs as part of the annual grant in February 2025 consisted of performance stock units and stock options. Our savings and retirement

plans are typically defined contribution plans that match a portion of employee contributions and have historically included an annual

discretionary contribution of 7% of salary and bonus for all eligible U.S.-based employees. We do not maintain any defined benefit

pension plans for our NEOs. We believe the limited perquisites and personal benefits we provide to our NEOs are conservative as

compared to market.

Our Compensation and Human Capital Committee believes that our compensation practices for our NEOs are appropriate in the

context both of Stryker's performance and the interests of our shareholders. Among the considerations in this regard are:

• An important part of our executive compensation philosophy is the alignment of the compensation of our NEOs with the interests

of our shareholders and achievement of key business objectives;

• In 2025, the value of the variable, performance and stock-based compensation elements for the NEOs that received a grant of

stock awards in 2025 averaged approximately 87% of the total value of the primary compensation elements (salary, actual bonus

and stock awards). See "Summary Compensation Table" on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u>;

• Our NEO bonus plans are based on challenging performance goals that, if met, should result in profitable, sustained business

performance over the long term and be reflected in stock price increases over time. The bonus payout for our NEOs for 2025

averaged 100% of target as a result of performance that generally achieved the target goals for all of the core bonus plan

measures. However, the adjusted operating income margin goal required for payout of any of the overachievement bonus plan

measures was not achieved which resulted in no payout related to the overachievement measures. Even though our financial

performance was adversely impacted by tariffs in 2025, the Compensation and Human Capital Committee did not make any

adjustments to the calculated 2025 bonus payout for any NEO. See "Annual Bonus" beginning on page <u>[22](#iabc0bd47dda9459786769bf3bb8fca0a_8107)</u> and "2025 Bonus

Plans" beginning on page <u>[23](#i00035fd7c2304a3b853c31a8704fd0fb_6256)</u> for additional details;

• Stock-based compensation realized by our NEOs is tied directly to the interests of our shareholders via stock price performance

and, for performance stock units, based on financial performance relative to pre-established financial goals for a three-year

performance period. The payout related to the 2023 grant of performance stock units, which is discussed under "2023

Performance Stock Units: Results for the 2023-2025 Performance Period" beginning on page <u>[27](#i3f7b4270619d4805b60d8f9aea1b700e_9147)</u>, was 200% of target as a result

of performance that reached the maximum goal for both average reported net sales growth relative to a comparison group of

companies and average adjusted net earnings per diluted share growth;

• We monitor a comparison group of medical technology and related companies to ensure that our compensation programs are

generally within observed competitive practices, review trends and practices with assistance from the Compensation and Human

Capital Committee's independent compensation consultant and make adjustments as deemed appropriate by the Compensation

and Human Capital Committee; and

• We evaluate key risk issues related to compensation and, in this regard, engaged a third-party independent consultant to

conduct a risk assessment of executive compensation programs in 2025 as discussed under "Compensation Risks" on page <u>[17](#i19e8df59cf664629a30b8392fea42164_0-0-1-1-328045)</u> 

and believe that our executive compensation practices do not create risks that are reasonably likely to have a material adverse

effect on Stryker.

The Compensation and Human Capital Committee considered the results of the advisory shareholder vote on executive compensation

at our 2025 annual meeting of shareholders at which the executive compensation program for our NEOs as disclosed in the proxy

statement for that meeting was approved by approximately 92% of the votes cast. The Compensation and Human Capital Committee

continues to believe that our executive compensation policies, practices and programs are appropriate and, in light of the results of the

advisory vote, believes our shareholders feel the same.

**Compensation Objectives**<br>

We believe that our executive compensation program, which is a key component of our ability to attract, motivate and retain talented,

qualified executives, should be designed to provide a meaningful level of total compensation that is aligned with organizational and

individual performance and with the interests of our shareholders. The Compensation and Human Capital Committee believes that,

consistent with the emphasis on rewarding executives for enhancing the Company's growth and profitability (as described more fully in

"Why We Chose Particular Performance Metrics and Goals" on page <u>[23](#iabc0bd47dda9459786769bf3bb8fca0a_8108)</u>), the Company's bonus plans should generally focus

executives on financially-oriented goals that reinforce a balance in achieving short-term and long-term goals and are aligned with

shareholder returns over time. The Company's long-term equity incentive compensation program likewise is intended to provide

executives with a personal financial interest in the Company's long-term success (as described more fully in "Long-Term Incentive

Compensation" beginning on page <u>[26](#i3f7b4270619d4805b60d8f9aea1b700e_9148)</u>). The Compensation and Human Capital Committee believes that the Company's incentive

programs balance risk and the potential reward to executives in a manner that is appropriate to the circumstances and in the best

interests of the Company's shareholders over the long term.

The principal objectives of our executive compensation policies and practices are to:

• Attract, motivate and retain talented executives who drive the Company's success;

• Structure compensation packages with a significant percentage of compensation earned as variable pay based on performance,

which balances risk with the potential reward;

• Align incentives with measurable corporate and business area performance;

• Provide flexibility to adapt to changing business needs;

• Align total compensation with shareholder value creation; and

• Establish compensation program costs that are reasonable, affordable and appropriate.

**Executive Compensation Philosophy**<br>

In setting compensation levels for members of our executive leadership team, the Compensation and Human Capital Committee

considers information from our comparison companies and broader compensation surveys. We position total pay opportunities for our

senior executive roles with the intent they be competitive relative to comparable roles in the market, taking into account a range of

factors, including: (i) the Company's or business unit's general performance relative to competitors; (ii) the scope of the executive's role

relative to the normal scope of this role at comparable companies; and (iii) the executive's tenure, experience, level of individual

performance, and potential to contribute to our future growth. Although we review and consider the compensation provided by our

comparison companies, broader compensation surveys and the results of the benchmarking studies described below under "The Role

of Benchmarking in Our Executive Compensation Decisions," we do not benchmark our NEOs' compensation to a specific percentile of

the market or of our comparison companies. Rather, we consider such data in addition to the factors described in (i) through (iii) above.

Individual compensation elements, along with an explanation of how we make decisions about each element, are described in detail

under "2025 Compensation Elements" beginning on page <u>[22](#iced5a35228d1480098b92dfca7cca25f_0-0-1-1-330546)</u>.

Underlying our executive compensation philosophy is the desire to facilitate and encourage long-term ownership of our Common Stock.

Our stock ownership guidelines reinforce this element of our philosophy by requiring senior management to accumulate and retain

significant stock ownership positions over time. For more information, see "Executive and Non-Employee Director Stock Ownership

Guidelines" beginning on page <u>[30](#i2d6c9855fa9b4a9eb35d319dc20db2e4_0-0-1-1-330553)</u>.

**The Role of Benchmarking in Our Executive Compensation Decisions**<br>

We regularly review our compensation policies, practices and programs to determine if they are both appropriate and responsive to our

business needs. Factors that were considered in determining the NEO compensation levels for 2025 included the results of the

Company as a whole and, where applicable, the specific business areas of the Company for which each NEO was responsible, the

individual's performance, changes in compensation levels over recent years, performance against bonus plan goals, comparisons

among roles internally, cost to the Company and market comparison data. Although we monitor the competitive landscape closely and

our current practice is to conduct an external market benchmarking of our NEO compensation levels and practices annually, we have

not focused solely on market comparison data when establishing compensation levels. The Compensation and Human Capital

Committee applies judgment and discretion when evaluating the appropriateness of using market comparison data as it does when

determining any compensation amount or outcome.

In mid-2024, Semler Brossy conducted a market benchmarking study in connection with establishing NEO compensation and the

results were among the factors considered when 2025 compensation decisions were made, which are discussed in detail under "2025

Compensation Decisions" beginning on page <u>[21](#iac39abfd30bf4c5ca99a51267b59f363_0-0-1-1-330544)</u>. The data provided to the Compensation and Human Capital Committee by Semler

Brossy showed compensation levels consisting of the primary elements of total compensation: salary, bonus and long-term incentive

awards. The study concluded that, for the NEOs who were serving in an NEO position at the time of the study and for which a sufficient

number of comparable benchmark positions at comparison companies could be identified, target cash compensation levels and the

grant value of long-term incentive awards were, on average, generally consistent with our executive compensation philosophy.

The comparison group companies used in the 2024 benchmarking study were:

---

| | | |
|:---|:---|:---|
| Abbott Laboratories | Danaher Corporation | Quest Diagnostics Incorporated |
| Amgen Inc. | Eli Lilly and Company | Regeneron Pharmaceuticals, Inc. |
| Baxter International Inc. | GE HealthCare Technologies Inc. | Thermo Fisher Scientific Inc. |
| Becton, Dickinson and Company | Gilead Sciences, Inc. | Viatris Inc. |
| Biogen Inc. | Labcorp Holdings Inc. | Zimmer Biomet Holdings, Inc. |
| Boston Scientific Corporation | Medtronic plc |  |

---

The comparison group was developed by Semler Brossy and members of our Human Resources department and approved by the

Compensation and Human Capital Committee. Similar to prior years, the comparison companies used in the 2024 study were selected

based on comparability to Stryker in terms of business focus and company size. The 2024 comparison group, overall, encompassed the

following:

• Product competitors or companies in the medical technology industry, as well as within adjacent industries, with which we

compete for executive talent;

• Companies with significant global operations; and

• Companies with revenues and market capitalizations of similar scale to Stryker.

Semler Brossy conducted an additional benchmarking study in mid-2025. The comparison group that was used in the 2025 study

included the same companies that were used in the 2024 study. The results of the 2025 study indicated that for the NEOs who were

serving in an NEO position at the time of the study and for which a sufficient number of comparable benchmark positions at comparison

companies could be identified, target cash compensation levels and the grant value of long-term incentive awards were, on average,

generally consistent with our executive compensation philosophy. The results of the 2025 benchmarking study were one of the factors

considered when the 2026 compensation decisions for the NEOs were made in February 2026. Those decisions are summarized under

"2026 Compensation Decisions" on page <u>[32](#iebd5f78570384dd9b41d5ae14df85eed_0-0-1-1-330569)</u> and will be discussed in further detail in the proxy statement for our 2027 meeting.

**Management's Role in Determining Executive Compensation**<br>

The Compensation and Human Capital Committee makes all final decisions regarding NEO compensation, except that the

compensation of the Chief Executive Officer is subject to final approval by the independent members of the Board. The Chief Executive

Officer's role in determining executive compensation includes making recommendations on compensation decisions for members of our

executive leadership team other than himself after reviewing information provided by our Vice President, Chief Human Resources

Officer and other members of the Human Resources department. Management's role in determining executive compensation includes:

• Developing, summarizing and presenting information and analyses to enable the Compensation and Human Capital Committee

to execute its responsibilities, as well as addressing specific requests for information from the Compensation and Human Capital

Committee;

• Attending Compensation and Human Capital Committee meetings as requested to provide information, respond to questions and

otherwise assist the Compensation and Human Capital Committee;

• Developing individual NEO bonus plans for consideration by the Compensation and Human Capital Committee, reporting to the

Compensation and Human Capital Committee regarding achievement against the bonus plans and providing recommendations

related to the final bonus payout values; and

• Preparing stock-based award recommendations for the Compensation and Human Capital Committee's approval, which includes

providing the Compensation and Human Capital Committee with regular updates on run rate (the rate at which stock awards are

being awarded under our equity plans) and overhang (a measure of potential earnings dilution from stock awards) levels, and

reporting to the Compensation and Human Capital Committee at the end of the performance period regarding the number of

performance stock units earned based on achievement of the pre-established goals.

Semler Brossy performs a similar role for the Compensation and Human Capital Committee with respect to compensation

recommendations for the Chief Executive Officer and the non-employee directors.

**2025 Compensation Decisions**<br>

In February 2025, the Compensation and Human Capital Committee reviewed and approved the 2025 cash compensation levels for our

then NEOs other than Mr. Lobo after receiving recommendations from Mr. Lobo and our Vice President, Chief Human Resources

Officer. Mr. Wells' 2025 annualized base salary amount of $725,000 and 2025 annualized target bonus opportunity of $616,250 (which

was prorated based on his promotion in April 2025, resulting in a prorated 2025 target bonus opportunity of $514,558) were approved

by the Compensation and Human Capital Committee in January 2025 in connection with his promotion to Vice President, Chief

Financial Officer in April 2025. Mr. Boehnlein's 2025 annualized base salary amount of $800,000 and 2025 target bonus opportunity of

$800,000 were unchanged from the 2024 annualized levels and were approved by the Compensation and Human Capital Committee in

January 2025 in connection with his transition to his role as Advisor to the Chief Executive Officer. The 2025 cash compensation levels

for Mr. Lobo were reviewed and approved by the Compensation and Human Capital Committee and independent directors of the Board

after they received recommendations from Semler Brossy. The recommendations and ultimate 2025 cash compensation levels for all of

the NEOs reflected subjective evaluations and decisions based on the scope of each NEO's responsibilities in his current role, the level

of performance in 2024 of the business areas for which he was responsible (if applicable), his time and proficiency in the job,

comparisons of pay levels relative to similar positions within the Company (if applicable) and consideration of the other factors

described under "Executive Compensation Philosophy" on page <u>[20](#i0837b9c6f8ba447eb21008bce79d7413_0-0-1-1-330538)</u>. The following table summarizes the annualized 2025 base salary

(effective as of March 1, 2025), the 2025 target bonus and the respective percentage increase relative to 2024 for both of those

amounts for each NEO other than Mr. Wells and Mr. Boehnlein whose 2025 cash compensation levels are described earlier in this

section:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **2025 Annualized Base** <br>**Salary ($)**<br>| **% Increase Relative to 2024** | **2025 Target Bonus ($)** | **% Increase Relative to 2024** |
| Kevin A. Lobo ..................... | 1500000 | 3.4% | 2250000 | 3.4% |
| Spencer S. Stiles ............... | 800000 | 6.0% | 760000 | 11.8% |
| J. Andrew Pierce ................ | 800000 | 6.0% | 760000 | 11.8% |
| Viju S. Menon ..................... | 680000 | 4.6% | 578000 | 4.6% |

---

In addition, performance stock units and stock options were awarded to all of the NEOs other than Mr. Boehnlein in February 2025.

See "Long-Term Incentive Compensation" beginning on page <u>[26](#i3f7b4270619d4805b60d8f9aea1b700e_9148)</u>. Prior to his promotion to Vice President, Chief Financial Officer, Mr.

Wells also received a cash award and a stock award in January 2025 at the conclusion of his tenure as the leader of one our internal

employee resource groups, which is consistent with our practice for leadership roles of such groups.

**2025 Compensation Elements**<br>

Each of the compensation elements and its purpose is described below.

***Base Salary:*** Base salary is provided to our NEOs to compensate them for the basic value of their job, their time and proficiency in the

position and the value of their job relative to other positions in the Company. We review each NEO's salary and performance annually

and make decisions about amounts and adjustments. Factors that are considered in determining the executive's salary include

performance, job experience, individual role responsibilities, comparisons among positions internally and market comparison data. Base

salary levels for 2025 were approved by the Compensation and Human Capital Committee or, in the case of Mr. Lobo, the independent

members of the Board.

***Annual Bonus***: Individually structured short-term bonus plans under our Executive Bonus Plan are intended to motivate and reward

our NEOs for achieving and exceeding specific annual performance goals. The Compensation and Human Capital Committee approved

the 2025 bonus plan target opportunities, bonus plan goals and actual bonus payments for our NEOs other than Mr. Lobo whose 2025

bonus plan target opportunity, bonus plan goals and actual bonus payment were approved by the independent directors of the Board.

The primary focus of the 2025 bonus goals for our NEOs was total Stryker performance. In the case of Mr. Stiles and Mr. Pierce, the

bonus goals also focused on the performance of the groups for which they were responsible. In addition, a potential modifier to the total

bonus payout was included in each NEO's bonus plan, which considered progress toward our CR commitments. The Compensation

and Human Capital Committee also considered quality and compliance performance in 2025 when determining final bonus payouts for

the NEOs.

For 2025, each NEO's bonus plan designated that adjusted consolidated operating income of approximately $5.21 billion (equal to 80%

of the target adjusted consolidated operating income amount in the core bonus) had to be achieved before any portion of the bonus

could be earned. In addition, each measure in our NEOs' bonus plans designated a threshold level of performance that had to be

achieved before any bonus could begin to be earned for that measure. Each 2025 bonus plan included an opportunity to earn an

overachievement bonus of up to an additional 100% of target bonus, which is included in the "Maximum Bonus Opportunity" column in

the table below, if 2025 goals for sales on a constant currency basis, adjusted operating income and adjusted net earnings per diluted

share were achieved. The maximum payout that could be earned under the NEO bonus plans was 200% of the target bonus

opportunity.

The 2025 bonus plan goals were originally approved by the Compensation and Human Capital Committee in early February 2025 but

were revised later in the year to reflect the divestiture of the majority of our Spinal Implants business and to include the projected

performance of Inari Medical, Inc. from the date of its acquisition in mid-February 2025. Sales on a constant currency basis excludes

the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Sales on a constant currency

basis is calculated by translating the actual results at the foreign currency exchange rate used when establishing the target amounts.

Adjusted operating income and adjusted operating income margin include adjustments for certain items that may not be indicative of, or

are unrelated to, our core operating results. Free cash flow excluding recall payments is calculated by adjusting cash provided by

operating activities by the amount of purchases of property, plant and equipment and proceeds from long-lived asset disposals and

removing the impact of certain legal settlements and recall payments. When calculating payouts related to sales on a constant currency

basis, adjusted operating income and adjusted operating income margin (for purposes of the core bonus measure), the impact of

acquisitions that occur after the target amounts are established is typically excluded. Adjusted operating income, adjusted operating

income margin, adjusted net earnings per diluted share and free cash flow excluding recall payments are non-GAAP financial

measures. Information with respect to adjustments made to GAAP operating income, GAAP net earnings per diluted share and GAAP

cash provided from operating activities in 2025, which resulted in the adjusted consolidated operating income, adjusted net earnings per

diluted share and free cash flow excluding recall payments, respectively, used in the calculation of the NEOs' bonus awards, is

described under "2025 Bonus Plans" beginning on page <u>[23](#i00035fd7c2304a3b853c31a8704fd0fb_6256)</u> and "Appendix A — Reconciliation of the Most Directly Comparable GAAP

Measure to Non-GAAP Financial Measure."

For any overachievement payout to occur for any performance measure, adjusted consolidated operating income margin performance

had to be equal to or greater than the target goal. The impact of changes in foreign currency exchange rates as well as the impact of

any acquisitions and divestitures that occurred during the year after the establishment of the bonus goals are included in the

measurement of adjusted operating income margin for purposes of determining overachievement eligibility.

The value of bonus payments for bonus eligible employees, including the NEOs, by their nature have the effect of reducing adjusted

operating income margin performance. As a result, adjusted operating income margin performance has the potential to impact the level

of overachievement payouts that can be made in bonus plans throughout the Company, including those of the NEOs, such that the

aggregate overachievement payouts across the Company, if any, would result in adjusted operating income margin performance not

being below the respective goal.

The individual NEO bonus plans are discussed in detail under "2025 Bonus Plans" below.

Under our Executive Bonus Plan, the Board and Compensation and Human Capital Committee may make adjustments to final bonus

determinations within the framework of the maximum bonuses that can be awarded under the terms of the Executive Bonus Plan.

The table below provides the target bonus, maximum potential bonus reflecting the overachievement award opportunity discussed

above, actual bonus payment and actual bonus payment as a percentage of target for each NEO in 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Target Bonus ($)** | **Maximum Bonus** <br>**Opportunity ($)**<br>| **Actual Bonus Payment ($)** | **Actual Bonus Payment as** <br>**Percentage of Target**<br>|
| Kevin A. Lobo ...................... | 2250000 | 4500000 | 2250000 | 100.0% |
| Preston W. Wells ................ | 514558 | 1029116 | 514558 | 100.0% |
| Spencer S. Stiles ................ | 760000 | 1520000 | 760000 | 100.0% |
| J. Andrew Pierce ................ | 760000 | 1520000 | 754148 | 99.2% |
| Viju S. Menon ...................... | 578000 | 1156000 | 578000 | 100.0% |
| Glenn S. Boehnlein ............ | 800000 | 1600000 | 800000 | 100.0% |

---

Our Executive Bonus Plan has a recoupment provision that is applicable in the event of either a material restatement of our financial

statements as a result of misconduct or an officer's material misconduct or negligence that results in a material violation of a law or

regulation or material Company policy. See "Recoupment and Clawback Policies" on page <u>[31](#ib26d10aff31c4c40b20caf650f5334ac_0-0-1-1-330563)</u> for information regarding our recoupment

policy that applies to all cash and equity incentive awards (including all time-vesting equity awards) and payments made pursuant to

awards granted to elected corporate officers after 2014 as well as our clawback policy related to the recovery of incentive-based

compensation for executive officers that complies with SEC rules and NYSE listing standards and was approved by our Board in

October 2023.

*Why We Chose Particular Performance Metrics and Goals*

We generally established our 2025 bonus goals with a focus on our projected financial performance for the year and comparison to

actual outcomes in 2024. We used sales, earnings and cash flow goals as the primary measures in the NEO bonus plans for the

following reasons:

• These are key measures that are the objectives of our strategic plan;

• These metrics focus our NEOs on growth, profitability and cash generation/utilization, which are important for our long-term

success;

• The goals for these metrics generally align with our financial projections; and

• We believe these are primary measures our investors monitor in evaluating our performance and making investment decisions

regarding Stryker stock.

*2025 Bonus Plans*

The 2025 annual bonus goals and weightings for the NEOs are shown in the tables on pages <u>[25](#i00035fd7c2304a3b853c31a8704fd0fb_6255)</u> through <u>[26](#i00035fd7c2304a3b853c31a8704fd0fb_17450)</u>. The following information

is relevant to an understanding of those tables:

• Adjusted consolidated operating income of approximately $5.21 billion (equal to 80% of the target adjusted consolidated

operating income amount in the core bonus) had to be achieved before any portion of the bonus could be earned.

• Threshold is the performance required before any bonus accrues. Performance below the threshold level results in no bonus

payment for that performance measure. Results for all quantitative bonus measures are prorated between threshold and target.

For core bonus measures, meeting the threshold goal results in the payment of 50% of the bonus opportunity for that particular

measure and meeting the target goal results in the payment of 100% of the bonus opportunity for the particular measure.

• Payout for each overachievement measure generally begins when performance exceeds the projected full-year value for the

respective measure and is prorated between the threshold and target overachievement levels. Performance that is equal to or

less than the threshold overachievement level results in no overachievement bonus payment for that performance measure. If

the adjusted operating income margin goal is not achieved, then an overachievement bonus payment cannot occur for any

performance measure.

• The goals for quantitative performance measures are expressed as a percentage change from 2024 actual results to show the

degree of change relative to the prior year to achieve bonus plan payment levels. For sales on a constant currency basis,

adjusted operating income and adjusted operating income margin, the 2024 actual results used in the calculation of the

percentage change include the impact of both acquisitions that occurred in 2024 and changes in foreign currency exchange rates

during 2024. We believe including these amounts in the 2024 actual results provides a more appropriate baseline for comparing

to the 2025 goals.

• Bonus plan goals are based on the Company's financial results as reported in conformance with GAAP but may be adjusted at

the Compensation and Human Capital Committee's discretion to reflect the impact of specified corporate transactions, changes

in foreign currency exchange rates, accounting or tax changes and items that may not be indicative of, or are unrelated to, our

core operating results so that the operating results of the Company are calculated on a comparable basis from year to year. The

2025 bonus plan goals were originally approved by the Compensation and Human Capital Committee in early February 2025 but

were revised later in the year to reflect the divestiture of the majority of our Spinal Implants business and to include the projected

performance of Inari Medical, Inc. from the date of its acquisition in mid-February 2025.

Information with respect to adjustments made to GAAP operating income in 2025 that resulted in the adjusted consolidated

operating income used in the calculation of the NEOs' bonus awards is set forth in the following reconciliation (dollar values in

millions), with adjustments made on a similar basis when determining the adjusted group operating income used in the

calculation of the 2025 bonus awards for Mr. Pierce and Mr. Stiles:

---

| | |
|:---|:---|
| **Item** | **Year Ended**<br>**December 31, 2025**<br>|
| Operating income, as reported  | $4889 |
| Inventory stepped-up to fair value | 173 |
| Other acquisition and integration-related costs  | 335 |
| Amortization of purchased intangible assets | 732 |
| Structural optimization and other special charges  | 191 |
| Goodwill and other impairments | 170 |
| Medical device regulations | 38 |
| Recall-related matters  | 58 |
| Regulatory and legal matters | 17 |
| Net currency adjustments | 7 |
| Operating income attributable to acquisitions and divestitures that occurred during 2025 | 4 |
| Adjusted operating income for bonus calculation | $6614 |

---

Information with respect to adjustments made to GAAP cash provided from operating activities in 2025 that resulted in the free

cash flow excluding recall payments used in the calculation of the NEOs' bonus awards is set forth in the following reconciliation

(dollar values in millions):

---

| | |
|:---|:---|
| **Item** | **Year Ended**<br>**December 31, 2025**<br>|
| Cash provided by operating activities | $5044 |
| Purchases of property, plant and equipment | (761) |
| Recall payments | 18 |
| Free cash flow excluding recall payments for bonus calculation | $4301 |

---

• Refer to "Appendix A — Reconciliation of the Most Directly Comparable GAAP Measure to Non-GAAP Financial Measure" for

information with respect to adjustments made to GAAP net earnings per diluted share in 2025 that resulted in the adjusted net

earnings per diluted share used in the calculation of the NEOs' bonus awards.

• The total bonus payout was subject to a potential adjustment of up to +/-10% based on progress toward certain CR

commitments.

**Bonus Plan for Mr. Lobo, Mr. Wells, Mr. Menon and Mr. Boehnlein**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025 Threshold** | **2025 Threshold** | **2025 Target** | **2025 Target** | **2025 Actual Performance** | **2025 Actual Performance** |
| | **Threshold** | **Goal as %** <br>**Change of** <br>**2024 Actual**<br>| **Target** | **Goal as %** <br>**Change of** <br>**2024 Actual**<br>| **Performance** <br>**Level**<br>| **Calculated** <br>**Payout**<br>|
| **Core Bonus Potential**<sup>(1)</sup>**:** |  |  |  |  |  |  |
| Adjusted operating income (20%) .................................... | $5.857 bil. | 2.5% | $6.507 bil. | 13.9% | $6.614 bil. | 20.0% |
| Adjusted operating income margin (20%) ....................... | 26.24% | 3.8% | 26.44% | 4.5% | 26.47% | 20.0% |
| Constant currency sales (40%) ......................................... | $23.382 bil. | 3.5% | $24.612 bil. | 8.9% | $24.990 bil. | 40.0% |
| Free cash flow excluding recall payments (20%) ........... | $2.954 bil. | (16.8)% | $3.693 bil. | 4.0% | $4.301 bil. | 20.0% |
| **Overachievement Bonus Potential**<sup>(1)</sup>**:** |  |  |  |  |  |  |
| Adjusted operating income (35%)<sup>(2)</sup> ................................. | $6.507 bil. | 13.9% | $6.833 bil. | 19.6% | $6.614 bil. | 0.0% |
| Constant currency sales (35%)<sup>(2)</sup> ...................................... | $24.612 bil. | 8.9% | $25.597 bil. | 13.3% | $24.990 bil. | 0.0% |
| Adjusted net earnings per diluted share (30%)<sup>(2)</sup> ........... | $13.24 | 8.6% | $14.03 | 15.1% | $13.63 | 0.0% |
| **Potential Bonus Payout Modifier**<sup>(1)(3)</sup>**:** |  |  |  |  |  |  |
| Progress toward certain CR commitments (+/- 10%) ..... |  |  |  |  | **See note 3** <br>**below**<br>| 0.0% |
|  |  |  | **Total Payout, as % of Target:** | **Total Payout, as % of Target:** | **Total Payout, as % of Target:** | **100.0%** |

---

______________

(1)The target weighting for each performance measure is noted in parentheses next to each measure.

(2)The consolidated adjusted operating income margin target goal of 26.44% was not achieved when measured on the basis that includes the impact

of changes in foreign currency exchange rates as well as the impact of any acquisitions and divestitures. As a result, there was no payout related to

any overachievement bonus measure.

(3)The Compensation and Human Capital Committee determined not to apply any adjustment to the bonus payouts for the NEOs based on progress

toward CR commitments.

**Bonus Plan for Mr. Stiles**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025 Threshold** | **2025 Threshold** | **2025 Target** | **2025 Target** | **2025 Actual Performance** | **2025 Actual Performance** |
| | **Threshold** | **Goal as %** <br>**Change of** <br>**2024 Actual**<br>| **Target** | **Goal as %** <br>**Change of** <br>**2024 Actual**<br>| **Performance** <br>**Level**<br>| **Calculated** <br>**Payout**<br>|
| **Core Bonus Potential**<sup>(1)(2)</sup>**:** |  |  |  |  |  |  |
| Adjusted operating income - group (10%) ................................. | $2.408 bil. | (2.7)% | $2.675 bil. | 8.1% | $2.780 bil. | 10.0% |
| Adjusted operating income - consolidated (10%) ..................... | $5.857 bil. | 2.5% | $6.507 bil. | 13.9% | $6.614 bil. | 10.0% |
| Adjusted operating income margin - consolidated (20%) ........ | 26.24% | 3.8% | 26.44% | 4.5% | 26.47% | 20.0% |
| Constant currency sales - group (20%) ...................................... | $8.699 bil. | (4.2)% | $9.157 bil. | 0.9% | $9.405 bil. | 20.0% |
| Constant currency sales - consolidated (20%) ......................... | $23.382 bil. | 3.5% | $24.612 bil. | 8.9% | $24.990 bil. | 20.0% |
| Free cash flow excluding recall payments (20%) ..................... | $2.954 bil. | (16.8)% | $3.693 bil. | 4.0% | $4.301 bil. | 20.0% |
| **Overachievement Bonus Potential**<sup>(1)(2)</sup>**:** |  |  |  |  |  |  |
| Adjusted operating income - group (17.5%)<sup>(3)</sup> ........................... | $2.675 bil. | 8.1% | $2.889 bil. | 16.8% | $2.780 bil. | 0.0% |
| Adjusted operating income - consolidated (17.5%)<sup>(3)</sup> .............. | $6.507 bil. | 13.9% | $6.833 bil. | 19.6% | $6.614 bil. | 0.0% |
| Constant currency sales - group (17.5%)<sup>(3)</sup> ............................... | $9.157 bil. | 0.9% | $9.615 bil. | 5.9% | $9.405 bil. | 0.0% |
| Constant currency sales - consolidated (17.5%)<sup>(3)</sup> ................... | $24.612 bil. | 8.9% | $25.597 bil. | 13.3% | $24.990 bil. | 0.0% |
| Adjusted net earnings per diluted share (30%)<sup>(3)</sup> ...................... | $13.24 | 8.6% | $14.03 | 15.1% | $13.63 | 0.0% |
| **Potential Bonus Payout Modifier**<sup>(1)(4)</sup>**:** |  |  |  |  |  |  |
| Progress toward certain CR commitments (+/- 10%) .............. |  |  |  |  | **See note 4** <br>**below**<br>| 0.0% |
|  |  |  | **Total Payout, as % of Target:** | **Total Payout, as % of Target:** | **Total Payout, as % of Target:** | **100.0%** |

---

______________

(1)The target weighting for each performance measure is noted in parentheses next to each measure.

(2)Goals labeled as group are specific to the Orthopaedics Group that reported to Mr. Stiles.

(3)The consolidated adjusted operating income margin target goal of 26.44% was not achieved when measured on the basis that includes the impact

of changes in foreign currency exchange rates as well as the impact of any acquisitions and divestitures. As a result, there was no payout related to

any overachievement bonus measure.

(4)The Compensation and Human Capital Committee determined not to apply any adjustment to the bonus payouts for the NEOs based on progress

toward CR commitments.

**Bonus Plan for Mr. Pierce**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025 Threshold** | **2025 Threshold** | **2025 Target** | **2025 Target** | **2025 Actual Performance** | **2025 Actual Performance** |
| | **Threshold** | **Goal as %** <br>**Change of** <br>**2024 Actual**<br>| **Target** | **Goal as %** <br>**Change of** <br>**2024 Actual**<br>| **Performance** <br>**Level**<br>| **Calculated** <br>**Payout**<br>|
| **Core Bonus Potential**<sup>(1)(2)</sup>**:** |  |  |  |  |  |  |
| Adjusted operating income - group (10%) .................................. | $4.457 bil. | 4.8% | $4.952 bil. | 16.4% | $4.876 bil. | 9.2% |
| Adjusted operating income - consolidated (10%) ...................... | $5.857 bil. | 2.5% | $6.507 bil. | 13.9% | $6.614 bil. | 10.0% |
| Adjusted operating income margin - consolidated (20%) ......... | 26.24% | 3.8% | 26.44% | 4.5% | 26.47% | 20.0% |
| Constant currency sales - group (20%) ....................................... | $14.683 bil. | 8.6% | $15.456 bil. | 14.3% | $15.586 bil. | 20.0% |
| Constant currency sales - consolidated (20%) ........................... | $23.382 bil. | 3.5% | $24.612 bil. | 8.9% | $24.990 bil. | 20.0% |
| Free cash flow excluding recall payments (20%) ...................... | $2.954 bil. | (16.8)% | $3.693 bil. | 4.0% | $4.301 bil. | 20.0% |
| **Overachievement Bonus Potential**<sup>(1)(2)</sup>**:** |  |  |  |  |  |  |
| Adjusted operating income - group (17.5%)<sup>(3)</sup> ............................ | $4.952 bil. | 16.4% | $5.348 bil. | 25.7% | $4.876 bil. | 0.0% |
| Adjusted operating income - consolidated (17.5%)<sup>(3)</sup> ................ | $6.507 bil. | 13.9% | $6.833 bil. | 19.6% | $6.614 bil. | 0.0% |
| Constant currency sales - group (17.5%)<sup>(3)</sup> ................................ | $15.456 bil. | 14.3% | $16.228 bil. | 20.0% | $15.586 bil. | 0.0% |
| Constant currency sales - consolidated (17.5%)<sup>(3)</sup> .................... | $24.612 bil. | 8.9% | $25.597 bil. | 13.3% | $24.990 bil. | 0.0% |
| Adjusted net earnings per diluted share (30%)<sup>(3)</sup> ....................... | $13.24 | 8.6% | $14.03 | 15.1% | $13.63 | 0.0% |
| **Potential Bonus Payout Modifier**<sup>(1)(4)</sup>**:** |  |  |  |  |  |  |
| Progress toward certain CR commitments (+/- 10%) ................ |  |  |  |  | **See note 4** <br>**below**<br>| 0.0% |
|  |  |  | **Total Payout, as % of Target:** | **Total Payout, as % of Target:** | **Total Payout, as % of Target:** | **99.2%** |

---

______________

(1)The target weighting for each performance measure is noted in parentheses next to each measure.

(2)Goals labeled as group are specific to the MedSurg and Neurotechnology Group that reports to Mr. Pierce.

(3)The consolidated adjusted operating income margin target goal of 26.44% was not achieved when measured on the basis that includes the impact

of changes in foreign currency exchange rates as well as the impact of any acquisitions and divestitures. As a result, there was no payout related to

any overachievement bonus measure.

(4)The Compensation and Human Capital Committee determined not to apply any adjustment to the bonus payouts for the NEOs based on progress

toward CR commitments.

***Long-Term Incentive Compensation:*** In February 2025, our NEOs other than Mr. Boehnlein were awarded performance stock units

and stock options. The target long-term incentive value mix for our NEOs is weighted more toward performance stock units than stock

options. See "Primary Compensation Elements" under the "Summary Compensation Table" on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u>. Additionally, Mr. Wells received

a stock award in January 2025 at the conclusion of his tenure as the leader of one our internal employee resource groups, which is

consistent with our practice for leadership roles of such groups.

The performance stock units granted to our NEOs on February 5, 2025 ("2025 PSUs") will be earned based on the achievement of a

pre-established threshold level of three-year average adjusted net earnings per diluted share growth of 2.0% or greater as of the last

day of the performance period, with the actual number of shares earned being determined based on the actual average adjusted net

earnings per diluted share growth as well as average reported net sales growth performance relative to a comparison group of

companies over the January 1, 2025 to December 31, 2027 performance period as shown in the table below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Average Adjusted Net Earnings Per Diluted Share Growth** | **Below Minimum** | **Minimum** | **Target** | **Maximum** |
| Goal | < 7.0% | 7.0% | 9.0% to 10.0% | 12.0% |
| Payout Level, as % of Target | 0 | 50 | 100 | 200 |
| **Relative Average Reported Net Sales Growth** | **Below Minimum** | **Minimum** | **Target** | **Maximum** |
| Goal (Percentile Ranking) | Below 33rd | 33rd | 50th | 75th and Above |
| Payout Level, as % of Target | 0 | 50 | 100 | 200 |

---

The following is the comparison group of 17 companies that will be used when determining the relative average reported net sales

growth performance for the 2025 PSUs:

---

| | | |
|:---|:---|:---|
| Abbott Laboratories | GE HealthCare Technologies Inc. | Siemens Healthineers AG |
| Baxter International Inc. | Johnson & Johnson (MedTech Segment) | Smith & Nephew plc |
| Becton, Dickinson and Company | Labcorp Holdings Inc. | Solventum Corporation |
| Boston Scientific Corporation | Medtronic plc | Thermo Fisher Scientific Inc. |
| Danaher Corporation | Quest Diagnostics Incorporated | Zimmer Biomet Holdings, Inc. |
| Fresenius Medical Care AG | Royal Philips (combined segments of Diagnosis<br>&nbsp;&nbsp;&nbsp;&nbsp;& Treatment and Connected Care) |  |
|  | Royal Philips (combined segments of Diagnosis<br>&nbsp;&nbsp;&nbsp;&nbsp;& Treatment and Connected Care) |  |

---

Any earned 2025 PSUs will vest and, along with any associated dividend equivalents, be settled in Common Stock in March 2028

following completion of the three-year performance period. The number of 2025 PSUs ultimately earned can range from 0% to 200% of

the target award.

The stock options granted on February 5, 2025 to our NEOs have an exercise price of $392.39 per share. The exercise price for the

stock options granted to our NEOs is equal to the closing price of our Common Stock as reported for NYSE Composite Transactions on

the last trading day before the grant date. Such stock options have ten-year terms, vest as to 20% of the underlying shares on each of

the first five anniversaries of the grant date and are subject to the other terms and conditions generally applicable to stock options

granted to other key employees. Our equity incentive plans prohibit repricing stock options without shareholder approval.

The details of the 2025 stock award grants to the NEOs are provided in the "2025 Grants of Plan-Based Awards" table on page <u>[35](#i04b4cb419c7249599c0f265898451cd9_0-0-1-1-330585)</u>.

Stock awards in 2025 for other key employees generally consisted of stock options and restricted stock units. Performance stock units,

stock options and restricted stock units are granted to provide employees with a personal financial interest in Stryker's long-term

success, encourage retention through vesting provisions and enable us to compete for the services of employees in an extremely

competitive market and industry. Objectives of the long-term incentive portion of our compensation package include:

• Aligning the personal and financial interests of management and other employees with shareholder interests;

• Balancing near-term considerations with a focus on improving the business and creating shareholder value over the long-term;

and

• Providing a means to attract, motivate and retain a skilled management team.

Management made recommendations to the Compensation and Human Capital Committee about the stock award levels and terms for

the NEOs other than the Chief Executive Officer, recommendations for whom were made by Semler Brossy to the Compensation and

Human Capital Committee. The stock award levels for the NEOs other than the Chief Executive Officer were approved by the

Compensation and Human Capital Committee after receiving recommendations from the Chief Executive Officer, and for the Chief

Executive Officer were approved by the Compensation and Human Capital Committee subject to final approval by the independent

members of the Board, which subsequently occurred. A number of factors are considered in determining the stock award levels for the

NEOs, but the final award is ultimately a subjective decision. While the Compensation and Human Capital Committee did not apply

specific performance measures or weightings to determine the individual NEO awards of performance stock units and stock options in

2025, factors considered included the level of responsibility and position within the Company, demonstrated performance over time,

value to our future success, the level of retention value from prior awards, Company and business area performance in recent years,

comparisons among positions internally, market comparison data and the other factors described under "Executive Compensation

Philosophy" on page <u>[20](#i0837b9c6f8ba447eb21008bce79d7413_0-0-1-1-330538)</u>. The Compensation and Human Capital Committee also considered, in the aggregate for the Company, share

availability under our equity plans, annual run rate, the financial expense of stock awards and potential shareholder dilution.

The terms and conditions of our stock awards include recoupment provisions that are applicable in the event of a violation of the non-

compete agreement to which each recipient has agreed. See "Recoupment and Clawback Policies" on page <u>[31](#ib26d10aff31c4c40b20caf650f5334ac_0-0-1-1-330563)</u> for information

regarding our recoupment policy that applies to all cash and equity incentive awards (including all time-vesting equity awards) and

payments made pursuant to awards granted to elected corporate officers after 2014 as well as our clawback policy related to the

recovery of incentive-based compensation for executive officers that complies with SEC rules and NYSE listing standards and was

approved by our Board in October 2023.

*2023 Performance Stock Units: Results for the 2023-2025 Performance Period*

In 2023, the Company granted performance stock units to members of our then executive leadership team. The vesting of all 2023

performance stock units ("2023 PSUs") was contingent on the achievement of certain specified performance metrics over a three-year

performance period from January 1, 2023 to December 31, 2025. The 2023 PSUs were subject to a threshold performance target of the

Company's achievement of average adjusted net earnings per diluted share growth of 2.0% or greater as of the last day of the

performance period (the "Threshold Performance Target"). The Compensation and Human Capital Committee chose this measure as

the Threshold Performance Target for the 2023 PSUs in order to require that a minimum level of earnings growth be achieved before

any portion of the 2023 PSUs would vest. If the Threshold Performance Target was achieved, grantees would become eligible to vest in

up to 200% of their 2023 PSUs, subject to further achievement of two equally weighted financial measures (average adjusted net

earnings per diluted share growth and average reported net sales growth relative to a comparison group of companies) over the same

three-year performance period. The Compensation and Human Capital Committee chose these as measures for the 2023 PSUs in

order to focus the executive leadership team on longer-term growth and profitability. The Compensation and Human Capital Committee

also believed that it was important to have a measure that assessed the Company's growth on a relative basis, which resulted in the

use of average reported net sales growth relative to a comparison group. We believe our investors monitor these measures in

evaluating our performance and making investment decisions regarding Stryker stock.

Following the completion of the three-year performance period, the Compensation and Human Capital Committee determined in March

2026 that the Threshold Performance Target had been achieved and, accordingly, our NEOs were eligible to vest in up to 200% of their

2023 PSUs. Under the terms of the 2023 PSUs, once the Threshold Performance Target is achieved, the Compensation and Human

Capital Committee can exercise negative discretion to reduce the number of 2023 PSUs that vest for our NEOs. Vesting of 50% of each

NEO's target number of 2023 PSUs was based on the Company's achievement of average reported net sales growth relative to a

comparison group of companies and the remaining 50% of each NEO's target number of 2023 PSUs was based on the Company's

achievement of average adjusted net earnings per diluted share growth. The 2023 PSUs vested and, along with the associated

dividend equivalents, were settled in Common Stock on March 21, 2026.

The following is the comparison group of 18 companies used to determine the relative average reported net sales growth performance

for the 2023 PSUs:

---

| | | |
|:---|:---|:---|
| Abbott Laboratories | GE HealthCare Technologies Inc.  | Siemens Healthineers AG |
| Agilent Technologies, Inc. | Johnson & Johnson (MedTech Segment) | Smith & Nephew plc |
| Baxter International Inc. | Labcorp Holdings Inc. | Solventum Corporation |
| Becton, Dickinson and Company | Medtronic plc | Thermo Fisher Scientific Inc. |
| Boston Scientific Corporation | Quest Diagnostics Incorporated | Zimmer Biomet Holdings, Inc. |
| Danaher Corporation | Royal Philips (combined segments of Diagnosis<br>&nbsp;&nbsp;&nbsp;&nbsp;& Treatment and Connected Care) |  |
| Fresenius Medical Care AG | Royal Philips (combined segments of Diagnosis<br>&nbsp;&nbsp;&nbsp;&nbsp;& Treatment and Connected Care) |  |

---

These companies were selected for comparison because, at the time the 2023 PSUs were granted, they competed with Stryker for

market share and/or executive talent. As permitted by the terms and conditions applicable to the 2023 PSUs, the Compensation and

Human Capital Committee modified the calculation of average reported net sales growth to adjust for distortions caused by significant

acquisitions and divestitures involving companies in the comparison group. This adjustment to the calculation of average reported net

sales growth is consistent with the methodology that the Compensation and Human Capital Committee has used for other performance

stock unit awards, beginning with the 2013 performance stock units.

The table below presents the performance goals, the performance results for average adjusted net earnings per diluted share growth

(to which no changes were made) and for relative average reported net sales growth, as adjusted by the Compensation and Human

Capital Committee as described above, and the calculated payouts for the 2023 PSUs:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Average Adjusted Net Earnings Per Diluted Share Growth** | **Below** <br>**Minimum**<br>| **Minimum** | **Target** | **Maximum** | **Actual** |
| Goal | < 4.0% | 4.0% | 6.5% to 8.5% | 12.0% | 13.4% |
| Earned 2023 PSUs, as % of Target | 0 | 50 | 100 | 200 | 200 |
| Weighted-Average (50%) Earned 2023 PSUs, as % of Target |  |  |  |  | 100 |
| **Relative Average Reported Net Sales Growth** | **Below** <br>**Minimum**<br>| **Minimum** | **Target** | **Maximum** | **Actual** |
| Goal (Percentile Ranking) | Below 33rd | 33rd | 50th | 75th and Above | 94th |
| Earned 2023 PSUs as % of Target | 0 | 50 | 100 | 200 | 200 |
| Weighted-Average (50%) Earned 2023 PSUs, as % of Target |  |  |  |  | 100 |
| **Total 2023 PSUs earned, as % of Target**<sup>(1)</sup> |  |  |  |  | **200** |

---

______________

(1) The value of the earned 2023 PSUs excludes the associated dividend equivalents.

For those NEOs who were granted 2023 PSUs, the number and market value of the 2023 PSUs that have been earned but remained

unvested until March 21, 2026 are included in the "Number of Shares or Units of Stock That Have Not Vested" and "Market Value of

Shares or Units of Stock That Have Not Vested" columns of the "Outstanding Equity Awards at 2025 Fiscal Year-End" table on page

<u>[37](#ib5724a0eadfb450aa18eb92f8d3ce7f4_0-0-56-11-398564)</u>.

***Retirement Plans:*** We offer a defined contribution 401(k) plan — the Stryker Corporation 401(k) Savings and Retirement Plan ("401(k)

Plan") — that is available to all eligible U.S. employees, including the NEOs, as well as a nonqualified supplemental defined contribution

plan — the Stryker Corporation Supplemental Savings and Retirement Plan ("Supplemental Plan") — in which certain employees,

including the NEOs, may participate. The purpose of these plans is to assist our employees and executives with retirement income

savings and increase the attractiveness of employment at Stryker. The Supplemental Plan is designed to provide a consistent level of

benefit as a percentage of current compensation by restoring benefits that would otherwise be limited due to the covered compensation

limits under the tax-qualified 401(k) Plan. The amounts of the Company's matching contribution to the accounts of each NEO are

determined by the NEO's eligible compensation and individual contribution rate. Participants may contribute up to 75% of total eligible

compensation (salary and bonus for the NEOs) under the 401(k) Plan and Supplemental Plan. Under the 401(k) Plan, we match fifty

cents per dollar of the first 8% of compensation contributed by the employee up to the Internal Revenue Code limits ($23,500 annual

deferral and $350,000 compensation in 2025). In addition to the Company match, the Company has historically made a discretionary

contribution in March of each year equal to 7% of the prior year's eligible compensation for all employees eligible under the 401(k) Plan

and Supplemental Plan, including the NEOs. The amounts contributed under the 401(k) Plan and the Supplemental Plan for 2025 on

behalf of each NEO are included in the "All Other Compensation" column of the "Summary Compensation Table" on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u>.

Additionally, the amounts contributed under the Supplemental Plan for 2025 on behalf of each NEO and their account balance under

the Supplemental Plan, along with a description of the 401(k) Plan and Supplemental Plan, are provided in the table on page <u>[38](#i2c66a95ccadd4629b72915da36e7a71f_0-0-1-1-330605)</u> and the

associated narrative.

We have defined benefit pension programs for some employees in certain international locations; however, no NEO participates in any

defined benefit pension plan sponsored by Stryker.

***Health and Welfare Benefits Plans:*** We provide benefits, such as medical, prescription, dental, vision, life insurance and disability

coverage, to each NEO under the same benefits plans that we offer to all our eligible U.S.-based employees. The benefits plans are

part of our overall total compensation offering and provide appropriate healthcare coverage and security for our employees and their

families at costs affordable to the Company. The Company does not pay for any form of post-retirement healthcare benefits for any

employee.

***Perquisites:*** We provide limited perquisites and personal benefits based on considerations unique to each NEO position. We believe

our practices regarding perquisites are conservative to market. In 2025, we paid for costs associated with an executive physical

examination for all of our NEOs who had such an examination. The Board approved a financial counseling benefit for our NEOs, other

than Mr. Boehnlein, and other members of senior management beginning in July 2025. The maximum annualized value of this benefit is

$16,000 and it was prorated for 2025. The Board believes the financial counseling benefit enhances the financial wellness of the NEOs

and members of senior management by providing for professional assistance with complex financial planning situations and allows

participants to maintain focus on their roles at Stryker. Mr. Boehnlein received a gift in connection with attendance of a Company event

and gifts in connection with his announced retirement from the Company.

In addition, we have a policy, which was approved by the independent directors of the Board, that provides for the personal use of

aircraft by Mr. Lobo and his immediate family members. The Board believes the policy maximizes the efficient use of Mr. Lobo's travel

time and helps to ensure his personal security and safety. Mr. Lobo is the only Stryker executive allowed to use aircraft for personal

use. Such personal use is subject to an annual hour limitation of 60 hours. The annual hour limitation and the actual personal use by

Mr. Lobo and his immediate family members is reviewed annually by the Board. The benefit to Mr. Lobo associated with personal use of

aircraft is imputed as income for tax purposes at Standard Industry Fare Level rates and he is responsible for paying the associated

taxes.

In accordance with SEC disclosure requirements, the perquisites and other personal benefits are included in the "All Other

Compensation" column of the "Summary Compensation Table" for 2025 on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u> and are identified for Mr. Lobo, Mr. Menon, and Mr.

Boehnlein, who were the only NEOs for whom the total value was $10,000 or greater.

**Impact of Decisions Regarding One Compensation Element on Decisions Regarding Other Compensation Elements**<br>

Our practice is to review each NEO's compensation elements individually and monitor the total of the various elements. We consider

each element and the total against our compensation objectives as stated in our executive compensation philosophy. Decisions related

to one compensation element (e.g., bonus payment earned) generally do not materially affect decisions regarding any other element

(e.g., stock award grants) because the objectives of each element differ. For example, we intend bonus payments to reward short-term

performance for achievement of annual bonus plan goals, while we make decisions related to stock awards to align the interests of the

recipients with the Company's long-term performance and enhance our retention hold on recipients.

Our 401(k) Plan and Supplemental Plan are funded on an annual basis and do not result in potential future liabilities to the Company.

Decisions about these plans do not impact outcomes related to salary or bonus decisions for our NEOs and vice versa.

Positions at higher levels at Stryker generally have a greater emphasis on variable pay elements of bonus and stock awards, although

no specific formula, schedule or structure is currently applied in establishing the percentage of total compensation delivered through

any compensation element.

**Equity Plans and Equity-Based Compensation Award Granting Policy**<br>

The Company provides the following discussion of the timing of option awards in relation to the disclosure of material nonpublic

information, as required by Item 402(x) of Regulation S-K. We have adopted a granting policy covering all stock awards (including stock

options), both off-cycle (including hire-on) and ongoing annual grants. Under the policy, stock awards are granted by the Compensation

and Human Capital Committee, subject to approval by the Board in the case of grants to non-employee directors, and approval by the

independent directors of the Board in the case of grants to the Chief Executive Officer. Generally, the granting of stock awards occurs

on a pre-determined schedule, as described below. The Compensation and Human Capital Committee has delegated to the Chief

Executive Officer the authority to make "off-cycle grants" to new employees as a result of the acquisition of another company, in

situations where we are seeking to attract a senior level hire or recognize an employee for significant achievements or in other special

circumstances. In 2025 we made off-cycle grants to new hires, including those who became employees as a result of an acquisition,

and to select employees to recognize significant achievements and create retention incentives. Annual limits for off-cycle grants are

defined both per individual employee (20,000 shares) and in the aggregate (300,000 shares), with shares issuable in connection with

awards other than stock options being counted against such limits as 2.86 shares under our 2011 Long-Term Incentive Plan, as

amended or restated from time to time (the "2011 Plan").

The fair market value of Stryker stock used to establish the exercise price of all options is the closing sales price per share as reported

for NYSE Composite Transactions for the last trading day prior to the grant date. No stock grant is backdated and the timing of the

public release of material information or the grant of any stock award is not established with the intent of unduly benefiting a grantee

under a stock award. The Compensation and Human Capital Committee and, with respect to the Chief Executive Officer's stock

awards, the independent directors of the Board, do not take material nonpublic information into account when determining the timing

and terms of stock awards. Instead, the timing of grants is in accordance with the compensation cycle described below. Each annual

grant and off-cycle grant of equity-based compensation is awarded on a pre-determined date as follows:

• The annual grant of stock awards for employees is generally made on the date of the February meeting of the Board. The annual

grant of stock awards for non-employee directors is generally made on the date of the Board meeting that coincides with our

annual meeting of shareholders. Any change in the annual grant date for employees or non-employee directors must be made

with the prior approval of the Board.

• Off-cycle awards may be granted by the Chief Executive Officer, pursuant to delegated authority from the Compensation and

Human Capital Committee, on or around the first business day of May, August or November following the date of hire or the

determination that an award is warranted in other circumstances. Off-cycle awards are reported to the Compensation and

Human Capital Committee and the Board at their next regular meetings.

The stock awards to our NEOs have historically included performance stock units, stock options, and occasionally, restricted stock

units. Where permissible by law, we require U.S. employees who receive stock awards to sign a version of the Company's

confidentiality, non-competition and non-solicitation agreement. The terms and conditions of our stock awards include recoupment

provisions that are applicable in the event of a violation of the non-compete agreement to which each of our NEOs has agreed.

The Company has not timed the disclosure of material nonpublic information to affect the value of executive compensation. Any

coordination between a grant of stock awards and the release of information that could be expected to affect such grant's value is

generally precluded by the granting policy and pre-determined schedule, using the methodology described above.

The information in the table below is provided in accordance with Item 402(x)(2) of Regulation S-K regarding the grant of stock options

in 2025 within four business days before, or within one business day after, the filing of a report on Forms 10-K, 10-Q, or 8-K disclosing

material nonpublic information. The stock options included in the table were granted on February 5, 2025 as part of the annual grant of

stock awards, which occurred within four business days of the Form 8-K that was filed on February 10, 2025 that disclosed the details

of a public debt offering.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Grant Date** | **Number of** <br>**Securities** <br>**Underlying** <br>**Award (#)**<br>| **Exercise Price** <br>**($/sh)**<br>| **Grant Date Fair** <br>**Value ($)**<br>| **Percentage Change in the Closing Market Price of** <br>**the Securities Underlying the Award Between the** <br>**Trading Day Ending Immediately Prior to the** <br>**Disclosure of Material Nonpublic Information and the** <br>**Trading Day Beginning Immediately Following the** <br>**Disclosure of Material Nonpublic Information**<br>|
| Kevin A. Lobo | 2/5/2025 | 48936 | 392.39 | 6920781 | (0.2)% |
| Preston W. Wells | 2/5/2025 | 9176 | 392.39 | 1297717 | (0.2)% |
| Spencer S. Stiles | 2/5/2025 | 13458 | 392.39 | 1903300 | (0.2)% |
| J. Andrew Pierce | 2/5/2025 | 13458 | 392.39 | 1903300 | (0.2)% |
| Viju S. Menon | 2/5/2025 | 8258 | 392.39 | 1167889 | (0.2)% |

---

**Executive and Non-Employee Director Stock Ownership Guidelines**<br>

Encouraging long-term ownership of Stryker stock among our management and directors is an important aspect of our executive

compensation policies and practices. This reflects our conviction that all senior executives and non-employee directors should have

meaningful share ownership positions in the Company to reinforce the alignment of the interests of management and our shareholders.

Stryker has stock ownership guidelines in place for all non-employee directors, executive leadership team members and select other

senior management positions in the Company. The policy provides that 25% of the net shares from option exercises cannot be sold until

the participant exceeds the applicable ownership guideline. Executives and non-employee directors in compliance with the ownership

guidelines may generally exercise stock options and sell the underlying shares, once vested, as long as they continue to meet the

ownership guidelines. In 2025, our stock ownership requirements for our non-employee directors and NEOs were:

---

| | | |
|:---|:---|:---|
| **Position** | **Market Value of Stock Owned** | **Expected Time Period to Comply** |
| Non-Employee Directors  | $600000 | 5 years |
| Chief Executive Officer  | 5 times salary | 5 years |
| Other NEOs  | 3 times salary | 5 years |

---

For stock ownership guideline calculation purposes, stock owned includes shares owned outright, including 401(k) Plan shares, as well

as restricted stock units awarded (for employees, using an estimate of the net number of shares to be received after taxes; for non-

employee directors, using the entire awarded amount as the Company generally does not withhold taxes upon vesting for non-

employee directors), but does not include outstanding performance stock units or stock options. The Compensation and Human Capital

Committee receives an annual update from management on compliance with the ownership guidelines. As of December 31, 2025, all of

our non-employee directors and all of the NEOs subject to the ownership guidelines at that time were at or above the applicable stock

ownership guideline requirement or projected to be by their targeted compliance date. The Compensation and Human Capital

Committee periodically reviews the guideline requirements to ensure they continue to be appropriate.

**Prohibition of Hedging and Pledging Transactions**<br>

The Company has adopted an insider trading policy governing the purchase, sale and/or other disposition of the Company's securities

that is reasonably designed to promote compliance with insider trading laws, rules and regulations and NYSE listing standards. Our

Insider Trading Guidelines prohibit short sales of and option trading on Stryker stock and prohibit our directors and officers, and other

employees of Stryker subject to the Insider Trading Guidelines, and their designees from engaging in hedging transactions, such as (but

not limited to) zero-cost collars, equity swaps, exchange funds and forward sale contracts, that may allow such individual to continue to

own Stryker securities without the full risks and rewards of ownership. Our Insider Trading Guidelines also prohibit holding Stryker

securities in a margin account or otherwise pledging Stryker securities as collateral for a loan, except for Stryker securities that had

been pledged as of the effective date of the Insider Trading Guidelines or that already have been pledged at the time an individual

becomes subject to the Insider Trading Guidelines. A copy of the Insider Trading Guidelines is filed as Exhibit 19 to our 2025 Annual

Report on Form 10-K for our fiscal year ended December 31, 2025.

**Recoupment and Clawback Policies**<br>

In 2015, our Board adopted a recoupment policy that applies uniformly to all cash and equity incentive awards (including all time-vesting

equity awards) and payments made pursuant to awards granted to our elected corporate officers after 2014. Under this policy, the

Compensation and Human Capital Committee may require recoupment from an elected officer if it determines that it is in the best

interest of the Company to do so and the amount of the incentive compensation was based upon the achievement of certain financial

results that were subsequently reduced due to a material restatement as a result of misconduct and would have been lower had it been

based upon the restated financial results or the elected officer engaged in material misconduct or was negligent in exercising his or her

supervisory responsibility to manage or monitor conduct or risks, in each case that resulted in a material violation of a law or regulation

or a material Company policy relating to manufacturing, sales or marketing of our products, including improper payments to foreign

officials to obtain or retain business, that caused significant harm to the Company. We will publicly disclose recoupment of

compensation under this policy in situations where the Board determines that it is in the best interests of the Company and our

shareholders to do so.

In October 2023, our Board adopted a separate, mandatory clawback policy in compliance with SEC rules and NYSE listing standards

related to the incentive-based compensation recovery provisions of the Dodd-Frank Act. The mandatory clawback policy generally

requires recoupment of erroneously awarded incentive-based compensation (including any compensation granted, earned, or vested

based wholly or in part upon the attainment of a financial reporting measure) received by current and former executive officers (as

defined in Rule 10D-1 of the Exchange Act), including our NEOs during the three completed fiscal years immediately preceding the date

that Stryker is required to prepare an accounting restatement due to Stryker's material noncompliance with any financial reporting

requirement under U.S. federal securities laws. As required by the SEC rules and NYSE listing standards, we will publicly disclose the

details of any such clawback of incentive-based compensation.

**Employment Agreements and Severance Policy**<br>

We generally do not provide employment agreements, with the exception of unique circumstances or if such agreements are customary

in foreign countries. We have no employment or severance agreement in place with any NEO. We have in the past made, and are likely

in the future to make, separation payments to persons who were NEOs based on the specific facts and circumstances.

On January 24, 2025, we entered into a letter agreement with Mr. Boehnlein in connection with his retirement and transition into a non-

executive officer advisory role beginning on April 1, 2025 until March 31, 2026. During the advisory period, Mr. Boehnlein will continue

to receive base salary at the annual rate of $800,000, he remained eligible for an incentive bonus opportunity for 2025 based on a

target bonus opportunity of $800,000, and he is entitled to receive an advisory period incentive bonus in the amount of $215,000

provided he remains employed in the advisory capacity through March 31, 2026 and continues to support the transition of his roles and

responsibilities. Mr. Boehnlein also received a transition services benefit from the Company with a value equal to $53,760. Mr.

Boehnlein did not receive an annual grant of stock awards in February 2025 and is not eligible to receive grants of stock awards during

the advisory period.

On January 27, 2025, we entered into a letter agreement with Mr. Wells in connection with his promotion to Vice President, Chief

Financial Officer, effective April 1, 2025, pursuant to which Mr. Wells' annualized base salary and annualized target bonus opportunity

increased to $725,000 and $616,250 (85% of base salary), respectively. His target bonus opportunity in 2025 was prorated based on

the start date of his new role. In addition, Mr. Wells received an award of 4,588 performance stock units (at target) and 9,176 stock

options in February 2025 with a target aggregate award value of approximately $3,000,000.

**Company Tax and Accounting Issues**<br>

In general, consideration is given to the tax and accounting treatment of our compensation plans at the time of developing the plans,

when making changes to plans, in light of any regulatory changes or when making specific compensation decisions related to individual

elements. The accounting treatments considered include any that may apply to amounts awarded or paid to our NEOs. The tax

considerations include Sections 162(m) and 409A of the Internal Revenue Code.

***Deductibility of Executive Compensation:*** In evaluating the compensation programs covering our NEOs and making decisions

related to payments, the Compensation and Human Capital Committee generally has considered the potential impact on the Company

of Section 162(m) of the Internal Revenue Code and the limits of deductibility on compensation in excess of $1 million. The

Compensation and Human Capital Committee generally intends to maximize deductibility of compensation under Section 162(m) to the

extent consistent with our overall compensation program objectives, but it may authorize compensation that does not meet the

requirements of, or that is not deductible under, Section 162(m), if it determines such payments are appropriate.

***Share-Based Compensation:*** We account for compensation expense from our stock awards in accordance with the *Compensation* —

*Stock Compensation* Topic of the Financial Accounting Standards Board Accounting Standards Codification ("FASB Codification") that

requires companies to measure the cost of employee stock awards based on the grant date fair value and recognize that cost over the

period during which a recipient is required to provide services in exchange for the stock awards, typically the vesting period. We

consider the impact on the Company's compensation expense when determining and making stock awards.

**2026 Compensation Decisions**<br>

The table below summarizes the 2026 compensation decisions for the 2025 NEOs other than Mr. Boehnlein. The compensation

decisions were made in February 2026 for the NEOs other than Mr. Stiles whose compensation for 2026 was approved by the

Compensation and Human Capital Committee in December 2025 in connection with his promotion to President and Chief Operating

Officer of the Company in January 2026. These decisions will be more fully discussed in the proxy statement for our 2027 annual

meeting.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Annualized Base Salary** <br>**($)**<br>| **Target Bonus** <br>**($)**<br>| **Number of Performance**<br>**Stock Units at Target (#)**<sup>(1)</sup><br>| **Number of Stock Options** <br>**(#)**<sup>(2)</sup><br>| **Number of Restricted** <br>**Stock Units (#)**<sup>(3)</sup><br>|
| Kevin A. Lobo ...... | 1550000 | 2325000 | 29100 | 58206 |  |
| Preston W. Wells  | 800000 | 800000 | 5986 | 11974 |  |
| Spencer S. Stiles  | 1000000 | 1000000 | 9978 | 19956 |  |
| J. Andrew Pierce  | 830000 | 788500 | 7650 | 15300 | 2771 |
| Viju S. Menon ..... | 710000 | 639000 | 5154 | 10310 |  |

---

______________

(1) Key design features for the 2026 performance stock units include the following:

• In order to earn any shares, a pre-established threshold level of three-year average adjusted net earnings per diluted share growth must be

achieved, with the actual number of shares earned based on actual average adjusted net earnings per diluted share growth and average reported

net sales growth relative to a comparison group of companies over the three-year performance period;

• Payout range of 0% to 200% of the target award; and

• Settled in Common Stock in early 2029 following the completion of the three-year performance period.

(2) Stock options to purchase shares of the Company's Common Stock were granted at an exercise price of $360.82 per share (the closing price as

reported for NYSE Composite Transactions on February 3, 2026, the last trading day before the grant date).

(3) Restricted stock units were granted to Mr. Pierce on February 4, 2026. The restricted stock units award vests one-third on each of March 21, 2027,

March 21, 2028, and March 21, 2029.

COMPENSATION AND HUMAN CAPITAL COMMITTEE REPORT

The Compensation and Human Capital Committee of the Board of Directors has reviewed and discussed with management the

foregoing Compensation Discussion and Analysis and, on the basis of such review and discussion, has recommended to the Board that

the Compensation Discussion and Analysis be included in this Proxy Statement.

---

| |
|:---|
| Submitted by: |
| Giovanni Caforio, M.D., Chair |
| Mary K. Brainerd |
| Emmanuel P. Maceda |
| Sherilyn S. McCoy |
| *Members of the Compensation and Human Capital Committee* |

---

EXECUTIVE COMPENSATION

**Summary Compensation Table**<br>

The following table summarizes all compensation awarded to, earned by or paid to each of the Company's NEOs during each of the last

three fiscal years or such shorter number of years that each of them was an NEO. The additional tables that follow the Summary

Compensation Table are intended to be supporting presentations to the Summary Compensation Table. Most compensation elements in

the supporting tables are aggregated and included in the Summary Compensation Table. You should refer to the section entitled

"Compensation Discussion and Analysis" beginning on page <u>[19](#i2547898784014edd82c5d43eb63a27de_79)</u> to help you understand the compensation practices and programs

resulting in the compensation elements in these tables. A narrative description of the material factors necessary to understand the

information in the Summary Compensation Table is provided following the table.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year** | **Salary ($)** | **Stock** <br>**Awards ($)**<br>| **Option** <br>**Awards ($)**<br>| **Non-Equity** <br>**Incentive Plan** <br>**Compensation ($)**<br>| **All Other** <br>**Compensation ($)**<br>| **Total ($)** |
| Kevin A. Lobo<sup>(1)</sup> | 2025 | 1491667 | 9764136 | 6920781 | 2250000 | 974911 | 21401495 |
| &nbsp;&nbsp;&nbsp;&nbsp;Chair, Chief Executive | 2024 | 1441667 | 8699604 | 8003983 | 2936250 | 897865 | 21979369 |
| &nbsp;&nbsp;&nbsp;&nbsp;Officer and President | 2023 | 1391667 | 6652884 | 8410645 | 3780000 | 532651 | 20767847 |
| Preston W. Wells<sup>(2)</sup> | 2025 | 653431 | 1841377 | 1297717 | 514558 | 103339 | 4410422 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vice President, Chief |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Financial Officer |  |  |  |  |  |  |  |
| Spencer S. Stiles<sup>(3)</sup> | 2025 | 792500 | 2685078 | 1903300 | 760000 | 188081 | 6328959 |
| &nbsp;&nbsp;&nbsp;&nbsp;Group President, | 2024 | 750000 | 2541612 | 2338707 | 917325 | 211695 | 6759339 |
| &nbsp;&nbsp;&nbsp;&nbsp;Orthopaedics | 2023 | 720833 | 1971068 | 2491904 | 1174500 | 129042 | 6487347 |
| J. Andrew Pierce | 2025 | 792500 | 2685078 | 1903300 | 754148 | 188081 | 6323107 |
| &nbsp;&nbsp;&nbsp;&nbsp;Group President, | 2024 | 750000 | 2541612 | 2338707 | 917325 | 211695 | 6759339 |
| MedSurg and Neurotechnology | 2023 | 720833 | 1971068 | 2491904 | 1174500 | 131544 | 6489849 |
| Viju S. Menon | 2025 | 675000 | 1647444 | 1167889 | 578000 | 167476 | 4235809 |
| &nbsp;&nbsp;&nbsp;&nbsp;Group President, | 2024 | 645833 | 1573770 | 1447799 | 745875 | 176229 | 4589506 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Quality and Operations | 2023 | 616667 | 1231918 | 1557388 | 956250 | 107811 | 4470034 |
| Glenn S. Boehnlein<sup>(4)</sup> | 2025 | 800000 |  |  | 800000 | 293046 | 1893046 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advisor to the Chief Executive | 2024 | 793334 | 2723253 | 2505420 | 1080000 | 237747 | 7339754 |
| Officer and Former Vice | 2023 | 755834 | 2020239 | 2554149 | 1368000 | 143262 | 6841484 |
| President, Chief Financial Officer |  |  |  |  |  |  |  |

---

______________

(1)Mr. Lobo's title changed to Chair and Chief Executive Officer effective January 1, 2026.

(2)Mr. Wells became Vice President, Chief Financial Officer effective April 1, 2025.

(3)Mr. Stiles became President and Chief Operating Officer effective January 1, 2026.

(4)Mr. Boehnlein retired from his role as Vice President, Chief Financial Officer effective April 1, 2025 and is employed (in a non-executive officer

capacity) as Advisor to the Chief Executive Officer through March 31, 2026.

***Salary:*** This column represents the base salary paid to the NEO during the reported year. This column includes the portion of salary

payments deferred into our 401(k) Plan and Supplemental Plan.

***Stock Awards:*** This column represents the aggregate grant date fair value of performance stock units and, for Mr. Wells, the stock

award granted to him in 2025 in connection with his leadership of an internal employee resource group, calculated in accordance with

the *Compensation* — *Stock Compensation* Topic of the FASB Codification. The grant date fair value of the performance stock units

reflected in the table is based on the target level performance, which was the probable outcome of the performance conditions on the

grant date. The grant date fair value of the NEOs' 2025 performance stock unit awards, if earned at maximum levels (200% of target),

was $19,528,272, $3,662,050, $5,370,155, $5,370,155 and $3,294,887 for Mr. Lobo, Mr. Wells, Mr. Stiles, Mr. Pierce and Mr. Menon,

respectively. Mr. Boehnlein did not receive a grant of performance stock unit awards in 2025. For a more detailed discussion of the

assumptions used to calculate the fair value of our stock awards, refer to Note 1 to the consolidated financial statements contained in

our 2025 Annual Report on Form 10-K for our fiscal year ended December 31, 2025.

***Option Awards:*** This column represents the aggregate grant date fair value of stock option awards calculated in accordance with the

*Compensation* — *Stock Compensation* Topic of the FASB Codification. Stock option values are derived using the Black-Scholes option

pricing model assumptions that are discussed under "Grant Date Fair Value of Stock and Option Awards" on page <u>[36](#ia4aac1b3eb19497683ee817bcafb3bdd_24435)</u>. Mr. Boehnlein did

not receive a grant of stock option awards in 2025.

***Non-Equity Incentive Plan Compensation:*** This column reflects the bonus plan amounts earned by the NEOs during the reported

year and paid in February of the following year under our Executive Bonus Plan. This column also includes any portion of such

payments that each NEO deferred into the 401(k) Plan and Supplemental Plan.

***All Other Compensation:*** This column includes the following items for 2025:

• 401(k) Plan matching contributions and discretionary contributions made in March 2026 pertaining to the 2025 Plan year, in the

amount of $36,250 for each NEO.

• Supplemental Plan matching contributions and discretionary contributions made in March 2026 pertaining to the 2025 Plan year,

in the amounts of $450,821, $62,089, $151,831, $151,831, $120,046 and $170,550 for Mr. Lobo, Mr. Wells, Mr. Stiles, Mr.

Pierce, Mr. Menon and Mr. Boehnlein, respectively.

• In accordance with SEC disclosure requirements, perquisites and personal benefits received by any NEO must be identified by

type if the total value was $10,000 or more. Mr. Lobo, Mr. Menon, and Mr. Boehnlein are the only NEOs for whom perquisites

and personal benefits exceeded $10,000 in 2025. These benefits for Mr. Lobo include costs associated with an executive

physical examination, the financial counseling benefit, and the aggregate incremental cost of $474,033 for personal use of

aircraft by Mr. Lobo and his family members. The incremental cost of usage of Company aircraft is based on variable operating

costs, such as the cost of fuel, aircraft maintenance, engine reserves, crew travel, landing fees, hourly fees, ramp fees and other

miscellaneous variable costs. The incremental cost of Company aircraft usage excludes items that do not change based on

usage, such as pilot salaries, insurance, depreciation, aircraft management fees and other fixed costs. In cases when chartered

aircraft are used, the incremental cost of usage is generally equal to the amount that the Company pays for the personal use of

the chartered aircraft. The aggregate incremental cost related to personal use of aircraft will differ from year to year based on

factors such as destination of flights, whether it is determined to be more prudent to use Company aircraft or chartered aircraft

for specific flights, the duration of flights and the variable operating costs for Company aircraft at the time of travel or the cost of

chartered aircraft at the time of travel. The benefit to Mr. Lobo associated with personal use of aircraft was imputed as income for

tax purposes at Standard Industry Fare Level rates and he paid the associated taxes. These benefits for Mr. Menon include costs

associated with an executive physical examination and the financial counseling benefit. These benefits for Mr. Boehnlein include

costs associated with an executive physical examination, a gift in connection with attendance of a Company event and gifts in

connection with his announced retirement from the Company with the value of such gifts totaling $26,569.

• A cash award of $5,000 made to Mr. Wells at the conclusion of his tenure as the leader of one our internal employee resource

groups, which is consistent with our practice for leadership roles of such groups.

• A transition services benefit with a value of $53,760 provided to Mr. Boehnlein in connection with his retirement from his role as

Vice President, Chief Financial Officer.

The Compensation and Human Capital Committee has directed that the Company avoid the use of tax gross-ups on perquisites and

personal benefits for NEOs except for relocation expenses and items related to expatriate assignments and in isolated cases where

particular circumstances warrant.

***Primary Compensation Elements:*** The following table indicates the percentages of our three primary compensation elements of

salary, actual bonus and stock awards consisting of performance stock units and stock options, but excluding the stock award granted

to Mr. Wells in connection with his leadership of an internal employee resource group, in relation to the total of such elements for each

NEO for 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Salary** | **Bonus Plan**<br>**Payment**<br>| **Performance Stock** <br>**Units Grant Date** <br>**Value**<sup>(1)</sup><br>| **Stock Option Grant** <br>**Date Value using** <br>**Black-Scholes**<sup>(1)</sup><br>|
| Kevin A. Lobo ............. | 7% | 11% | 48% | 34% |
| Preston W. Wells ........ | 15% | 12% | 43% | 30% |
| Spencer S. Stiles ....... | 13% | 12% | 44% | 31% |
| J. Andrew Pierce ........ | 13% | 12% | 44% | 31% |
| Viju S. Menon ............. | 17% | 14% | 40% | 29% |
| Glenn S. Boehnlein .... | 50% | 50% |  |  |

---

______________

(1)Uses aggregate grant date fair value in accordance with the *Compensation* — *Stock Compensation* Topic of the FASB Codification for 2025 awards

of performance stock units and stock option grants. See "Grant Date Fair Value of Stock and Option Awards" on page <u>[36](#ia4aac1b3eb19497683ee817bcafb3bdd_24435)</u>.

**2025 Grants of Plan-Based Awards**<br>

The table below sets forth additional information regarding the range of annual bonus plan payout potential for 2025, the range of

payout potential for performance stock unit awards ("PSUs") granted in 2025, the stock award granted to Mr. Wells related to his

leadership of an employee resource group ("ERG Award") in 2025, and the stock options granted to the NEOs in 2025 that are

disclosed in the "Summary Compensation Table" on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u>. The PSUs and stock options granted to the NEOs in 2025 were awarded

under our 2011 Plan. The ERG Award granted to Mr. Wells in 2025 was awarded under our 2011 Performance Incentive Award Plan, as

amended and restated.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Estimated Future Payouts**<br>**Under Non-Equity Incentive** <br>**Plan Awards** | **Estimated Future Payouts**<br>**Under Non-Equity Incentive** <br>**Plan Awards** | **Estimated Future Payouts**<br>**Under Non-Equity Incentive** <br>**Plan Awards** | **Estimated Future Payouts**<br>**Under Equity Incentive Plan** <br>**Awards** | **Estimated Future Payouts**<br>**Under Equity Incentive Plan** <br>**Awards** | **Estimated Future Payouts**<br>**Under Equity Incentive Plan** <br>**Awards** | **All** <br>**Other** <br>**Stock** <br>**Awards:** <br>**Number** <br>**of** <br>**Shares** <br>**of Stock** <br>**or Units** <br>**(#)** | **All Other** <br>**Option** <br>**Awards:** <br>**Number of** <br>**Securities** <br>**Underlying** <br>**Options (#)** | **Exercise** <br>**or Base** <br>**Price of** <br>**Option** <br>**Awards** <br>**($/sh)** | **Closing** <br>**Market** <br>**Price** <br>**on** <br>**Grant** <br>**Date**<br> **($/sh)** | **Grant** <br>**Date Fair** <br>**Value of** <br>**Stock** <br>**and** <br>**Option** <br>**Awards** <br>**($)** |
| <br>**Name** | <br>**Grant** <br>**Date**<br>| **Threshold** <br>**($)**<br>| **Target**<br>**($)**<br>| **Maximum** <br>**($)**<br>| **Threshold** <br>**(#)**<br>| **Target**<br>**(#)**<br>| **Maximum** <br>**(#)**<br>| **All** <br>**Other** <br>**Stock** <br>**Awards:** <br>**Number** <br>**of** <br>**Shares** <br>**of Stock** <br>**or Units** <br>**(#)** | **All Other** <br>**Option** <br>**Awards:** <br>**Number of** <br>**Securities** <br>**Underlying** <br>**Options (#)** | **Exercise** <br>**or Base** <br>**Price of** <br>**Option** <br>**Awards** <br>**($/sh)** | **Closing** <br>**Market** <br>**Price** <br>**on** <br>**Grant** <br>**Date**<br> **($/sh)** | **Grant** <br>**Date Fair** <br>**Value of** <br>**Stock** <br>**and** <br>**Option** <br>**Awards** <br>**($)** |
| K. Lobo |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Annual Bonus |  | 1125000 | 2250000 | 4500000 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;PSUs | 2/5/25 |  |  |  | 12232 | 24466 | 48932 |  |  |  |  | 9764136 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock Options | 2/5/25 |  |  |  |  |  |  |  | 48936 | 392.39 | 399.09 | 6920781 |
| P. Wells |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Annual Bonus |  | 257279 | 514558 | 1029116 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;PSUs | 2/5/25 |  |  |  | 2294 | 4588 | 9176 |  |  |  |  | 1831025 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ERG Award | 1/17/25 |  |  |  |  |  |  | 27 |  |  |  | 10352 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock Options | 2/5/25 |  |  |  |  |  |  |  | 9176 | 392.39 | 399.09 | 1297717 |
| S. Stiles |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Annual Bonus |  | 380000 | 760000 | 1520000 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;PSUs | 2/5/25 |  |  |  | 3364 | 6728 | 13456 |  |  |  |  | 2685078 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock Options | 2/5/25 |  |  |  |  |  |  |  | 13458 | 392.39 | 399.09 | 1903300 |
| J. Pierce |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Annual Bonus |  | 380000 | 760000 | 1520000 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;PSUs | 2/5/25 |  |  |  | 3364 | 6728 | 13456 |  |  |  |  | 2685078 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock Options | 2/5/25 |  |  |  |  |  |  |  | 13458 | 392.39 | 399.09 | 1903300 |
| V. Menon |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Annual Bonus |  | 289000 | 578000 | 1156000 |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;PSUs | 2/5/25 |  |  |  | 2064 | 4128 | 8256 |  |  |  |  | 1647444 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock Options | 2/5/25 |  |  |  |  |  |  |  | 8258 | 392.39 | 399.09 | 1167889 |
| G. Boehnlein |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Annual Bonus |  | 400000 | 800000 | 1600000 |  |  |  |  |  |  |  |  |

---

***Estimated Future Payouts Under Non-Equity Incentive Plan Awards:*** Amounts in these columns represent the possible range

(threshold to target to maximum) of cash payments possible under the 2025 individual bonus plans for the NEOs. A minimum level of

adjusted consolidated operating income must have been achieved before any portion of the bonus could be earned. If the minimum

level was achieved, a threshold level of performance related to each bonus measure must have been achieved to earn a payout related

to the respective measure. In addition, the total bonus payout was subject to a potential adjustment of up to +/-10% based on progress

toward certain CR commitments. The "Summary Compensation Table" on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u> shows the actual non-equity incentive plan

payments received for 2025.

***Estimated Future Payouts Under Equity Incentive Plan Awards:*** Amounts in these columns represent the possible range (threshold

to target to maximum) of performance stock units, which will be settled in shares of Common Stock, that would be earned based on the

achievement of pre-established goals for the 2025 to 2027 performance period. A minimum level of three-year average adjusted net

earnings per diluted share must be achieved before any performance stock units can be earned. Even if the minimum level is achieved,

the number of performance stock units earned could be zero if performance is below threshold for each performance measure.

***All Other Stock Awards: Number of Shares of Stock or Units, All Other Option Awards: Number of Securities Underlying***

***Options, Exercise or Base Price of Option Awards and Closing Market Price on Grant Date:*** The ERG Award and stock option

grants are shown in number of shares. The exercise price of all option awards is the closing market price of our Common Stock on the

last trading day before the grant date in accordance with the terms of our equity-based compensation plans.

***Grant Date Fair Value of Stock and Option Awards:*** This column represents the grant date fair value of performance stock units,

based on the target level achievement, the ERG Award and stock options granted in 2025, calculated in accordance with the provisions

of the *Compensation* — *Stock Compensation* Topic of the FASB Codification.

The performance stock unit awards that were granted in February 2025, if earned based on achievement of the pre-established goals,

will vest 100% on March 21, 2028. The actual value an NEO realizes from the awards of performance stock units will depend on the

price of our Common Stock on the date of vesting and the number of shares earned.

The stock option grant date fair values throughout this Proxy Statement, unless otherwise noted, have been calculated using the Black-

Scholes option pricing model and the assumptions for each year as set forth in the following table:

---

| | | | |
|:---|:---|:---|:---|
| **Black-Scholes Model Assumptions**<sup>(1)</sup> | **2025** | **2024** | **2023** |
| Risk-free interest rate  | 4.4% | 4.3% | 4.0% |
| Expected dividend yield  | 0.9% | 1.1% | 1.2% |
| Expected stock price volatility  | 29.1% | 29.9% | 29.0% |
| Expected option life (years) | 6.4 | 6.3 | 6.2 |

---

______________

(1)The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Expected stock price volatility is based on historical

volatility of the Company's stock. The expected option life, representing the period of time that options are expected to be outstanding, is based on

historical option exercise and employee termination data.

The stock option awards that were granted in February 2025 have a ten-year term and become exercisable as to 20% of the underlying

shares on each of the first five anniversary dates of the date of grant. The actual value an NEO realizes from the stock option grants will

depend on the difference between the market price of the underlying shares at exercise and the exercise price of the option established

at the time of grant.

The ERG Award granted to Mr. Wells in January 2025 was immediately vested upon grant and was not subject to any forfeiture

conditions.

**Outstanding Equity Awards at 2025 Fiscal Year-End**<br>

The table on the following page sets forth information as to unexercised options, unvested restricted stock units and unvested

performance stock units held by the NEOs on December 31, 2025 (dollar values, except option exercise price, are based on the closing

price of our Common Stock of $351.47 as reported for NYSE Composite Transactions on December 31, 2025):

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Option Awards**<sup>(1)</sup> | **Option Awards**<sup>(1)</sup> | **Option Awards**<sup>(1)</sup> | **Option Awards**<sup>(1)</sup> | **Stock Awards**  | **Stock Awards**  | **Stock Awards**  | **Stock Awards**  |
| **Name** | **Grant**<br>**Date**<br>| **Number of**<br>**Securities**<br>**Underlying**<br>**Unexercised**<br>**Options (#)**<br>**Exercisable**<br>| **Number of** <br>**Securities** <br>**Underlying** <br>**Unexercised** <br>**Options (#)** <br>**Unexercisable**<br>| **Option**<br>**Exercise**<br>**Price**<br>**($/sh)**<br>| **Option**<br>**Expiration**<br>**Date**<br>| **Number of** <br>**Shares or** <br>**Units of** <br>**Stock That** <br>**Have Not** <br>**Vested (#)**<sup>(2)</sup><br>| **Market** <br>**Value of** <br>**Shares or** <br>**Units of** <br>**Stock That** <br>**Have Not** <br>**Vested ($)**<br>| **Equity Incentive** <br>**Plan Awards:** <br>**Number of** <br>**Unearned** <br>**Shares, Units or** <br>**Other Rights** <br>**That Have Not** <br>**Vested (#)**<sup>(3)</sup><br>| **Equity Incentive** <br>**Plan Awards:** <br>**Market or Payout** <br>**Value of Unearned** <br>**Shares, Units**<br>**or Other Rights** <br>**That Have Not** <br>**Vested ($)**<br>|
| K. Lobo .......... | 2-10-16 | 206955 |  | 96.64 | 2-09-26 |  |  |  |  |
|  | 2-08-17 | 193860 |  | 122.51 | 2-07-27 |  |  |  |  |
|  | 2-07-18 | 162190 |  | 154.14 | 2-06-28 |  |  |  |  |
|  | 2-06-19 | 146360 |  | 179.35 | 2-05-29 |  |  |  |  |
|  | 2-05-20 | 124800 |  | 216.35 | 2-04-30 |  |  |  |  |
|  | 2-03-21 | 102072 | 25518 | 235.13 | 2-02-31 |  |  |  |  |
|  | 2-02-22 | 76932 | 51288 | 248.60 | 2-01-32 |  |  |  |  |
|  | 2-09-23 | 40266 | 60399 | 268.22 | 2-08-33 | 50332 | 17690188 |  |  |
|  | 2-07-24 | 13539 | 54156 | 339.77 | 2-06-34 |  |  | 50768 | 17843429 |
|  | 2-05-25 |  | 48936 | 392.39 | 2-04-35 |  |  | 48932 | 17198130 |
| P. Wells .......... | 2-07-18 | 1555 |  | 154.14 | 2-06-28 |  |  |  |  |
|  | 2-06-19 | 4040 |  | 179.35 | 2-05-29 |  |  |  |  |
|  | 2-05-20 | 3640 |  | 216.35 | 2-04-30 |  |  |  |  |
|  | 2-03-21 | 3404 | 851 | 235.13 | 2-02-31 |  |  |  |  |
|  | 2-02-22 | 2595 | 1730 | 248.60 | 2-01-32 |  |  |  |  |
|  | 2-09-23 | 1492 | 2238 | 268.22 | 2-08-33 | 311 | 109307 |  |  |
|  | 2-07-24 | 677 | 2708 | 339.77 | 2-06-34 | 564 | 198229 |  |  |
|  | 2-05-25 |  | 9176 | 392.39 | 2-04-35 |  |  | 9176 | 3225089 |
| S. Stiles .......... | 2-10-16 | 13840 |  | 96.64 | 2-09-26 |  |  |  |  |
|  | 2-08-17 | 11630 |  | 122.51 | 2-07-27 |  |  |  |  |
|  | 2-07-18 | 10135 |  | 154.14 | 2-06-28 |  |  |  |  |
|  | 2-06-19 | 22305 |  | 179.35 | 2-05-29 |  |  |  |  |
|  | 2-05-20 | 26575 |  | 216.35 | 2-04-30 |  |  |  |  |
|  | 2-03-21 | 22968 | 5742 | 235.13 | 2-02-31 |  |  |  |  |
|  | 2-02-22 | 22326 | 14884 | 248.60 | 2-01-32 |  |  |  |  |
|  | 2-09-23 | 11930 | 17895 | 268.22 | 2-08-33 | 14912 | 5241121 |  |  |
|  | 2-07-24 | 3956 | 15824 | 339.77 | 2-06-34 |  |  | 14832 | 5213003 |
|  | 2-05-25 |  | 13458 | 392.39 | 2-04-35 |  |  | 13456 | 4729380 |
| J. Pierce ......... | 2-10-16 | 13840 |  | 96.64 | 2-09-26 |  |  |  |  |
|  | 2-08-17 | 11630 |  | 122.51 | 2-07-27 |  |  |  |  |
|  | 2-07-18 | 10135 |  | 154.14 | 2-06-28 |  |  |  |  |
|  | 2-06-19 | 22305 |  | 179.35 | 2-05-29 |  |  |  |  |
|  | 2-05-20 | 26575 |  | 216.35 | 2-04-30 |  |  |  |  |
|  | 2-03-21 | 22968 | 5742 | 235.13 | 2-02-31 |  |  |  |  |
|  | 2-02-22 | 22326 | 14884 | 248.60 | 2-01-32 |  |  |  |  |
|  | 2-09-23 | 11930 | 17895 | 268.22 | 2-08-33 | 14912 | 5241121 |  |  |
|  | 2-07-24 | 3956 | 15824 | 339.77 | 2-06-34 |  |  | 14832 | 5213003 |
|  | 2-05-25 |  | 13458 | 392.39 | 2-04-35 |  |  | 13456 | 4729380 |
| V. Menon ........ | 5-01-18 | 51645 |  | 169.42 | 4-30-28 |  |  |  |  |
|  | 2-06-19 | 24395 |  | 179.35 | 2-05-29 |  |  |  |  |
|  | 2-05-20 | 21955 |  | 216.35 | 2-04-30 |  |  |  |  |
|  | 2-03-21 | 17864 | 4466 | 235.13 | 2-02-31 |  |  |  |  |
|  | 2-02-22 | 13275 | 8850 | 248.60 | 2-01-32 |  |  |  |  |
|  | 2-09-23 | 7456 | 11184 | 268.22 | 2-08-33 | 9320 | 3275700 |  |  |
|  | 2-07-24 | 2449 | 9796 | 339.77 | 2-06-34 |  |  | 9184 | 3227900 |
|  | 2-05-25 |  | 8258 | 392.39 | 2-04-35 |  |  | 8256 | 2901736 |
| G. Boehnlein . | 2-08-17 | 9015 |  | 122.51 | 2-07-27 |  |  |  |  |
|  | 2-07-18 | 38925 |  | 154.14 | 2-06-28 |  |  |  |  |
|  | 2-06-19 | 37635 |  | 179.35 | 2-05-29 |  |  |  |  |
|  | 2-05-20 | 36975 |  | 216.35 | 2-04-30 |  |  |  |  |
|  | 2-03-21 | 28920 | 7230 | 235.13 | 2-02-31 |  |  |  |  |
|  | 2-02-22 | 22326 | 14884 | 248.60 | 2-01-32 |  |  |  |  |
|  | 2-09-23 | 12228 | 18342 | 268.22 | 2-08-33 | 15284 | 5371867 |  |  |
|  | 2-07-24 | 4238 | 16952 | 339.77 | 2-06-34 |  |  | 15892 | 5585561 |

---

______________

(1)All stock option awards vest as to 20% of the shares on each of the first five anniversary dates of the date of grant.

(2)For the NEOs other than Mr. Wells, the numbers shown represent the 2023 PSUs for which the three-year performance period had concluded as of

December 31, 2025 and which remained unvested until March 21, 2026. For Mr. Wells, the numbers shown represent restricted stock units that

were outstanding as of December 31, 2025. The restricted stock units granted to Mr. Wells in 2023 have a vesting schedule of one-third on March

21, 2024, one-third on March 21, 2025 and one-third on March 21, 2026. The restricted stock units granted to Mr. Wells in 2024 have a vesting

schedule of one-third on March 21, 2025, one-third on March 21, 2026 and one-third on March 21, 2027.

(3)The performance stock units awarded in 2024 and 2025 will be earned based on the achievement of pre-established goals covering the

performance periods of 2024-2026 and 2025-2027, respectively. The numbers shown represent the maximum number of units (200% of the target

number of PSUs that were granted) that can be earned, excluding dividend equivalents that cannot be calculated until the date of vesting. If earned,

the 2024 PSUs vest on March 21, 2027 and the 2025 PSUs vest on March 21, 2028.

**2025 Option Exercises and Stock Vested**<br>

The table below includes information related to options exercised by and stock awards (restricted stock units, performance stock units,

including dividend equivalents, and Mr. Wells' ERG Award) vested in respect of each of the NEOs during 2025. The table also includes

the value realized for such options and stock awards.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** |
| <br>**Name** | **Number of Shares**<br>**Acquired on**<br>**Exercise (#)**<br>| **Value Realized**<br>**on Exercise ($)**<sup>(1)</sup><br>| **Number of Shares**<br>**Acquired on**<br>**Vesting (#)**<br>| **Value Realized**<br>**on Vesting ($)**<sup>(2)</sup><br>|
| Kevin A. Lobo .......................................................................................... |  |  | 45592 | 17061438 |
| Preston W. Wells ..................................................................................... |  |  | 2087 | 760047 |
| Spencer S. Stiles .................................................................................... | 10210 | 3084339 | 13230 | 4950931 |
| J. Andrew Pierce ..................................................................................... | 9455 | 2856261 | 13230 | 4950931 |
| Viju S. Menon .......................................................................................... |  |  | 7865 | 2943240 |
| Glenn S. Boehnlein ................................................................................. |  |  | 13230 | 4950931 |

---

______________

(1)Calculated using the difference between the market price of the underlying shares at exercise and the exercise price of the option established at the

time of grant.

(2)Calculated using the market price of the underlying shares on the date of vesting.

Our NEOs must exercise stock options by their expiration date, which is ten years after the grant date, to avoid forfeiting the options.

The values historically realized by our NEOs for stock option exercises have generally been significantly greater than the grant date fair

value of the option awards due to strong stock price appreciation from when the options were granted to the date of exercise. We

believe this has served the Company well as it demonstrates alignment with our compensation program objectives outlined in the

"Compensation Discussion and Analysis" section beginning on page <u>[19](#i2547898784014edd82c5d43eb63a27de_79)</u> of aligning the compensation of our NEOs with the interests of

our shareholders and helping to attract, motivate and retain a skilled management team.

**2025 Pension Benefits** <br>

No NEO participates in any defined benefit pension plan sponsored by the Company.

**2025 Nonqualified Deferred Compensation**<br>

NEOs are eligible to participate in the 401(k) Plan, a qualified defined contribution plan that is available to all eligible U.S. employees,

and the Supplemental Plan, a nonqualified supplemental defined contribution plan in which select U.S.-based executives may

participate. Under the 401(k) Plan, we match fifty cents per dollar of the first 8% of compensation contributed by the employee up to the

Internal Revenue Code limits ($23,500 annual deferral and $350,000 compensation in 2025). The Supplemental Plan provides benefits

comparable to the 401(k) Plan after Internal Revenue Code limits have been reached. Participants may contribute up to 75% of total

eligible compensation (salary and bonus for the NEOs) under the 401(k) Plan and Supplemental Plan. In addition to the Company

match, a discretionary Company contribution may be made to the 401(k) Plan and Supplemental Plan each year. For 2025, a

discretionary contribution of 7% of eligible compensation for all employees eligible under the 401(k) Plan and Supplemental Plan,

including all of our NEOs, was paid in March 2026. The following table shows information about NEO participation in our Supplemental

Plan.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Executive** <br>**Contributions** <br>**in Last FY ($)**<sup>(1)</sup><br>| **Registrant** <br>**Contributions** <br>**in Last FY ($)**<sup>(2)</sup><br>| **Aggregate** <br>**Earnings** <br>**in Last FY ($)**<sup>(3)</sup><br>| **Aggregate** <br>**Balance** <br>**at Last FYE ($)**<sup>(4)</sup><br>|
| Kevin A. Lobo ............................................................................................ | 2286771 | 450821 | 3930434 | 27805048 |
| Preston W. Wells ....................................................................................... | 43065 | 62089 | 70888 | 522915 |
| Spencer S. Stiles ...................................................................................... | 147483 | 151831 | 984255 | 7280286 |
| J. Andrew Pierce ....................................................................................... | 744663 | 151831 | 2471288 | 17683084 |
| Viju S. Menon ............................................................................................ | 582406 | 120046 | 1929137 | 10917293 |
| Glenn S. Boehnlein .................................................................................. | 157000 | 170550 | 1183588 | 8570153 |

---

______________

(1)These amounts were reported as compensation in 2025 in the "Salary" column and in 2024 in the "Non-Equity Incentive Plan Compensation"

column of the "Summary Compensation Table" on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u>, other than for Mr. Wells whose compensation prior to 2025 is not required to be

disclosed.

(2)These amounts, contributed in March 2026 but earned for 2025, are included in the "All Other Compensation" column of the "Summary

Compensation Table" on page <u>[33](#if2b0f1b9b9c64d8e989b044ac8199702_0-0-1-1-330571)</u> (along with 401(k) Plan matching contributions and discretionary contributions in the amount of $36,250 for each

NEO).

(3)None of the amounts reported in this column are reported in the "Summary Compensation Table" because we do not pay guaranteed, above-market

or preferential earnings on deferred compensation under the Supplemental Plan.

(4)Aggregate balance consists of employee and Company contributions and investment earnings. The 2025 year-end balance includes registrant

contributions made in March 2026 that were earned in 2025. The following aggregate contribution amounts, comprised of executive contributions

and registrant contributions, for 2024 and 2023 are included in the reported aggregate balance and were previously reported in the "Summary

Compensation Table" as Salary, Non-Equity Incentive Plan Compensation or All Other Compensation for the NEOs other than Mr. Wells whose

compensation prior to 2025 is not required to be disclosed:

---

| | | |
|:---|:---|:---|
| **Name** | **Aggregate Contributions in 2024** | **Aggregate Contributions in 2023** |
| Kevin A. Lobo ....................................................................... | 3458566 | 1495046 |
| Spencer S. Stiles ................................................................. | 580395 | 189503 |
| J. Andrew Pierce .................................................................. | 1091520 | 581577 |
| Viju S. Menon ....................................................................... | 1311642 | 778537 |
| Glenn S. Boehnlein ............................................................. | 387731 | 209150 |

---

Matching and discretionary contributions to our 401(k) Plan and Supplemental Plan vest based on the total service years of the

participant as follows: 20% with two years of service; 40% with three; 60% with four; and 100% with five years of service.

Earnings on all amounts in the Supplemental Plan are based on the returns of the investment choices made by the individual. The

selected funds and individual allocation may be changed by the participant at any time. The investment alternatives for the NEOs in the

Supplemental Plan are identical to the investment alternatives for all eligible employees under the 401(k) Plan, except that the

Supplemental Plan does not allow investment in the Stryker Stock Fund (our matching contribution under the 401(k) Plan on the first

4% of compensation is invested in the Stryker Stock Fund) or life-cycle funds. The investment alternatives are regularly reviewed and

periodically change. As of December 31, 2025, participants could choose among several different investment types, including domestic

and international equity, fixed income, short-term investment and balanced fund investments. No guaranteed interest rates or returns

are provided on investments in the 401(k) Plan or Supplemental Plan.

Benefits from the Supplemental Plan may be paid following termination of employment as a lump sum or in installments, or a

combination thereof, based on the individual's payment election. Supplemental Plan benefits payable to NEOs for amounts subject to

Internal Revenue Code Section 409A (generally, amounts that were earned and vested after 2004) will not be paid earlier than six

months from termination of employment if termination was for any reason other than death. Effective January 1, 2026, all participants in

the Supplemental Plan, including the NEOs, will have the option to have any of their employee contributions that are made on or after

that date to the Supplemental Plan paid prior to, or following, termination of employment. This flexibility only applies to employee

contributions that are made on or after January 1, 2026. Any contributions made by the NEOs to the Supplemental Plan prior to January

1, 2026 will continue to be paid no earlier than six months from termination of employment if termination was for any reason other than

death.

**Potential Payments upon Termination or Change in Control**<br>

We have no employment or severance agreement in place with any currently employed NEO. We have in the past paid, and are likely in

the future to pay, severance to NEOs based on the specific facts and circumstances at the time of separation. As of December 31,

2025, Mr. Pierce has agreed to Stryker's Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement that

provides for potential monthly payments to compensate the individual for not competing in circumstances following termination if the

individual is unable to be re-employed without competing, demonstrates efforts to find work that does not violate the non-compete

provisions, meets certain other requirements and Stryker does not elect to waive enforcement of the non-competition provisions of the

agreement. The non-competition provisions of the agreement are effective for 12 months following termination of employment and, if

Stryker is required to make payments, the agreement requires monthly payment of 1/12<sup>th</sup> of the total salary and incentive bonus

(exclusive of benefits, stock awards, and any indirect or deferred compensation) paid in the 12 months preceding termination of

employment, less any compensation the individual has received or has the right to receive from Stryker or any other source during the

12 months following termination, including severance payments. The Company could be required to pay Mr. Pierce such amounts in

installments totaling $1,554,148 if we elected to enforce the non-compete provisions and he satisfied the other requirements. The

amount set forth above for Mr. Pierce assumes 2025 salary and bonus levels, a December 31, 2025 termination date and no reduction

in payment due to severance payments or other sources of compensation, including amounts received as a result of employment by a

non-competitor. Actual future amounts to be paid would vary from the figures above based on factors including termination date,

termination event and circumstances, compensation rates at the time, severance payments, the Company's decision whether to enforce

the agreement, compensation paid by future employers and other factors and assumptions. Mr. Lobo, Mr. Wells, Mr. Stiles, Mr. Menon

and Mr. Boehnlein have signed a version of Stryker's non-compete agreement that does not contemplate any payment to enforce its

restrictions.

Stock options and awards of restricted stock units and performance stock units have the following treatment at various terminating

events:

---

| | | |
|:---|:---|:---|
| **Reason for Employment Termination** | **Vested Options Exercisable** | **Unvested Options or Units** |
| Death or Disability<sup>(1)</sup> | For one year from termination | Options and restricted stock units become 100% vested and options <br>remain exercisable for one year. Performance stock units continue to <br>vest according to the original vesting schedule and are earned based on <br>performance covering the entire three-year performance period.<br>|
| Retirement<sup>(1)(2)</sup> | Until original expiration date | Options continue to vest according to the original vesting schedule and <br>are exercisable until the original expiration date. Restricted stock units <br>continue to vest according to the original vesting schedule. Performance <br>stock units continue to vest according to the original vesting schedule <br>and are earned based on performance covering the entire three-year <br>performance period. However, if an individual does not remain <br>employed for 12 months following the grant of the respective <br>performance stock units then those performance stock units have <br>prorated vesting through the date of retirement and are earned based <br>on performance covering the entire three-year performance period.<br>|
| Other Reasons | For 30 days from termination | Forfeited. |

---

______________

(1)Performance stock units granted prior to 2024 have prorated vesting through the date of termination or retirement and are earned based on

performance covering the entire three-year performance period.

(2)In our 2011 Plan, for stock awards granted after 2019, retirement is defined as termination at or after age 65, or age 55 if the individual has been

employed by Stryker for at least 10 years. For stock awards granted in 2019 and prior years, retirement is defined as termination at or after age 65,

or age 60 if the individual has been employed by Stryker for at least 10 years. As of December 31, 2025, Mr. Lobo and Mr. Boehnlein have met the

age and service requirements for retirement as defined in the 2011 Plan for all of their stock awards. Mr. Wells, Mr. Stiles, Mr. Pierce and Mr. Menon

have not met the age and service requirements for retirement related to any of their stock awards.

Our 2011 Plan expressly permits the Compensation and Human Capital Committee at its sole discretion to accelerate vesting and take

other actions on awards that it deems appropriate following a change in control of the Company. We will publicly disclose the actions

the Compensation and Human Capital Committee intends to take regarding the treatment of awards in the event there is a proposed

change in control of the Company.

The estimated value of unvested options, performance stock units (including the estimated value of any accrued dividend equivalents)

and restricted stock units that would not be forfeited upon termination due to death, disability or retirement and could be vested upon

the occurrence of a change in control as of December 31, 2025 is set forth in the table below for each NEO. The unrealized values of

the unvested options and units are based on the closing price of our Common Stock of $351.47 as reported for NYSE Composite

Transactions on December 31, 2025.

---

| | | |
|:---|:---|:---|
| | **Unrealized Value of Unvested Stock Options, Performance** <br>**Stock Units and Restricted Stock Units ($)**<sup>(1)</sup> | **Unrealized Value of Unvested Stock Options, Performance** <br>**Stock Units and Restricted Stock Units ($)**<sup>(1)</sup> |
| <br>**Name** | **Change in Control,**<br>**Death or Disability**<br>| **Retirement** |
| Kevin A. Lobo ...................................................... | 67377140 | 55911485 |
| Preston W. Wells ................................................. | 4043057 |  |
| Spencer S. Stiles ................................................ | 19274050 |  |
| J. Andrew Pierce ................................................. | 19274050 |  |
| Viju S. Menon ...................................................... | 12014902 |  |
| Glenn S. Boehnlein ............................................. | 15255683 | 15255683 |

---

______________

(1)The unrealized value of unvested stock options is calculated using the difference between the closing price of our Common Stock of $351.47 on

December 31, 2025 and the exercise price of the option established at the time of grant.

The timing of payment of certain amounts, such as the Supplemental Plan payments, is structured to comply with Internal Revenue

Code Section 409A, which generally requires payments (other than grandfathered payments) to our NEOs to be made no earlier than

six months following termination. See "2025 Nonqualified Deferred Compensation" beginning on page <u>[38](#i2c66a95ccadd4629b72915da36e7a71f_0-0-1-1-330605)</u> for more information regarding

the payment of benefits to our NEOs from the Supplemental Plan following termination of employment.

The Company does not pay for any form of post-retirement healthcare benefits for our NEOs or any other employee.

**Pay versus Performance**<br>

The following table presents, for the five most recently completed fiscal years, the Summary Compensation Table total compensation

for our Principal Executive Officer ("PEO"), the average Summary Compensation Table total compensation for our other NEOs that are

not the PEO, the compensation actually paid amounts for our PEO, the average compensation actually paid amounts for our other

NEOs that are not the PEO, our total shareholder return, the total shareholder return for the Standard & Poor's ("S&P") 500 Health Care

Index, our net income and our company-selected measure, which represents our reported net sales growth. Compensation decisions

are made independently of the Pay versus Performance disclosure below. See "Compensation Discussion and Analysis" beginning on

page <u>[19](#i2547898784014edd82c5d43eb63a27de_79)</u> for a description of the compensation decisions made for fiscal year 2025.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | **Average** <br>**Summary** <br>**Compensation** <br>**Table Total for** <br>**non-PEO** <br>**NEOs ($)** | | **Value of Initial Fixed $100** <br>**Investment Based on:** | **Value of Initial Fixed $100** <br>**Investment Based on:** | | |
| <br>**Year** | <br>**Summary** <br>**Compensation** <br>**Table Total for** <br>**PEO ($)**<br>| <br>**Compensation** <br>**Actually Paid** <br>**to PEO ($)**<br>| **Average** <br>**Summary** <br>**Compensation** <br>**Table Total for** <br>**non-PEO** <br>**NEOs ($)** | <br>**Average** <br>**Compensation** <br>**Actually Paid** <br>**to non-PEO** <br>**NEOs ($)**<br>| **Total** <br>**Shareholder** <br>**Return ($)**<br>| **Peer Group** <br>**Total** <br>**Shareholder** <br>**Return ($)**<br>| <br>**Net Income**<br>**(in $ millions)**<br>| <br>**Reported Net** <br>**Sales Growth** <br>**(%)**<br>|
| 2025 | 21401495 | 24776477 | 4638269 | 5450024 | 151.03 | 148.36 | 3246 | 11.2 |
| 2024 | 21979369 | 48190172 | 6361985 | 12965592 | 153.30 | 129.46 | 2993 | 10.2 |
| 2023 | 20767847 | 42471951 | 6072179 | 11389954 | 126.33 | 126.21 | 3165 | 11.1 |
| 2022 | 18563214 | 11419346 | 5246489 | 3676892 | 102.05 | 123.67 | 2358 | 7.8 |
| 2021 | 16359898 | 27844502 | 5769074 | 8859654 | 110.22 | 126.13 | 1994 | 19.2 |

---

***Summary Compensation Table Total for PEO:*** This column represents the total compensation value for our PEO as reported in the

Summary Compensation Table. Mr. Lobo was the PEO for each of the covered years in the table.

***Compensation Actually Paid to PEO:*** This column represents the compensation actually paid value for our PEO calculated according

to the methodology prescribed by the SEC. The following table summarizes the adjustments to the Summary Compensation Table value

which resulted in the compensation actually paid amount for our PEO in 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year** | **Summary** <br>**Compensation** <br>**Table Total ($)**<br>| **Grant Date Fair** <br>**Value of Equity** <br>**Awards Granted** <br>**During the Year** <br>**($)**<br>| **Year-End Fair** <br>**Value of Equity** <br>**Awards Granted** <br>**During the Year** <br>**that Remain** <br>**Unvested as of** <br>**Year-End ($)**<sup>(1)</sup><br>| **Change in Fair** <br>**Value as of Year-**<br>**End of Equity** <br>**Awards Granted** <br>**in Any Prior Year** <br>**that Remain** <br>**Unvested as of** <br>**Year-End ($)**<sup>(1)</sup><br>| **Fair Value of** <br>**Awards Granted** <br>**During the Year** <br>**that Vested** <br>**During the Year** <br>**($)**<sup>(1)</sup><br>| **Change in Fair** <br>**Value as of the** <br>**Vesting Date of** <br>**Equity Awards** <br>**Granted in Any** <br>**Prior Year that** <br>**Vested During** <br>**the Year ($)**<sup>(1)</sup><br>| **Compensation** <br>**Actually Paid ($)**<br>|
| 2025 | 21401495 | (16684917) | 12568907 | 3800709 |  | 3690283 | 24776477 |

---

______________

(1)The fair value of equity awards (performance stock units, restricted stock units and stock option awards) is calculated in accordance with the

*Compensation — Stock Compensation* Topic of the FASB Codification. Stock option values are derived using the Black-Scholes option pricing

model. The assumptions (risk-free interest rate, expected dividend yield, expected stock price volatility and expected option life) used in the

calculation of the fair value of stock option awards at each measurement date for purposes of determining the compensation actually paid amounts

have been updated, as necessary, relative to the assumptions used in the grant date fair value calculations for the respective stock option awards.

***Average Summary Compensation Table Total for non-PEO NEOs:*** This column represents the average total compensation value as

reported in the Summary Compensation Table for Named Executive Officers other than the Principal Executive Officer. The following

table lists by year the non-PEO NEOs included in the calculation of the average values in the table:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **2025** | **2024** | **2023** | **2022** | **2021** |
| Preston W. Wells | Glenn S. Boehnlein | Glenn S. Boehnlein | Glenn S. Boehnlein | Glenn S. Boehnlein |
| Spencer S. Stiles | J. Andrew Pierce | J. Andrew Pierce | J. Andrew Pierce | J. Andrew Pierce |
| J. Andrew Pierce | Spencer S. Stiles | Spencer S. Stiles | Spencer S. Stiles | Spencer S. Stiles |
| Viju S. Menon | Viju S. Menon | Viju S. Menon | Viju S. Menon | Viju S. Menon |
| Glenn S. Boehnlein |  |  |  | Timothy J. Scannell |

---

***Average Compensation Actually Paid to non-PEO NEOs:*** This column represents the average compensation actually paid value for

our non-PEO NEOs calculated according to the methodology prescribed by the SEC. The following table summarizes the average

adjustments to the average Summary Compensation Table value which resulted in the average compensation actually paid amount for

our non-PEO NEOs in 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Year** | **Average** <br>**Summary** <br>**Compensation** <br>**Table Total ($)**<br>| **Average Grant** <br>**Date Fair Value** <br>**of Equity** <br>**Awards Granted** <br>**During the Year** <br>**($)**<br>| **Average Year-**<br>**End Fair Value** <br>**of Equity** <br>**Awards Granted** <br>**During the Year** <br>**that Remain** <br>**Unvested as of** <br>**Year-End ($)**<sup>(1)</sup><br>| **Average Change** <br>**in Fair Value as** <br>**of Year-End of** <br>**Equity Awards** <br>**Granted in Any** <br>**Prior Year that** <br>**Remain** <br>**Unvested as of** <br>**Year-End ($)**<sup>(1)</sup><br>| **Average Fair** <br>**Value of Awards** <br>**Granted During** <br>**the Year that** <br>**Vested During** <br>**the Year ($)**<sup>(1)</sup><br>| **Average Change** <br>**in Fair Value as** <br>**of the Vesting** <br>**Date of Equity** <br>**Awards Granted** <br>**in Any Prior Year** <br>**that Vested** <br>**During the Year** <br>**($)**<sup>(1)</sup><br>| **Average** <br>**Compensation** <br>**Actually Paid ($)**<br>|
| 2025 | 4638269 | (3026237) | 2278059 | 805683 | 2070 | 752180 | 5450024 |

---

______________

(1)The fair value of equity awards (performance stock units, restricted stock units, the stock award granted to Mr. Wells related to his leadership of an

employee resource group and stock option awards) is calculated in accordance with the *Compensation — Stock Compensation* Topic of the FASB

Codification. Stock option values are derived using the Black-Scholes option pricing model. The assumptions (risk-free interest rate, expected

dividend yield, expected stock price volatility and expected option life) used in the calculation of the fair value of stock option awards at each

measurement date for purposes of determining the compensation actually paid amounts have been updated, as necessary, relative to the

assumptions used in the grant date fair value calculations for the respective stock option awards.

***Total Shareholder Return:*** This column represents the total returns (including reinvestments of dividends) of our Common Stock

assuming $100 was invested on December 31, 2020.

***Peer Group Total Shareholder Return:*** This column represents the total returns (including reinvestments of dividends) of the S&P 500

Health Care Index used for purposes of Item 201(e) of Regulation S-K. Refer to Item 5 in our 2025 Annual Report on Form 10-K for

further information on the peer group. Values in this column assume $100 was invested on December 31, 2020.

***Net Income:*** This column represents our net earnings (in $ millions) as reported in conformance with GAAP.

***Reported Net Sales Growth:*** This column represents the annual percentage change in our reported net sales as reported in

conformance with GAAP. We believe this measure is the most important financial performance measure (that is otherwise not required

to be disclosed in the Pay versus Performance table) used in linking compensation actually paid to our PEO and other NEOs to our

performance for the most recently completed fiscal year. Sales metrics are prominently used in the NEOs' annual bonus plans and

performance stock unit awards. Our reported net sales growth in 2025 is a large factor in determining the fair value as of December 31,

2025 for three performance stock unit cycles (the grants of performance stock units made in 2023, 2024 and 2025) thereby significantly

influencing the 2025 total compensation actually paid amounts to our PEO and other NEOs.

**Most Important Financial Measures**

The measures listed below represent the most important financial performance measures used to link compensation actually paid to our

NEOs to our performance for the most recently completed fiscal year. Refer to the section entitled "Compensation Discussion and

Analysis" beginning on page <u>[19](#i2547898784014edd82c5d43eb63a27de_79)</u> for a description of the compensation programs and practices applicable to our NEOs.

---

| |
|:---|
| Reported net sales growth |
| Constant currency sales |
| Adjusted net earnings per diluted share growth  |
| Adjusted operating income  |
| Adjusted operating income margin |

---

**Relationship of Our Total Shareholder Return and the Peer Group Total Shareholder Return**

Our cumulative total shareholder return during the five-year period of 2021 to 2025 was greater than that of the S&P 500 Health Care

Index.

**Relationship of Compensation Actually Paid and Our Total Shareholder Return**

The compensation actually paid to our PEO and other NEOs was strongly aligned to our total shareholder return during the five-year

period of 2021 to 2025. This is largely a result of the significant weighting of equity-based compensation, which is directly linked to the

price of our Common Stock, in the pay program for the PEO and other NEOs.

**Relationship of Compensation Actually Paid and Our Net Income**

The compensation actually paid to our PEO and other NEOs had limited alignment to our reported net income during the five-year

period of 2021 to 2025. Reported net income is not used as a performance measure in the pay programs for our PEO and other NEOs,

nor is it used when determining any other component of pay for this group.

**Relationship of Compensation Actually Paid and Our Reported Net Sales Growth**

The compensation actually paid to our PEO and other NEOs was aligned to our reported net sales growth during the five-year period of

2021 to 2025. Our one-year reported net sales growth performance is used in the performance stock units program when calculating

our three-year average reported net sales growth performance relative to a comparison group of companies, which has represented

50% of the target award opportunity in each grant of performance stock units that is included in the calculation of compensation actually

paid during the five-year period of 2021 to 2025.

**Ratio of 2025 Compensation of the Chief Executive Officer to that of the Median Employee** <br>

Pursuant to the SEC's guidance under Item 402(u) of Regulation S-K, we are required to disclose the annual total compensation for

both our Chief Executive Officer and median employee and the ratio of those two amounts. The pay ratio discussed in this section is an

estimate based on the Company's good faith efforts to reasonably calculate it. As a result of the flexibility permitted when identifying the

median employee and the Company's specific pay practices and workforce composition, the Company's pay ratio may not be

comparable to the pay ratios of other companies.

• The 2025 annual total compensation of our Chief Executive Officer was $21,401,495.

• The 2025 annual total compensation of our identified median employee was $81,018.

• The ratio of the annual total compensation of our Chief Executive Officer to that of our identified median employee was estimated

to be 264 to 1.

As permitted by SEC rules, because there has not been a meaningful change to our employee population or a change in our employee

compensation arrangements since our pay ratio disclosure in 2025, we used the same median employee that was identified in the proxy

statement for our 2025 annual meeting when calculating the pay ratio that is disclosed in this Proxy Statement. An overview of the

methodology used to identify the median employee that was used to calculate the pay ratio in this Proxy Statement is summarized

below.

---

| | |
|:---|:---|
| **Item** | **Description** |
| Determination date | Our global employee population as of October 1, 2024 was used to identify the median employee. |
| Employee population | The total employee population (excluding the CEO) as of October 1, 2024 was approximately 53,600. When determining <br>the median employee, we excluded approximately 600 employees that joined the Company in 2024 through acquisitions <br>that occurred through October 1, 2024 (Artelon, Inc., approximately 40 employees; mfPHD, LLC, approximately 10 <br>employees; MOLLI Surgical. Inc., approximately 30 employees; NICO Corporation, approximately 50 employees; SERF <br>SAS, approximately 200 employees; Vertos Medical, Inc., approximately 100 employees; Vuaant, Inc., approximately <br>100 employees; 1000 Shapes GmbH, approximately 30 employees). As a result, the employee population used to <br>determine the median employee was approximately 53,000.<br>|
| Consistently applied <br>compensation measure<br>| Actual cash compensation, measured over the twelve month period of October 2023 through September 2024. Values <br>were converted into United States Dollars using the exchange rates in effect on September 30, 2024.<br>|

---

COMPENSATION OF DIRECTORS

The structure of our non-employee director pay program in 2025, determined by the full Board, was unchanged from 2024.

• Mr. Lobo received no additional compensation for his service as a director.

• The annualized fixed fee for our non-employee directors was $130,000.

• The additional annualized fee for serving as the Lead Independent Director was $40,000.

• The annualized fee for serving as the Audit Committee Chair was $25,000 and the annualized fee for serving as either of the

other Committee Chairs was $20,000.

• The target value of the annual stock award of restricted stock units was $215,000. On May 8, 2025, each non-employee director

was awarded 560 restricted stock units other than Mr. Golston who did not stand for reelection. The restricted stock units granted

in 2025 vest in May 2026 and each non-employee director had the ability to voluntarily defer the settlement of the restricted stock

units until his or her departure from the Board or a specified date in the future.

• Stock ownership guideline for each non-employee director equal to $600,000 with a five-year time frame for compliance.

The 2025 compensation for our non-employee directors was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Fees Earned**<br>**or Paid in Cash ($)**<br>| **Stock Awards ($)**<sup>(1)</sup> | **Total ($)** |
| Mary K. Brainerd | 150000 | 212324 | 362324 |
| Giovanni Caforio, M.D.<sup>(2)</sup> | 142967 | 212324 | 355291 |
| Allan C. Golston<sup>(3)</sup> | 52747 |  | 52747 |
| Emmanuel P. Maceda<sup>(4)</sup> | 84286 | 212324 | 296610 |
| Sherilyn S. McCoy | 170000 | 212324 | 382324 |
| Rachel M. Ruggeri | 130000 | 212324 | 342324 |
| Andrew K. Silvernail | 155000 | 212324 | 367324 |
| Lisa M. Skeete Tatum | 130000 | 212324 | 342324 |
| Ronda E. Stryker  | 130000 | 212324 | 342324 |
| Rajeev Suri | 130000 | 212324 | 342324 |

---

______________

(1)The Stock Awards column represents the aggregate grant date fair value of restricted stock units calculated in accordance with the *Compensation* 

— *Stock Compensation* Topic of the FASB Codification.

(2)Dr. Caforio began serving as the Chair of the Compensation and Human Capital Committee after the 2025 Annual Meeting. The annual fee of

$20,000 for serving as the Chair of the Compensation and Human Capital Committee was prorated for his partial year of service.

(3)Mr. Golston served as a director until May 8, 2025 and did not stand for reelection at our 2025 Annual Meeting. The fixed annual fee of $130,000

and annual fee of $20,000 for serving as the Chair of the Compensation and Human Capital Committee were prorated for his partial year of service.

(4)Mr. Maceda was elected as a director on May 8, 2025. The fixed annual fee of $130,000 was prorated for his partial year of service.

The number of outstanding restricted stock units, which includes both unvested as well as deferred restricted stock units, and

unexercised stock options held by each non-employee director as of December 31, 2025 was as follows:

---

| | | |
|:---|:---|:---|
| **Name** | **Stock Awards**<br>**Outstanding at**<br>**December 31, 2025 (#)**<sup>(1)</sup><br>| **Option Awards**<br>**Outstanding at**<br>**December 31, 2025 (#)**<br>|
| Mary K. Brainerd | 560 | 3005 |
| Giovanni Caforio, M.D. | 876 |  |
| Allan C. Golston<sup>(2)</sup> |  |  |
| Emmanuel P. Maceda | 560 |  |
| Sherilyn S. McCoy | 4596 |  |
| Rachel M. Ruggeri | 1213 |  |
| Andrew K. Silvernail | 5775 | 8175 |
| Lisa M. Skeete Tatum | 1551 |  |
| Ronda E. Stryker  | 560 | 8175 |
| Rajeev Suri | 560 |  |

---

______________

(1)The settlement of 316 of the outstanding restricted stock units held by Dr. Caforio, 1,985 of the outstanding restricted stock units held by Ms.

McCoy, 653 of the outstanding restricted stock units held by Ms. Ruggeri, all of the outstanding restricted stock units held by Mr. Silvernail and 991

of the outstanding restricted stock units held by Ms. Skeete Tatum have been deferred by a voluntary election until departure from the Board. The

settlement of all of the outstanding restricted stock units held by Mr. Maceda and 2,611 of the outstanding restricted stock units held by Ms. McCoy

have been deferred by a voluntary election until a future date.

(2)Mr. Golston did not stand for reelection at our 2025 Annual Meeting.

Restricted stock units granted in 2025 vest on May 6, 2026. Stock options were last granted to non-employee directors in 2017. All of

the unexercised stock options in the table above are fully vested and exercisable.

The following changes to the non-employee director fees are scheduled to be effective May 6, 2026:

• The target value of the annual stock award of restricted stock units will increase to $225,000 (from $215,000).

• The stock ownership guideline value for each non-employee director will increase to $650,000 (from $600,000).

AUDIT COMMITTEE REPORT

We constitute the Audit Committee of the Board of Directors of Stryker. We serve in an oversight capacity and are not intended to be

part of Stryker's operational or managerial decision-making process. Management is responsible for the preparation, integrity and fair

presentation of information in the Consolidated Financial Statements, the financial reporting process and internal control over financial

reporting. Stryker's independent registered public accounting firm is responsible for performing independent audits of the Consolidated

Financial Statements and an audit of the Company's internal control over financial reporting as of December 31, 2025. We monitor and

oversee these processes. We also approve the selection and appointment of Stryker's independent registered public accounting firm

and recommend the ratification of such selection and appointment to the Board.

In this context, we met and held discussions with management and Ernst & Young LLP, the Company's independent registered public

accounting firm, throughout the year and reported the results of our activities to the Board. We specifically did the following:

• Reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2025 with Stryker's

management;

• Discussed with Ernst & Young LLP the matters required to be discussed by the applicable requirements of the Public Company

Accounting Oversight Board (PCAOB) and the Securities and Exchange Commission; and

• Received the written disclosures and the letter from Ernst & Young LLP as required by PCAOB Ethics and Independence Rule

3526, *Communications with Audit Committees Concerning Independence*, regarding its communications with the Audit

Committee concerning independence and discussed with Ernst & Young LLP its independence.

Based on the foregoing, the Audit Committee recommended to the Board that the audited financial statements be included in the

Company's Annual Report on Form 10-K for the year ended December 31, 2025.

---

| |
|:---|
| Submitted by: |
| Andrew K. Silvernail, Chair |
| Rachel M. Ruggeri |
| Lisa M. Skeete Tatum |
| Rajeev Suri |
| *Members of the Audit Committee* |

---

ADDITIONAL INFORMATION

**Proposals for Inclusion in our 2027 Proxy Materials (SEC Rule 14a-8)**<br>

SEC Rule 14a-8 permits shareholders to submit proposals for inclusion in our proxy materials if the shareholders and the proposals

meet the specified requirements. If you would like to submit a proposal under SEC Rule 14a-8 for inclusion in the proxy materials for

our 2027 annual meeting, the proposal must be received by our Vice President, Corporate Secretary at 1941 Stryker Way, Portage,

Michigan 49002 on or prior to November 23, 2026. The inclusion of any proposal in the proxy statement and form of proxy for such

meeting will be subject to applicable SEC rules.

**Director Nominations for Inclusion in our 2027 Proxy Materials (Proxy Access)**<br>

Under our Bylaws, if a shareholder (or a group of up to 20 shareholders) who has owned at least 3% of our shares for at least three

years and has complied with the other requirements in our Bylaws wants us to include director nominees (up to the greater of two

nominees or 20% of the Board) in the proxy materials for our 2027 annual meeting, then the nominations must be received by our Vice

President, Corporate Secretary at 1941 Stryker Way, Portage, Michigan 49002, no earlier than October 24, 2026 and no later than

November 23, 2026. Additional information about these proxy access requirements can be found in our Bylaws, which are available in

the Governance area of the Investor Relations section of our website at www.stryker.com/investors/bylaws or may be obtained by

written request to our Vice President, Corporate Secretary at 1941 Stryker Way, Portage, Michigan 49002.

**Other Proposals or Nominations to be Brought Before our 2027 Annual Meeting (Advance Notice)**<br>

Under our Bylaws, any shareholder proposal, including a director nomination, that is not submitted for inclusion in the proxy materials

for our 2027 annual meeting and is instead sought to be presented directly at our 2027 annual meeting, must comply with certain

procedures. Among other requirements set forth in our Bylaws, these procedures require that notice of an intention to nominate a

person for director and/or to bring an item of business before our 2027 annual meeting must be received in writing by our Vice

President, Corporate Secretary at 1941 Stryker Way, Portage, Michigan 49002 no earlier than January 6, 2027 and no later than

February 5, 2027. The notice must contain certain information about the shareholder making the proposal, including a representation

that the shareholder intends to appear in person or by proxy at the annual meeting to nominate the person named in the notice or bring

the item of business before the meeting, and about the nominee and/or the item of business and, in the case of a nomination, must be

accompanied by a written consent of the proposed nominee to being named as a nominee and to serve as a director if elected.

Additional information about these advance notice requirements can be found in our Bylaws, which are available in the Governance

area of the Investor Relations section of our website at www.stryker.com/investors/bylaws or may be obtained by written request to our

Vice President, Corporate Secretary at 1941 Stryker Way, Portage, Michigan 49002.

In addition to satisfying the foregoing requirements under our Bylaws, to comply with the universal proxy rules, shareholders who intend

to solicit proxies in support of director nominees other than our nominees must also comply with all applicable requirements of Rules

14a-19 under the Exchange Act. The advance notice requirement under Rule 14a-19 does not override or supersede the longer

advance notice requirement under our Bylaws.

**Delinquent Section 16(a) Reports**<br>

Section 16(a) of the Exchange Act requires our directors and officers and persons who own more than 10% of our Common Stock to file

reports of ownership and changes in ownership with the SEC. Specific due dates for these reports have been established and we are

required to report in this Proxy Statement any failure by directors, officers and greater-than-10% holders to file such reports on a timely

basis. Based on our review of such reports and representations made by the directors and executive officers, we believe that all such

filing requirements were met with respect to 2025 except for the following: for Ms. Stryker, (i) two gift transactions were timely reported

on two separate Form 4s in February 2025, but both of the filings were later amended to disclose corrections to the filing date that

resulted in two delinquent transactions, and (ii) one other gift transaction was reported late on a Form 4 in February 2025; and for Mr.

Maceda, a grant of restricted stock units was reported late on a Form 4 in May 2025.

**Other Matters**<br>

At this time, we do not know of any matter to be brought before the meeting other than those referred to above. If any additional matter

should properly come before the meeting, it is the intention of the persons named in the enclosed proxy to vote the proxy in accordance

with their judgment on any such matter.

**Expenses of Solicitation**<br>

The cost of solicitation of proxies for the annual meeting is being paid by the Company. In addition to solicitation by mail, proxies may

be solicited by officers, directors and regular employees of the Company personally or by telephone or other means of communication.

In addition, we have retained Innisfree M&A Incorporated to act as proxy solicitor for the annual meeting for a fee of $17,500 plus

reasonable out-of-pocket expenses. The Company will, upon request, reimburse brokers and other nominees for their reasonable

expenses in forwarding the proxy material to the beneficial owners of the stock held in street name by such persons.

**Householding**<br>

In accordance with a notice sent to certain street name shareholders of Common Stock who share a single address, shareholders at a

single address will receive only one copy of this Proxy Statement and our 2025 Annual Report on Form 10-K unless we have previously

received contrary instructions. This practice, known as "householding," is designed to reduce our printing and postage costs. We

currently do not "household" for shareholders of record.

If your household received a single set of proxy materials, but you would prefer to receive a separate copy of this Proxy Statement or

our 2025 Annual Report on Form 10-K, you may visit www.proxyvote.com, call 1-800-579-1639 or send an email to

sendmaterial@proxyvote.com. If sending an email, please include your control number in the subject line, and the documents will be

delivered to you promptly upon receiving the request.

You may request or discontinue householding in the future by contacting the broker, bank or similar institution through which you hold

your shares. You may also change your householding preferences through the Broadridge Householding Election system at

1-866-540-7095 using the control number provided to you.

---

| | |
|:---|:---|
|  | By Order of the Board of Directors |
|  | Tina S. French |
|  | Vice President, Corporate Secretary |
| March 23, 2026 |  |

---

APPENDIX A — RECONCILIATION OF THE MOST DIRECTLY COMPARABLE GAAP

MEASURE TO NON-GAAP FINANCIAL MEASURE

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United

States (GAAP) with certain non-GAAP financial measures, including adjusted net earnings and adjusted net earnings per diluted share.

We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding

our financial results and assessing our prospects for future performance. Management believes the adjusted measures described

above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core

operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP

financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in

connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of

operating results and the trend of earnings. These adjustments are irregular in timing and may not be indicative of our past and future

performance.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other

companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be

considered in isolation or as a substitute for net earnings and net earnings per diluted share, the most directly comparable GAAP

financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations when viewed with

our GAAP results and the reconciliations to corresponding GAAP financial measures below. We strongly encourage investors and

shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial

measures:

---

| | | | |
|:---|:---|:---|:---|
|  | **2023** | **2024** | **2025** |
| **Net Earnings ($ millions)** |  |  |  |
| **Reported** | **$3165** | **$2993** | **$3246** |
| Acquisition and integration-related costs: |  |  |  |
| Inventory stepped-up to fair value |  | 34 | 131 |
| Other acquisition and integration-related | 45 | 85 | 299 |
| Amortization of purchased intangible assets | 503 | 495 | 581 |
| Structural optimization and other special charges | 132 | 110 | 140 |
| Goodwill and other impairments | 27 | 852 | 120 |
| Medical device regulations | 74 | 44 | 30 |
| Recall-related matters | 14 | 30 | 48 |
| Regulatory and legal matters | 63 | 29 | 12 |
| Tax matters | 43 | 28 | 660 |
| **Adjusted** | **$4066** | **$4700** | **$5267** |
| **Net Earnings Per Diluted Share** |  |  |  |
| **Reported** | **$8.25** | **$7.76** | **$8.40** |
| Acquisition and integration-related costs: |  |  |  |
| Inventory stepped-up to fair value |  | 0.09 | 0.34 |
| Other acquisition and integration-related | 0.12 | 0.22 | 0.78 |
| Amortization of purchased intangible assets | 1.31 | 1.28 | 1.49 |
| Structural optimization and other special charges | 0.34 | 0.29 | 0.37 |
| Goodwill and other impairments | 0.08 | 2.21 | 0.31 |
| Medical device regulations | 0.19 | 0.11 | 0.08 |
| Recall-related matters | 0.04 | 0.08 | 0.12 |
| Regulatory and legal matters | 0.16 | 0.08 | 0.03 |
| Tax matters | 0.11 | 0.07 | 1.71 |
| **Adjusted** | **$10.60** | **$12.19** | **$13.63** |
| **Effective tax rate - Reported** | **13.8%** | **14.3%** | **28.1%** |
| **Effective tax rate - Adjusted** | **14.1%** | **14.8%** | **15.1%** |
| **Weighted average diluted shares outstanding (millions)** | **383.7** | **385.6** | **386.5** |

---

Refer to "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2025 Annual Report

on Form 10-K for further details regarding the adjustments to our net earnings and net earnings per diluted share.

![Stryker Proxy Card 2026.jpg](syk-20260323_g19.jpg)

![Stryker Proxy Card 2 2026.jpg](syk-20260323_g20.jpg)